var title_f15_45_16080="Nevus globular pattern";
var content_f15_45_16080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of a nevus with a globular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16080=[""].join("\n");
var outline_f15_45_16080=null;
var title_f15_45_16081="Ripstein anterior rectopexy";
var content_f15_45_16081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Ripstein anterior rectopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the classic Ripstein anterior rectopexy with mesh. The mesh should be wrapped around the rectum without tension to avoid complications of stenosis and obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16081=[""].join("\n");
var outline_f15_45_16081=null;
var title_f15_45_16082="Cap polyposis Endosc II";
var content_f15_45_16082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cap polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAeADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAUUlFFAC0UVbsLbz5QXyIx1IGaAWpVoro1tYD/yzT/vkUNbxcHyo+vPApXK5Wc3ijFbzwRb8eUg46bRQYYs/wCrTjvtFK4cphUVtmGItgRp+QoMMIGCiZ9cD/Ci4cpiUma3RBGR/q0x64FIkEROPLT8hRcOUwqK32giAz5afkKYYohx5aHPoBTuHKzExRit2EpEzYt4pAw2gFRx79KakKdWjj6dlFFxcrMOit0xxDIMafXA4pDFD/zzQ/gKLhYw6XFbIiiyf3a/kKY0cWeEXHuBRcGrGVRWoY04/dr+Qq5BbQiIBo1MpPTAxihysNK5z9J+NdfbwWzADyIjjqSgrSj06z2ZaGEseg8sf4VLqJF+zfc8/wAUlejpY2ioMWkJJ9Y1/wAKljsbRyoFnbA+8Q/wqXVS6D9i+55nilr1E6dZKf3lnbDjIxGP8KimsbMKCLO3A94gP6Ue2XYfsX3PM6TFelnTrLymf7LBgdB5Yyf0pItPs2hV/scIyf4ox/hR7ZdhrDvuea4oxXqA02xwN1pbA+mxc/yqJtPsgf8Aj2gI9o1/wo9suw/q77nmmKMV6UdPsjjFpF1x/qxj+VJ/Z1mCR9mg6/8APNf8KPbLsH1Z9zzek/GvSv7NsgoJtYB6/IKVdOsSCPssOfXy1o9quwvq77nmn40V6Uul2bRNi3h3D/pmv+FUl0+2LENbwjBx9wUe1XYFh2+pwdJiu/On2oU/6PD/AN8CnrptrnH2eInH9wf4Ue1QfV33PPcUYrup9MtijZhQZBxhBmuU1OwkspsHJQ/db1/+vVRmpGc6TiZ9FL3pKszCiiigAooooAU0lFFABRRRQAUUUUAOptLmkoAKKKKACiiigApRSUUAW7K1a5kwB8o5JrcjiSJ8ImFAwARXMUUmmyk0uh1yAg5JFNYbTzu556EZrk629HP+gvzg+Yf5CpasVzXJyD5p9B7UrZbgYB+tIMqTt5z+NKASCSTx1OKYWGkMuc496UfMPp3pQTjoSM80oUr1OM9qm47AcjoQARTVyx4IxT9oLZZjt701lVJWVCTHngkYNMAKOxwc/XFIUVSDjn6U8tgfLyM+tQyMMnHehCuKz4IAPSoy5z8uBxTSeh5+lHzkkLk5HYVQbgzEDJOaaWzwOTVmG0kl5ZsDFXoLNFYjA4AycZqHNItU3Iywkhydhx2BqRbaVx8oIPvW1HCkikkDcBxg4pq2U3BUYIyc5yTU85oqPcyBayowLDOTxnFWVeQHBA3e9aqWzMUByCOc4pf7LMjfuyARyARnNS53H7JLYgjRJIRuADdiOKmgMsDkEBlA4NUp4ri3m2sMbs/e5zVy0uJFKoxBz1GegoumLl7lyCcHG7AYfwmralW3EH5s8VFBFbzy+a20NjBUHim3MTwsZQSyg5GAelSwWhdyCF5PHXnvU1vAkskjORsRec9/pWZDdb2w3BAyRmrkWWwSQWxnB6mk1fYq4qYC4yFyT0pQV3BTgepxwaYY8LleGByeMURY+YuMN2BNSlbctNEkcaGU5bCk9T1/z+FDbRtJ4yT7ikIwwz09SamYhh84HAyCelDKViExgsDkDJ6kdaDEGOcEHPPpUhIK4znmkjVlYHHy56AigaaI9ucLnv6fyphUhjgjB6cYqc5DAqQBnkd6bKoDYbO0ntinYGrlQeYs4MYyB0J6VXmVmm3ttBz2FX5YQAShO3t61FNbNhWIOG6cdaYW7jfI3Qg5G09Qe9OiQk5ONvt60q5EahgMLxjvUsYJV1XAIOR7VLD0Kl08ETxSXSObdGHmbepXPOK3viN4Cl0zw9YeJE2Lo+olVht3z50QZcgtjjJxng96yJEDRlJDkHrVbVLvU7q0t7XUNRuLnTbc5ggdvljwMDA+lCv0YrdGefXlo9rLsYEjsccGqvOa7e/W2vbbyJXBcDchXtXH3UEltM0cgww/WuqE1JHFUpuL8ivRTqbVmQUUUUAFFFFABRRRQAUUUUAFFFFABRS0UAJRS0+GNpnCICWJ7CgCOiuz07SIIIAs0UUsp6llB/CrJsrMKSLW3J9PLH+FZuokbRotq5wdFd2LC16m1g5/6ZiorqytUiBW2gB90FHtEN0GupxNbmiDNnLnpu/wqzJbQI3+ojx/ujmnqqpE6xKqfQYp81yVFpkHJkwOQO+KnVSV5BAAqKBdzFjzVtl+ViSMHtQCK6DvzntT2AxnLHjHFOACgcZJ/SmuNwK8DnvS2G/IjyVBzwO1NZhjkfSgkA/MD9KacOctkKOgprUQxffNNZsngZPanP2Cjr2NTwW5PoST1NDdgS5iCOANjcTn2q9b2pJAXGferEUHz7FAyByxrUt4EjUHBz7nrWTmbwpohghEUZVV3k98CrEenloyzZAxnirkSAQM8g9gBVtGCqqKMcck9KzbZtotjKt7UK3yru46HtWlaAM6lgNqjGaZKojmDqQT93aec/lTisoAKjYCc4zSfmG5pNb27hQMBz1HFMSxELZUk+xrMiV1lJZiTng1pw5ZiGJLdu4pWE0yveWQuoXR1AIBIY8EVylzDJa3DrKBxjBruEmO11cDcPasvWbUyocqSO3PSmm0Lc52NnByCemT7Vdt75/uS/MuPQc1Ut5Whl8t1AxwasBUcsNwAzxzV3HyaEpUMfMhI+n9KsxShcEZRh1z0qi0ZtnDKSQepqRZixDDCt3A9KLEtWL5dyrkMCnccUqqrBd2QcdarxuHQEEZ9KlEp4GwZA9M4pNBoh5QocM4KjqKVTvYHcNgPQHt70yNPMJJIDdxjpTlhCtnHvSGlcsMwJ+UAjscUbQSOTzzUSgjAySOop2SAAxyfei40SEDyyyqW9vU0lnYa1rE9xBoWmzXk0Cb5Ai52DsTQAVACkHd2PaiPWdZ0mW4XQry5tJLpRFMYIwxdR26H17Ur3KWhb8ReGtb8KmyXXEhSe8iMiRo2SPY+hrLZixiHmMdnHHb2pt9q1/qd402uXtze3saCPMq4aNR0GABitC9h0G10HSTptzJea1cfvLzjCwf7PuaNnuK/cqBRkhwc9RTkUE5HQjoKVSJYsL1PX29qdgrwBgDvRcLajHUSHLcewqhrUJktHEYbAB6DtWl7gkECgjdHguDxtIosNmx44uPBN14M0K38KjOsKVM64G4KAQwb0Oa5rxrfHxPZ2luNLtbN7RNqSQgAtwB83Az0FU1tI4ZXaNArDPIHJzVwEnGFA9/8mnFqOsSHDmVmeZXED28zRSqVdTgg1FXea5oy3sDyx4W4TnOPvDB4rhWBViGBBHBzXVGSkjjnTcGMoooqjMKKKKACiiigAooooAdTaKKACiinUAKqlmAA5JwK6vRdPW1RZJQDK45Bxx7D3qholkAFnfBJ5UdcV0cSEqCAQe1ZVJdEdNGn1ZIxOT1GeBk9aGB3KFOQetOCgAEg596WNBtPBO7uPWsbnQxAgXOeCOnaq9ySygEAgc1cZQqgMcDpjFV5lDDj72ONtNEsy7jDSfLxVI8BucH0NXnA+c5wc9TVJ+oyScmtEYyRJZruHBOf0pbhgo2qfmJycGmxEq+MkA/zpJwAwIIOeuKpmSv0JvMDRqVOd3BzTioA5xuI4ApkagqpJAA5xUrELwDkY4NCKvoVLgAMQDzjrUJbaCW69etSNksT3PWmJH50yJ2HJ9aNgs2T2UWT5jEbversEDSS8EBecmpLa1MjhTwoHNaK24RcLgp+ZrJtnRTjoLb2iohJPJwTmrUGxphkgjHaovNG7youD3PXIqzBCI4wVBL55PNZu7NUrE0jFom2jIzyuc02aKV4kZT5fIJBODj9KljCxAhWO1juPfn8ahKTTB1BJA5GPSi4JCahA0i5tmy+OABnH5VbtpXkgUXBCucZBODmm2GFiLkhsHb6YqykaMxYjIA96TYFeaNi+EQOvqOp/SrEMnlxujr5ecYotkdFZicg9O9WIV3OpcAj09aV0JlZQ4bzAxPGPX+tTBkuEIIw4HX3q/HGjKQgAPfPSqogWK4YqQQ3UDPFPQnU5jVrNAcPjce5HWs0b4cJyyngZFdbq1nI0e9QMjnJ4NYOoQhQrYHHUiqTRpF3Q1HDLkgEgD5Tjn8KQwiRt6koxHA6YptuwjG8rnJ5x1xU6sDnb91hx9aoTGrFhw6joefSrlrKgkRZACSfUVFECpPIKk5PtT0WNLrOVyeaVyC3sU3jjGMDkj/ABpyKcM2RjOKjZibgnGFI6kc1KCPLyCMZouCTEYY7DjoOtRyxqyjqW6irOCxz6jjvUbxksNuemCakpMa6hUUscsB2NaPhzxRqvhbUze6VFBM5QoBKMhQe45FZ86hSeRgd6iBDAdiO1Fk1ZjVzVs/F85tvEk2o6Rb3Gt6w+VucDbCMAEAZ9qxrSMQxqGADqOSD1pyofm5I/HoaciBWJcnOPlGetKMEtitXuTKVIyDlj2zQMs7DGABmo1wMg5BFSIMMS2CccDP+NDQWIgrm4Ug5jI5Gc094uOCRz2NOZRsIU4J6GolVwcMRnsRSGVFIeZzySDwCaUo24gHC9cHvTeRI+3GT0qVoSrHe445HNIW4xcAEFR+ArnvEejG5Vrm2X96PvLnlh6/Wuljb5vmBx7jg1FIpDZUEHqAD1q4ScWZ1IqSszy0gg4PWm10/ijS1QNeQjaCf3i44BPcVzVdifMrnBKLi7MbRRRTJCiiigAooooAKKdTaACl9KSl70AdjpCZsYTj+EfjWoigquAMntzxVDR0LWFvgcbAevvWxFCQSVHUd655vU7aeiuRlCrZBIwOeOalOFU9yalVQM7gCQMcChstt4BOMGotcq9yvIzAKwB+bsagnXanzc4HIAxVuT767gMr1NVLvd5TE85FUmNszGYeWxHBOcH+lZz5Ln9a1CuYcA8Dk8VmyqWlIUfMOvFWjCWojMMYPOO1SqyMjbgCOlRtCcncTyPegxEYOf1q7IzsPJCnKnr1BFEjh1AI4qIBhkA5A9DUTMc4IxSsLUlJAGSavaeipH5rDLt0zWWpyyqTncfWugtI1CL0JA4B5pTZrTTbEgllLMEGCRyTWjHA0VuGYck8gc0tnAQTK2D26YAq/dzozoqoCoHJB4FYm+2wz7KIrfzVB3kZ4NFjIZJcOMZHI9aT7ZudFC5JO0AdhWvb2qoWZkGCO4pXHcqpEQxRUwD0xT5bSVlEcRH+0QRWr8iwncMPjgiqMPmLLkFju7E1NhpjRA1uq+WMtjk96fFCZMZJA6kdatKrq2ZAdp7GrkJjDqFjIY8Dj/61JibIEhCgBfpTngfzcAbkAB44q9FakbmbhT7VIqoqsWYEEY4xS5kGpQjQOrgfLnjNRxxqrMMjHTJq+sGCCpBU8cVHPAFOF4yfSi4kkVyw2bAMLjqayNQtYZEJUEn0Uj+ta7o4QFzkDt1rOuYis/BIU8j0popbnLz28isUBwoPpzRGhU53/MOorc1C2JjJUZPYqOvtWQ0e6IyxqQy/eTnP8v6VSZdhYyCrFRznkY/lUmwsP9sdCD/jVaKQFSVIGTyOhqdGVQpHToRiqJaLME5KbHALAHkipkVVVTkgk557VXVS0hPQKKkgY7iCd2D2oJSLoywOAR70g3AhIhljT7eUAEMoIPGcdKkLRlyYzhsY4qWgSIxCxJLDkHjpUbRgOSVIz39PyqfeC5wcn3NSMhYYxx35pGiuZ7xY7g475oRcNnHHbmp3jOzDAknoQKb5RZsdT3oQ9Bi9TuPHvTvL3nCgAntSgAhwARgc5HNEZAcFcdPrigVmMUFWKv0z2HFKSArHOCozwDUh6N0IJ5Gf6UyRSEYjkDjHTFDCxmCQqd2Pmzk1avFkwh42kZBHeoI4GZtnBIGatKWltgGBBXgcYzU2C1iFcOqkkg56GmkZ4JHfAxgfnUiblBJILZwO1RMGLcjG49KNkD1MPxQCNHnzz8y/zrhDXfeK126NN0+8vT61wJrro/CcFf4hKKXvSVqYhRRRQAUUUUAKKSiigAp1J3oNAHe6AhbT7fBz8g4zWychVGAMVkaCP+JZbn/ZArXVgME4IPUVzS1Z2xdooMDopPvmkJIGe/504MCeAAB1HpUU7joBkDqKmzRRExHHU89elVL9vlwOp6dqssw2tgYNUmGdxUgg4HWmgYzadqggAHris4qDO+SABwMjr9a0bmRfJOOvTJBrOiQ/McAknNaLQxk7iljnaM4I7dqiKksoGSD2BzU7x5YgEHB/P8KVYtrDnP17UXItqMSFieFHHvTZYctyByPWtBQ2D3wOMVBdtuC7gPyouVymelqTdrghQOfpXURQrE0ZKhiVHQmsjTInmdixyQwHNdJEqqyFgOmOKzm9TSC5UFhD5sxVRhB1571bSwA3IQRk9Sas6bGEQlRnJzxVgykNhlIJPoam5XNYqWunRidiw+705zzVx5wvyMM46DtSwxKN7ux5PAp0KKqFiPmz1BqSr3GEtNuJICDuCeadFLC2FiySp5b/ACaABNG74winBqewEQZvlAUjGcGhspIcN88gRRkDvirERIlctgleMgDFQLboq5VgDkmpLB5EVjwFJx/nmpbLSuaRLNGuBgMOAKT7NkAckDk02KQs5w2/A6+lW4iSACAMHPFQwatsRJGAMDg5pJYiylQBnrmpRKN2F5JOe9ODsXbC8DrQKxn+WdhVsYx9Kz9QgKglQCo6ZrcyuM5H0zUE6KTk5A64zVJiSOXkdwrKwyoGcetZTyqrB0UAjqO1dBqKBi7xAkDOR7VzshLShgpAHB5qk0aJFO6jRJDLCcKev1pIJgzhWA3nkH1qa5jZC2wAjPOeoqpJEhmBRwGB/wAirRLRoIzF+ASpGMY71cjXaABxjkn0rMgnKuVcFWFaNvOGG3jNGoE0Dhiy5+7yfcVZjUY3DOD2z0qCJSrsWAyRip1bay4OVI/Kh6k3JguW+VVHqfWpApGBz+AqIAlsAEn17CpgBjBGQaQakEobzNowAe/agqehO3nqRU7BSvGQQOlNliSUBSTjuBRsUtSrLHuICkZUgsfWlCxqw2/d7nNSGNFJCgjPU1Gcou1ABg55xSTGNaMBdxOO+KVXga1cBXNxnJbtj8/6UiKWjYHqfU8Co3i8piQMuByQeKTQJFaMl7gAggkc1ONwjIXGwd+majgBBJZsueQMVMqnBycEnNKwMiKFRkHljnkdKrtuBxhcHvjGferrqu3Jyc1W4ZlDR5Azye1K4rGF4pBGhThwM7l+vWuAr0bxio/sKfgAhl6d+a84PWuyj8Jw11aQGkoorUwCiiigAooooAKKKKACl70d6D1oA9B0BSNJgP8AsCtMH5RxgDv61m6Ex/su1GP4BmtHOSoABKn15rmlozsgtBHyFzkhT6cmmSgqMMAS3Q8VLkgMRj8agd9xwSB68Ui0iGdS2MA/TOajATaVAJYD0qzKoI2gc9feq0TKMknJHBH/ANanEJFHUcGREAxkZJxxSMg8tcAcDtTWUyXDluATx0qSRHXAVScYyT2qrmTbuNRM4znp2qaCIHLsRgdMikDIrEkgnGMYzUsKFwvQ4ODS6CV7ism4bsfd6t1zVa8I2hlIJPcir5LooRuV7DFMdYxbkbBychs9D6UIbZW0PdvuEYZJIb3rftFWTKsMY6GuRiu2t9RRkOA52nJrqLJ2V1ViMEbvX9amSsOOqNUebCVaPqP4QeoqdryNogWKiVSSFJ5qkt0CCVJ4ODxUWrbIVSVjhcg4BpJFpGpHO0qKzKBuPpx+dWo1DMQ/A61mw30RSHZnbjK4FaUPzgseSRmobKUSeOBGgZFI68+hqREXbghBtPBpF7AuAF9utPjeNSff0z+dQ2WlYbF5SOEUZduuelXI1XcEWJeeuMf4UwIhYttwwHFWbOHYxZiSTzUNlpMjwqkbUIycHFWmUbQBLg9+akjQNkHHPTHeo3tlYkAgc9cmkmVa5Gquq5UgtnjBFIjzsHIBA74yKmt7R0bLMMdMAVZ8napxwDwadyXYziVWJSMlx1HpUEl1FwHGM9MnrVt1QkqUJPbn/wCvVe4tY5iFC4cHGQTzVJj6aGa0JcymIk4xhV5J/AVnrCN+94TvHBCj/wCtW0qfZmY8A9ADz/OkTCnDAYbvTuCZzUsaQzlmjLI5544Wsy6giWSQgLtJyhWuuZUkYjaNpOCCKz7/AE1SjBQeRkCmmF0cvMoaDKnEo646sKRZXhjSQMSrduRgipriOS3lO+MjaOpFEU0DExucBuc9hVp3BpdDQtLvzlwx5HrVtZAzAHIYDqKwY4WEzrExZex9auQXkok8uRMAH7xqiWmbkD73YNnJ6c1dtYpLolIELy5GEXkn2FYsVyCRggsDir9nK9vL59uzxy5BDKTwfY9qCdjVsvDviDW1vxpVnH5lhgSrI4UgnkAZ6modb0HWvDN3bW3iC3jhkuFLRmOQOCB1zjvU3hDVNM07xnHdeKNQvIrOZcs0c7KC/GGfB5HB610vjOb/AIWt8QI/+ESuo5LLTLQrLNI+ELFj93t0xWMptPRaAnrojiQqMWAOQPeoZMo3IGDxUxgdGeFnUyRSFWZTkEg44p0inPI/SqT5kaLUp7SCwUAE0wthShHzKck/5H9atyDJGB259qgmRWjJGQ4HfvSbE0ym0Z3Iwfgn/PeplwvPbB796rguyjAyQcGp1wyMSPx9KkNRSuecFsnr6VWlQurBS2cfeHY1NGDl9xIU9OetKVZTggkHngc00Fjn/FqlPDs6kkkMuc/71ecmvTPGaY8P3Hsy5/76rzM12UvhODEfEJRRRWpgFFFFABRRRQA6m0UUAdH4a8NS6zBPcSXUNjaRssYnnB2s7HAUY79T+FS2vhC8Op39rqLx6etiAZ5pwdq5OF6c85GK2dPgl1r4c2djpxMlzZ6izzRAc4kVVVvcAgg+m6tfxas9/wCItTk0u6jvmsLezWe3I3C7ZFCscDqA2T+NIBo0h9L0+zUXEdzBLEHimjB2uM84zzTpbV4Y4WmTDSqGUd9p6H9K6OeFLuPw9HPElgklsDLAp2iLkljjtkZOPpWPqlwl5qEs8SEQkhUGfuqBgD8gK55bnXTehHeWDwWVrOxBS5VmUDsA2Ofyq2nh2ZFdWnjN4AW+ygnfgDJPp05xT9XIXQNI4HCzYXP/AE0Nb0+86jJGsUIg+zH/AE7+Iv5Z+bdnqTxj3xRylczOKtrWW6eZYIy3loZG9lHU/rRZ6SLrT5rm4u4bOBJBGJJQcMxBOBj2H61pGUWOguVlU3GoMVZVOdsSHkH0JbH4LVXR9LkvdMa/v47mfSoZWjitoG+Z5SFy3AOAFxyevFNIUpaEcXhW7F7cWszoiQL5kk7AlVTBIbjs3GPrRPoF2uoQ2SFZvOAaOVQdroR976D+ldDa38+paVr1pKpt794YDFDsKlo4yflA7nbj64rTsbiOH+x9OllCXi6fPEc8bGk5VSfYflVWRmmzgdX8NTWslqbeWO5triQRrNEGI3A4K+uR1qfU9JttMWYLqtpNPG+1oow2Sd2DyRjiultWudJ0CyiVo49QfUBNDHKcKm0EZbPQE/yqje2jz6NrzavYWlrJAq+VLGm0tL5g6HPII3dKGhXuck8gkUljhQcZ9arXtwy2JEIOQfvH0qASlk2tgBTt+X+tJLKEgKLnHt9aEi3toX/EdtaxaHo0og3CWFiLmLqZcjKtn0/rVHStWmVkinOCuAGPpUMup3raKulMY/sSzmdBj5g2MHn0qg67uQegzn3qmk0RFtPc625mdc7SAwwTjvV1W+1RgSAbSOpOK5nTb0mNjKQZF4we4rbijlaPdISCeigkZrCWh1w95XRo6ctsDKjsQVHygdv0rdaNtg8kjYF5OelcyF+zMmISWk+8T6flzWk17O0SBIpFVDtIGfm/Tp+dYtmvKW4bUs2Dn5jgA4/OtayskWVlYZUYGcVV0uVprhA6BSCFMbHBP6f0rYnUxXEyYwgIGeg+lQ3fYdhZY90bGEDA4B70sQfyssMYwKsQTwINhK/mKYZopLgKWBVTnaDnNRdjSHmZY0VjjYTtJ64NWHu08r5OT2PNRRm1cbDAAgO7B5yfpii1VIrd0ZAZWJAJHT9KLjtZEouGhA8wgFvY1OLgMmAR6nFQyQJMF3gFlpGtUGMOVz1AOMUXFZMJiwBZFBBHWsq6tZ5p2khALICzZKgYHJ6kVszRvEFVSSgHeqV1Kq48p3ErEq6rleD71cWNK2xkyTkqWUbsDJwKkDxzxKUIDDkihrZ1kdFB2n0H+c1DZ2rQzyHGSB6dKvcGkSK0ck21lIYH04JqTzUyVaLJPQ1PJaIzAADf/eIpktqVACsTg+lS/MTjoU7ixinUiVAyntjmue1Tw0Y8yWhBGN20g8V1kICMCwJXofWny7Mgx5HsTVJtbEpNHmokngkKODEy8DI4qZJHRiJVDKejetdZewQXm6K4XkfxdDXOahp8toPKDBoQMg9xVpjuimLgxnLjDA9q1rS9WQN5Zzx/EelZ0cG5kDAbsHnNOGmOilxLjJz8p61VyWkz1P4UWuhxm91rVxHqeoqpht9NGNxHHzDdgZPP4Vy10ljq/jJhoySeHNOuJQjqWIKYByWwT71iWdqkc8c8D4uwOHU4IrTX5iwuDvdiSxbnJqfZre7MrO5c1K0stL1a5tNLu2v7aMKVnI+8SMn8QabawzXW8bPmUZ64wKSLy41+UKB0wAKU7TjI5zQo2LTI1XJPr04pkiKBhj07f5FW2TbgAA88kVHIoLsc8+9S0aKzMy6tRtLw5DdcDvTYwY0IYHnoTWjb2VxeXEVtavDHJKdoaVwij6seBVnX9AbQp7dJdVtL9rgMSLchhHjscGpukJvWxjFMgADkHn3p0oGxXBx/OlfcrKF4yeSae6qx2kZ7+1NOwnfqc940JPhy4JGCWT+deYGvUfHbf8SC42qApdfr1FeXGu2k7o4K6tISiiitDAKKKKACiiigAoop1AHQ+CbKbUdZNrDqEljvidi8blSwVSdowRkkgcVL4N0xry8u7qW+nsLS0iMk9zCfmXPCqORklsDH1pPh3Ikfiq2aRlVQknJOB/q29aueC0TUNO1vSFkWO6uoo5IdxwGMbZK59wT+VIDtbiwe1t7N1uXvbe4hWSG4c5Z1I79efUVFcWcts7JNGUkwDtbjAIyP51euIFsdG0WwWUSzWtuBKwOQrE7io+nSmaxM7XDtLcLcNgDzFGAeBx+HT8Kwk9Tqpu6INXhEGlafN5m5Z0divUJhiMD8sn3q22mlbaSxa9mN6E8w2wH7sADdjr1wPTrVXWJC2i6SpIDbJQcHpmQkV0djdLDGl3dpaEC2KG8BOTmMqBj1zgE4pdSm2le5wBt55re8lgjaSOABpGUZCA9z6U/wvbTXVy0TajdWlmgMjtGxAByAABkAkkqKLBpzBqYiv0hidUEkTDmcc/KOO1aekX+nxaXb6fdQ3Ic3YmMkWMMPlADZ5wCCfxppibutSKz024l1nVJJ72cW+mO6TXRJLgAlQF56kjGM+tRa3YPplxBdC5lmgu0E0MzE5Ye5zwQetbtw9peSeK9MtZHSa7m8yIsRh5I3YlQR2OTjNYXjC7ih07RdLVvMnsYGWZgcgO7biv4dKohasx7q8nuTumleQgYDOxY4/Goru8ubmDy5p5pUByA8jMM/iaqRyNk85B6ZomuCQMDODx7UIp+RA5ZckEAnr71AZCQCT35p8jFiQeSTzUWMjB6dqpEtgW6gDPuajPQdakwNuSODUcUct3cLb2iFnYgcDOPei6QuVyZJpNu95qiRx5CryxAyABXaSNiREXPp061JpOiR6XbrDlXnb5nfv9PpVq3gAnw2Dzkn1rmqTUmdlKm4oaEbzIiRuA6jNa0I2kSOg8sfw98064uorGHyiCZJwAB2FPtZEWPylx0/KsdGa6otSyqzq8KmNycgrxn8OlV5J5VcOX3qDk5HJpxdo4SVYBRngdabCsqwPhQFkB+Y9/1pWQ3csW86SksQQx96uRxxFlkU52+hrnovMt0wxBQn8anjuWjbJPyngEA0mik7HTwfwkE57ZqdgpYEA+5zWDFJPGMoAY8ZPr/OtCC6DRLuGD7CpsUaisFU45P50izAuA3Ax6VTaUgggjp09/zpjs+ASQCfepaGo3LssozhST25NUrmeKExyyKCAQSvc81AzHrlmPUEVHKXkdQUBDdc9qaLULGpqXlyPHLp4wk5+6x4HQYHvTZLN7WV0YZfIJxzVTT5p4JWEbYVcHBGcH2q5JMRMrSNkP1Y85NWmzNxsRE4ZxIAAejUxFMRYuSUPCn0oInnYo8ePmwvPaq8k7RyMhGUHB46VXULWLCwgLvXBB6jmlW3TkqODwT6UlrK0mARlSPTmrAKorBhkHrTIlEoz2iMTggMMEH1rOvYkZSrAEkc1sSKitlSME9CeKq3EKuGJGQRgUXsTucpeWPkjzInyvcelQCQhducoRkE9q6EQxoWBBGeOn/1qxr20KyNsBK98VSZLiylC0gmVxICo44HX9K3IGjkIDjOPQ1zbwGNdwPIPetfTrorEGON3FXdMhqxbMipOApwCeM1ZQ7iS3FPmCSwK68N3JqrCqgZByc4pWBF9pFD5BAFRFgznA61BLPHDHulIGehNV4pzfXMEFiXdycOyqWCg9zjtUuyLjdmnomgP4q1+20hbn7NHKGaSU4yFAycA9TWVeaTY6TrN5Zafd/bYIJGRbgY+cj6flW3q3hOTTPC9vrr63EZ3l2LBGSrkFiMEdR0zWVDCqDEaAHO4nuTWe70Y7NPoBQlhxxjgGoypcEDPHtVlsKeT8x5FQM3lRl2yarYtK5zvjlc+HrgsMFWQD868uNeneMxv8P3UitlSU/9CrzKu2i7xPNxKtMbRRRWpzhRRRQAUUUUAFFFFABS96WkxQB6p4eGNGsiOMQj+dWJ2URsFOPaqGhSE6HaAdowv61afLKAQAOw965pvU7Ka0M+WRgyk8/Wo5WL7QMZOc81LOnys2MkcGool3OpAz6gnpU2NrsngiGB8oyw5zUhgJXBGARnPpUkWCcA4OPSp1AZBgA8c0rsTujBurdoGJXO1s5+tUZBGRnGCe5Fb96pCMADgZHIrn5ztbBHNaRIkVZMbwTyBzxSPKGbCKAo7E//AFqBxwOfWmNw2R0+lWjJonRFkiclwGGDtx1FNlngWxVDGUnUnLdiD2qoZW8wRxAvITgAda6HS/DcjbLjVGKg8iIdT9aUpKKuyoxctjHsLG71R/LtwRFnlm4A+ld9omnW+lWwS2XdcMPnkPerGk6W7r8iGKAHoBitSa0EMCBTudjjgdB9a5KlVydjqp0lHVmQsLi4eaZjzxycD8qsW0QWQBcFia07mKNQhddxA4HYVDHFyWJAPoBWaNipqETT3ivtO1cKDzV9YYyysSwbHPHBosvmuvLIyGP5Vr3FokDAkBlx90Ek/rRcVl2Kf2dWQbecn04NPmV5YFhCAKg4IHNXYoQ0yIowG5Bq99niiGHHzH09aVx2SOZsoIlVzdI0uDwpHH8jUk01sSo+zqm3uMD+laVwygOEUDnA96zZYAwOAMn1PSncaVyzMTJt8vAVhnaD1qs2UBRyVOM8j+lIDKoJLY2jA4qWAh+HGXJ60NFxVtxIZWU4cnj3qSWVxyCcHpzmqskeJCAec8HNRmVg3OTzjnpStc2SRbMsm0FiB+NMEsnmKGJIbjGarea5JxkjHWnWpLy7iSQOmfWlYq2hqKQwBAII4NTNuup4IkxlTnB4pLeKS6yiADABJFK9stvfxeZKUAOdwNNNGUrHQsiqBnaSOvAFY2ptbm3eC2gEcjEF3HcD8B/OtW4CSsfLJwOAw71lupefDLlM4DDoaNzKO4zTo1iKBjlSMDNTXAjAZ0xgZyoFWLeCI4LcY7c1Sv5RAxRSCjH8h61aQNXZWYK5yrEjIJANQBSrMWYnd2zSy7bLUVhkIRZlLK2eM/5NLEsZY4lEiEZypyBRYGrdCG+TAVgAeOoFZxTcxDAZrXYiXdEBk9ARWdewtHcRuDtz8pGM09iWjHvLVRkAEqT6cVXgj+zThd2VHzY9a1bjIuJkONpAIFUL62AmgcEnsRmqUkZSiagctbMFxnHFVbIsNqvw460+xmALRuMKehNLd2xRxKhyh64ppkWsXbK6stP1i3u9W086jaRbiYAcAnGBn1AzV218V3Nl4vm1XwpaW+i2s0awmKSPeCOCSVBHfmsuISNDyCC5CgkVZn0t4biSG6lCyLg4B4wRkUpRT1KiUb23+0azeX91KLi5mkLtKBgEnrgdqlDAkgDg8ZqRoVgiwWDOe3bFNQYJB5zyDjpUbaI2SGTYBX5STjBNUbibZxOQEYYH1qa+uDDtYtgE/nWVfO7/ADzxyRg5KrIpAPvR5s0TtuU/GOxfDFwi/eDIOv8AtV5ea9g+Kuj6HpOh239i+IP7VmnUGdFA2xkEHqD1yTx7V4+a7aDTjoeTinedxKdRTa2OYKKKKACiiigB1NoooA7RbHTdC8NaRqd/YjUZ9TErLG8jIkSIwUngglifwwajih0i/wBL1iPTLSVXtxHdRSynMm0EK6cHGMsCPpSxarpuq+HNM0vV5ntH04yeVMiFwyOwJUgc5zzn2xSeHdY0nS/GlvdQwzQ6K2IbiOU+azRMNsnQDORkgUAekaHplrYxWFo9sk0kOmGeTdnDyFN6g454yBTNasoPslrdRRi3ll3BoOwwQAR3wfeovD+s+ZNJqDyMHmglKuo53MDjA7dvpiql1PLd3DyyyGR2PLN1OOlc8mrnTBOxW13TDp7RI80biWJZNyHIXPY+/FaOt6Nb2OkWc1uoNxGEW4b1Mihx9MD5eaYv9mtqNqZ0kjsQV88E7iRnkjH8qmPiY3banBeRQJBcozbo4iCzqCYyTn1/rS0tqa6vYq6fbwt4e1CZgTcpJEqt/dBLZx9cU3RbdLmSY3LMkEUbO7L1z0CjtySP1qHTrqOHTdSgYsHneJkGOCFLE/TqKBqQXRTZJEUkkm3yOe4A4X8CSaWgO63JdKt0aWS7vYg9jbAtICcBzg7V+pIxXP8AjO3htvEV9BaxiGJWG1V6KCAf61owa1PYWcluIraaB5PMKzJu5Axxz6Vm+NNVh1TWZrmBUEJAVWC7SwAHJHr2/KqWwrO5zzEIMkgDHU0tjY3OqS+VbqQmeXI4Aq5pOlyanMJJwRajOSDgn6V3mnWKQ26pGoRQAAoPWpnVUdEXGlfVlPQ/D9npsY3KJbjA3SEdPpW/DDE4ClSSehYVUKurFE4TPJ71qWavO6tgBU4B9a5JScnds6Yq2iRZCrDbnI2Ljp61A6M0ACkbSeB3xUF4bi+vVjh5gVsMelabtFBDsfJcDHAzUGqM+EED96cpnHIqbyhvAUYDcVM0QuLZQuQ6nOKl+zHepI5HP1obBoi0CAtfTlVGFGM1vyp+7ICAEDn3/Wq2ngWyuSg+Y/57VamnDt5ajDY5xSu2Q0Z0bGGQMAM5q85V4VdWJbPT0qJYwWIYZyOCatwQLGAGGd396k2N2KEkKEHk7j1ORWfPbMp+UZHqTW89oFkIz1HQVHd2B8pApJBPOR/9emmNNHOCNy/Awvc5FSWlr5t0oJJLHOF6/rmulgsYRHgqGAGSSBTTAkEivbxqJAOABx+lJ1Crow7mydFYtng8Zqp9ieYMFGWUZODXRzI9yMcAYII96SzhFishZSzsME+1UpJlqdjk/JPILhcdaVYQpXY4DZ7V0M1nbhVlkjLbgc44pbSwtHgZWiIlYHDE5Ipo0jNPcy42eJwFlIOcHHenPIHcNKd20YAPY+tJcWps7hiOUGCBnJpgliHmSEHIGcUA0nsXra6+zyFHLyI2PoK1blzNHF5caoqDIx/+uqmnwtdJFPKgVAQxU9SKu3RW4OY0aNOg57UzGUdSvesPkIGOOcVmXzxTaczuCWVwpKg5C5Fad3hRhlB2gck1GDb+RsCriThtw607oqMTMvZlu7vyE2eUrRxRwMrEyAjkg+3fJ71Vtbd7G/vIfLJiiO31z0rV07UDY3TRuA2TtjbbkqPY9qcsMK38irKzqepPcmmrlTlG1rGdE0cdxhOQ3zcnpROhlJyMkcir13pcKSPJFMFIH3SarWrhkcPgkenem2zFu+xzupM8U6kjJHJ9xTCyyMjgkA9h2rT1KJJLfzGGcHGPaspYUjbaSCCfXO2hMlxuicKqlHJyc9RVgMRH14z+dQ4VQdxwuOCaEk+VQxz2BFF2ZNWJbUySsoAJTPT0q1deXuwmd3di2Saz2nMLhVOFPXmlBL85AB5J7mq1ErEijcxLYI7ZpWkMaM33jjgCol6gAfXFbPhPwtc6+b+aDU7SwazG+MTEZLYJBxngdOaiTstTROyuYTz3MVzC4tHiuImWaNZkIViDnHPWtTxR4w1fxYsNtf2VlZW8XzFbdMb27EkjPGTRq+u614guIf7fnime1QxIYRhWwcFhyc5wOapPGBnaxB7GkknuUve1ZyvjC0SLw1cv5YVw6DIHXmvMDXrPj5mPhq4B+6HT+deTGvQo/Cebi3eYlFFFanKFFFFABRRRQAUUUUAei2V9HpHw50mf7FbTi6vriKffGpZowsfAOMj7x5rnPHWjxaJ4imtrVma1dI54SwwQkihgD7gHH4VradrWnxeELCz1LTryY2lzLcxsABDIzBQFYnnHy84rPfxDBqepanea/bNdy3FuY4NpAELcBSOnAAxQB6H8NldrSDy41lcWcjIrANlgDjg+9W9be/ZokvrZIACWXbEFz2Ocdaz/AARK1to0MkcUjb7RowUB4YggHNLI0jSHe7nBxhiSR+dc0nqdcE7BrMFtbeWtrOZ0aNWZgPuk9R1rEKjzOpHfFbuqzC4iV1gEaKoX5c4YjufesPbkMc42nuKhs2Q9ThSQCR/KmTzEP8pyAO4pXV027kPzDIBGOKqTzBiR1buKaBop32CuDn29qr6fYvqd4EYFYEIzjqeelLfMzuqxcuxwMV2vh/TktbRCVG8gEn1NTOXKioxuy1Z2AijSPbtRRwoGK1IoAqE7cselSRQnCswLE8Y9KuxKFySMHGAPWuSTbZtFFOK03ZOcHHJPatCOJ44RAoAXqXxShlijIjQl+/FW7KJ7ghpm+UDlQKjUvRBa2iRRYQYGO/Gat2NpbGVjdo2F5BAzT4dhUlRntyDxUsbbQwYc9QKkV2RzLFPcO0MXlrwoXGM+9MWAmXBXAFTsSQHEYGDz61IJVZuD8wBzx39KNQvcjuYwsO1QQcelUQgjhIUEyE5JNWld3lYSDCjnFRSHZbtI44BPAFFykiIOVChh8zHitJFBVAx5UZ9KpqMwK5XBPNaliu+HDDJNCCWhBOQpBUDJ70APMCXOFHQDvVyVRHGUP3uopsEDSsG6KDziqZCl3CGErHgEYYflVZFZWY7eAOtaoiBUk5AqF3GxkU9evFZ2uNMzJnS3izggdz71FDdCVMsmVPsKJFJ+QjCZpIkLSHjA6DFWlY0S6gI0Ys2SFxjaR/8AXpkMQSbzMkY4qa4gHljafmHNQTW8cxOJNr+nr+lUmNKxFcrGZD5hyWPB9akNrasWAiOduCcVIlpBAEkfllGcnpmpZfMnjPkqNxHUY/xqi1KxArBSkaZ5zUtwuyJAHOT/AA07TrKSZRK64dc4GRjOPr/WieN0WNrlAGyeAc9/qaGyW02Zl1KFt3Rj82c1Fblbiy3KehwRjmrlyiOpYcMfTtTIIRArZJ65AznNF0aWstCHyTGpOB8w6mq1qr+aXK5UnJIreZEljVVOW9KiKRwR7ZAQ2eABmqTM2yndQL5qSkna/bJqH7LH5hMZKZHIyasyEzBIiMbTmhYgJGHXA4xVXuZu5janCEiZSvB5BzXOqjMxJJIBOa6+dDMrxzA8Hg1iywRwRkKSNx5GaEUndWKGQVAPYY571GGDMoxggnIz2p6sFkdcHAORUJeKOfdKSBg4+tMxkrkstqjyF4blXZOSnGRVmMKciTgAYGBTbKO2hgt1gjzM+5ppDnnJ4BpUwxkLEgA4Hoatu3USiTOI0jGwHmqj2iMxkDSKzAqdrEbh6H1FWJhuYADAHQ0AYGCeT0JqL6l2SIWMdrGMkBFHT0qGG/gnwELHcDhiMDj3q5YjTP7e04a/k6d5w87HTHvjnHrXW/Evxfomq+RoXhfTYVsbUhheKoA4H3VPXvzmk3rsQ52fKkeXePZFHhu4TOWLIf8Ax6vJzXrHj5VHhu4IA3B05/GvJ26130fhODFfGGKSnU2tTmCinU2gAooooAKKKKAPW5rCTWfAXgzSor9oHuEuGEGwssu2RjuJHQjGB9a5S/0LT/D+oXdnrs0pmNgk9uYwRiV1VgrDHQbiD9Kl0/xwbSw0aAadG8+liVYpvOIJWQsSMYwPvdfaqGu+K7nVNRluzBCjS2kdo4YCQkKqruBIyGOM596APU/BV/Cng7TIIr+W1lCFpAEJyTgDn0wBUOqW8kGozJO3mOHJLevfP45qHwbqUUPhzToprOOYxoGVidp5OSDgc1aurl7u7knmA3OdxAFc02rnXTjobt1YrdtFokbxxQCFZkYoSxYoGJz9M/lXGRJYf2ZeAvJJeiYCE4IVkzyT6GuiTxNLY20YMEcjxhlDNwSpUqBnGeM1yNteOtpJbARmOVwxJUFgR6HqKm6uXGLR20qre3OjMif6RYPbLIQOGicKQfwOR/wIV5pPGAZ5HBLAnlT90ZrpbbxHPpuqi+WEECFYTGzHDAKBz75UH61xl9MzJI4cjd1UHpzVX0BJplvw7bi+1EzE5jh6H1rvdOjLSgE/KB06ZrnvBNqItP3umC/OR0NdnpoXd0GG6H0rlqO7OiCsi9DECdoXBHIqytuplTBJxySRVm1iQHKnNXmtwkeSMDqTXM3qaKVjJ4aR0VSSP4iOP8/jU0MbLGFRzjnLA/8A16miAl8wrGUVeMnvU8CIFALZanfQdyTTrfMbAjOT1IzVo2jLkgnJ7miCQxgbR+WK0EfcoLDBI71BLbuZ81uyx5JyfX0qg6BXUE/NnnrzWtIDhtxPFZl9KpAVRhjnBGKpJDhdkhjUyAqRjvUFyFMoiZQUYc5HA/TFWbRMxqMjI780+VF34GGPUGlY0TsM8gqoC4HHFXLRSkBZyQR0qJYnaZS5+VRUs5OEQZ3N+gqkiW2xrq0ysSeau26COHJPAGTmoYlxGwH40tw+2IRg7d3GfUVVrka7EM9wZGKRAkDk7STxUDspjyp2k9aeqtays4wQ42j3/MVVvT5MKIeNx7f/AF6VrI0hG5FG4kk4GVyehppPlynnAJ+lRWshW8VFPyng1cuIMToWIIJ6Cp3NbKLIpWDBQCD/AEqGSBTiQMMDkgVIzqsjgj3GO1LaAbXDDII5oSKSSKsrIwKq27phc1p2sLxRR7jtUg5psFlEkiyMBzg4yTtrUCpMBtBKiqSMpu+xBaSxhmRXAGeBkVHqcMt1HhWIKgkDGSfpzVhLeB5MoSSD0yf8au+SvlAk4I6UNmV7HIRwNEdjHJA5VjjBouLeUTkFiVA68gGuklgiLbyg3HrjIpq28W/LDcMcc/8A16FI1VQwrUkSKuBnPPtU1wokuBgA46+lSXNkRexCMhVkOMc8fpStH5Ekyg7s/KTnpVRdwbuVLhQJN4I/Kq0XzTOxHzZ7irc6bhgEYAqrwki8g47CrTCzYy4xtdnUe3Fc9f8A72PcoxtJJ4rVuJfMuGCE4zngcVSu/LSN0bv0NCaBKyMQYLE5xn0/xqrKqyvgjJHbrVi4UQSheoboPSomidZdw5H1qiH5FuCeQ25jwBtGNyjBxUiElNm8BVGfrVaNljcjO0N+NWY1GeDkepNCsZ31JAS2CxqNvMaRCuNg/iJp2MtkjI/Gl2hQc52+lCKGSKjSbGAOfTpTFhSHcEUDuaewJKHAB6ZFOcjPbntVIi5znj4E+G5zk5DJxn/aryY16v4848N3JPd0/wDQq8oNdlH4ThxPxCUUUVqcwUUUUAFFFFABRTqbQAveg9aSnUAeseGsDQ7IgDPlLWkXYdccnp6Vl+GD/wASO0GOfKGDWq4LBTj/AIF61xy3Z3QWiM/Vt5tiF4yfeqW0BEI449Kv6gd0LYABzngVUb/UgD73apNOhV1Alohnv3yKxLhV3BCQPetu6YYCsck9cHisYx+ZdRrgYLDGO/41V9AS1PQdKg8ixgReBgcY6V09nDtVMgA1j2ahngQDgAE4rpoowShUEAYrjqM3WiNCzjGwcEE96vzRgKoXnIqG3iO1Rxk9quFUjX5jk+n+TWC3EZ0KhZHU53dSKTG4HpuFPc7ZHYKQCKgglCjDAbjzzTNIpsuWqh2wTyKnaMt93IweTVOLI3MpIHoD1q5DPuXa6Ffc/wD6qaBxY4EOjJnjH61mTq7TqGUBc4q+3yPkMTjpg1DIzNghDgHnNPQaVgg/dMy4BUetTzKFCvggEdxSIoxnP3u3apGVzEAecenNK42iaEh1Gex4pMGW8I42gdajidUDBj8xPGKsoCu4rjaR6VaM5aMl8oKMxY296guEG8ZIIHJxT7XeqMSMrnv3qG6LzFYoVJmkIVVAySTVIlO2pXmAb5yRhecVnm5EzYYc9j6V3Vt4A1GfT2e5lRH25EanqfQmuZ8T2NhYT28NuczKuZVAOFb0zScHa5pTqwbsmYIRVu0JPU5Oa0tQlAgRUYEt2PaqK5M28dFNMjYG7aSQgrkKFqEjqcb6ktnbyBATyck+lXLS1fzU3A7hluegqzuEUYYqM9hU8kwitHkwS7DgA9KqxjKT2KtxlD0Bzx9KjeFniBY5PZcj+tJGzMymQkA9qmeB5JfkZiAMDbn/ABouUloJEwiKBRlwRwM1qFiYwOjH0qiuLVSSoZx1J/yasWTiT55GC55AJ6UIzknYXcseEmzt74qO4QOjRoTg/nj8qtGJZX5IIPPSopYSl1vQ8EbTTsZLcqPbqEUZOAMfSqF1aysz7cAKu7qOa2ZUGQCcHr9aztSWURgRuwJG1sE9KVmjRPUxIg5VjIRnOAOtLcN5QfAJIHPPSi4lCqVjXJXgnPP8qrzOFifccs3Uk5q0b2uZq4DMSMkjvUV7HuVRjHenMRnIOVIxwaWdi8eQRheDQmEloY1yuZiSMsBtHFKitkAgdOtSFMMzdT6etTDG3IA4qtTFogRFlchgDikjVTIUwRtPWrCW5jUOjFycknHApixHzHJAySO9VEzaSF2gZwSPTNOYghRkkd6JcjaQeMdjzTQcnoOnpTRLXYdKNwwQx2jj2qGM/uyMHnqanChmYEgcelRRbtx2gEg4471ROu5znjzB8MXJ6kOnP/Aq8nr1jx5j/hG7rjrInf3ryc110vhODEfEJRRRWpgFFFFABRRRQAUUUUAFOopO9AHrHhvA0Ky75jFabYxwT64rJ8PEf2FZZwcRKcd6vSvtUnGBXFPdnoUtkVbiQO6hScHqKhcEnbkEc4NKMsxJ4J9BUbnDN3Hb2qd2UVbkjlRjAHp/k1UtkcXkCspJLZGat3SkKm3of7v9aZaqBqMByQN3PFU9iopNno+hJG92GnJ2KMYHriuotY/3gIHynnmsXQTF9jf5Mu3IPYVv2k4VcsQAOBXJNGjReRgm4nnHQdKZu3nDZHpzUW4SPjqD04pnnBJxuH6VkkhpNklw4VwDyTxj0qC4RDECoPTrUVy4MokbkA1Ii+dAXwQScKMUWN0rIjsZGfdnnBxwBWpbuVYB1AH0rPtGMLEEYHU1fmlVol2jqfvU9CpK7HTMzSkIBjHbmqaXBJZXJABIJwKU3KxXGzmTI6KCaqyxMC5jSRCxOVZSD+tDVwUe5eSYbDvJyO9W7InkM2Qa56OUq7BiQcYOavB54k3RNuz6UrWKlT0ujUmiMLB1II7DFPWR5iCq/dPPPFR2t00+xJo/mA53VbRURugwCCcUJmEtNx7TpbQmSYcDjFafhjUrDTtS+06jGApA8tyM7c96y7pI54thXK5zVS6h3si5GxRjmrvYycVJWZ6JrPje0XTLltJInnBCD5uOQeR9K8onV3jllmctKxJLHnnNW41CK6AYHoOlVyAqgHBTuTVSqNqxdLDwg7pFCXKoqqc7vTrVhYgpjJwMc9M5p6hBOzsfkXgDHSpGjDLknA61nqdbasLl5SuemcVdaMNGB0BPNVolAjBUjaOcmo5LnO5FIGOPlHWmQldly6nt4toCE44/zzVa31EJzg4/CqUbkuyvyM9ae0ilRtximi1TH3M0hYbmwDyeB/hSGRl2BGIBqJmYDOOMZ61BueU8nHOAKZp7NW2NS3vJApBYnB7AVeFy+4Z5yKyIFSGYHjkc5HSr8MwCFRyxPGO1NHNOCRDd3zm4RVGCp6cU+WQvHvkwc8YqZUVA2PvHGc8USRIUwWJX09/yqrGasc5IUKYUEOzHPv8ASs3UcbFVCdx65HNb9xbgDK8KM81zmoES3GxT8o4zikzppu5TwQQhOT1xSuCFwxzUsaiNWboScDPSqzMXZmxk5oQptbDVieQkqN3sO1OOxFxkk5+76fkaWPKgAfKwOSR1qJ5WmlJwNq9DjGaaMWKpYRgqSQTyP6c1KNoADcPj07+9MUADI4GBgd80OPmVjzkY57VaM3uKULbSwAP97/61IyqWwuQ2MjFSD5EJGOB0IqvG5G4j3wKpENiliVOTyO9RxKAuSSD1xT7iRlA4yTgDNJ/Dg4I9aZDOa8en/inLkdRvT/0KvKa9W8fEHw5cE9S6cenzV5TXXS+E4a/xDaKKK1MAooooAKKKKACiiigApT1pKU9aAPUvDxxolntHzeWM81ZuHBUhT35OapaA23RrQdf3QOPWrGSxYkEA+1cM3qzvprQjGEIz0A5x3qJTjJY9egzSzsG4Uk/Wm57jOPXtSSRpYSUqoy2QwHTNQD/j6gc5wrdQamZXYfKpOOetRyRkYfBJBHFD2Kjoeo6UAlnGMjLAE1cmYqIjk7c8gGqOjMWtIS2CpAArZktw8aAY4PrXOzW5YgkRlZVPI5ApJHDSBmXB/vZqJV2Odp5PXFSxRbiQxO01LRcUhfJEpOSAnsetWrRSjGPI46c81HGPL4OQOwqaBcSkDJY9KhmqbsTNCm1hIKcnleV5Y5XFOK7T87cN1FQXASHBDYz2zSTHvojpfAOpeHtNmkW/yuolywZkJAXHGD271F418baRqcyW9khbaTulZCpHsM1yEoimlO0AnHXFZd3Zox3bwHBOAeKuMuUlYNTlzNsvy3EU+4xAZz3pBM3y7OGHYniqcK/Kozhh1x3q+FRoVIODUvU63BRVjTtpJZQCuOOvNaEZzHh87qwbGVwQqHI9a2oJCP8AWjnHH+RU7HJUjYnVSVyo49O9VbrcpIBIGfpmrYlClSuST2IqvI4ZmJHHrVp6GMU0UmDBSTkr9KqlTIuH4X0PetGQqEBBHtiqMpMpIzhscYpM3iyBVVhk4BB7DrU0pZ05ACjpUYUx7RjJA5+tMmZyuGPPbHFSXuVryaRdsaE7W7Kev5U61V1t/wB4TuY8ZPSmRqWkXcMn1q5KAyttOMCr6G0dCFUYuRjGe+KkktyFBTOO5xmo0mGURclgepFW7y+Rk2IdmO/rTQ7MoGTCsjED36U2JFIDeYDg9F5/kallRGjJPJPTtUcUOxMq2c9BVFvbUeAZrh0TkKATyTWhbgrJkEkDk1XtIvLJCn52GTzV5VAUgglup9qEjkqNbImDb1ZxwOg9SKRIwYmYjGOAKaTIRjAC8U28uljRixwoH61V7GFm2ZWu3Agt8LgMRiuZgIMju4wOw9f8at6ncNdyDrsUnAPes29uBDEIlB3nA9hU3udUUorUjurjzXMaH5U6gHpSRZOduenUGq8TBIzk7mJ5pTch2CR5A6E1VjJyuTTMUG1Tlj1NN2lUwKRFLFRkHB5JqVCFcnIIH600iLiE8Z70856AZ4+9Uc8ifMVGSBzg8CiVb2ysIb65tJodPmO2K4ZTsc88A/gad0tyWmx8uWxGg68mlISONjnI7fWkicmMSLzuHOaaVYxu5HQZAJ4NNMyaRFMRlN2Oegp0xCrgHr1XtXSaD4JsfGGj3moaNq0kepWSYewIBy+CQSScgNg4rkbaZp7YGVNjj5WXPQjrTU4t2TIaSe5iePMDwzcgDP7xMH0+avJzXq/js58MTj/bT/0KvKDXbS+E4K/xCUUppK1MQooooAKKKKACiiigApT1pKXvQB6RohJ0a02jJ8sdO1WmYKwzwc8cZrP0CYw6ZbBgcFBirk7BgW3ZJ71xTXvHfS+FEDMzthccVYVcxkAd+eOtVrUDJPA7dauJnOevGM5oSsaJiDCnhTx29aJAGibco555qTliCOuDnJpXjzFkcnuQal3KTR2nhmcvp0RyCRhea6a3fLbDjtXD+DJs2jowAKtxXYRk4UqcZ7A1zyRqtUaDwHGVxzSoCjKB68060csoDHOOxP8ASpSm2XkAg1I1oLLGJFB6YNS28TlSxBAFGwnABIFSuWQBd2AB0xSZomRzOIkBY8npmsqWWWaQhzkE8emKvSMshOQD6ZNMZN6BVwMHqDUpG9OwllPBBJ5UkJdm4GOxqvqFxZ2kvlNZtcO2SSvJUfnVryEWaFxwVOTk9a17OW2smvJ7S3M1xOhVGLDEZxzkfjT5UW2lqc5fWcYt7e7syfIkHK9x9aQKjwjYfmHY066vWt7I27AFy2TgcVDDC7KJAw2kZFK5aTauSwMIiACM57VpxuxAOee9ZbBEYZIz64qeOYxOACCp9aRlOLNZZiF2NgjscUyWQNE2BzjjPeqjSbsEYA+tJ5hYkFsD600c9kPZi0a5GBimkkL68UpchVAGQerVXuLryhjIz7mgpIjZjuYL0B54pkisFyBndycnGKU3EUYJcgk9FyMmsm/vZZnYRAqM4wpNG5tBFyIgtvZ8Y4AFPWc+YcAFOp4NVIVdIAJASxPTBNTRb+TsIA7daZukiVwkjrtzknJH+RViOGMybHBIHaqUSv5oIz196vFSpLclj35poGmNZArsFXPPHNShomIOdrDgjFZ7zEMSJCGz2bFQozNM28lvXmqVhNNo3rRcIxQg7jgd6tuBEpxzkdKxbSY28YG9ic9z2p09+WUksMAdc9Kps5XBtlm7vPKRtx/Q1zeoXbzpgjA7AcZqee5Eis2cnPOaxb++RFIU5fHAxUmkY8qG39+I0IJwQMBR3rEXe0huDwxPANTTI8u5m5bHTPFXrG0DRebdhWRUKhQcEHsapKxlOTbKcMJlkBJJY9ulTXDRQMsbsAzd80SyvLtSzUtJ93p0Hqa6fw5pfhjw/qk0vi6UXepxQ+dBDG3mROCDwcDG7PbPFNJ7mTcerOXAbahBOxuRx2pWdYwS7YHTB71p3F8+oSs6QJDApJhj/uqTnFJpN3Z6drUN5q1gL60UENCehyCAfwPNCaB26MksvDUF98O9T8RNq8SXMLHZbKRkhSAVI65OeMVq6LrHiL/hFILjVrS11Hw5bJ5X2eQgMTnAIxg5GP1rjb6x0ya7u7m2gNtayT+Yik5Malv14rZ1+3022u7WDQ7+e5sGQM6SAjbJgDPI+v0qGk372vyJSaRRtWaVcRoY0ZiwT+6Cela/hPw1q3jC9aHS9sVrF8slxIDsVscDjqaoSqzZVSAcY3eortvD/jtbG20vwt4dEOltNkXGoXK7k3beTjIwTjGe3FO7itCJJtaI5fxF4M8UeArqS+juWSGZhE9zbAgEEdwR9axFTyYVXGSTksfXNdD4s8ReJbi+n0K+1a31DTbYjE0K4MuRn5myc4zXPybdygksAKuLT1sRyuO6Oe8eEL4duFJG4unT615Ua9Q8dDOgXDYwAyAfnXl5rvo/CcFf4hKKKK1MQooooAKKKKACiiigApe9JSnrQB3OkS79PgDdVQKOMfyq0rEAA5AB+uao6ZE/9kRzAABUB3E/061ZjcSqm3IK8k4rmkrs7absi9Eq7QASfXIq0FyCRnA4IqraMx+XIz61oxD5c4wQMZJ61lI0VmQqmV+YkL0BA/SptuFJAI7GnFSTkcevHWnKhK4P5f8A6qlmsbGh4b/dlzzgt0rsbeUHaeRmuT0xSi4U4Oa6axyyjPJxzzWEtzdK5rRPtkAGQPUVeaXaVPJ9eKycN5fOSeelMVZGYIn3ieDSsXGKZ0MD72LAZI6ZpjsWkIbII9qh8h7e3UtwSMkmkhnRwQ33h3AqWm2FuxcMISPJGVP51TnlMR+UZXtVc3Do7BWDIT0Iq1HMk0QRyFYdOKpJG8YtFd7nehbBVR34p6bmCvCzDPvUVzK0KFCQV9QP/r1DazTpIGVAyjoCP/ripaN1G62LF1AxGXCsf8+1VzLIkPliMACpLiaSXd5gIb6dKy7iaVDgjI9cUNGkY3LLy7pAG4Y9OetSQyh85yNtVVvnRgUVQAOc55/WmNPJMdxAAPJ29v1qGKdM1YGMrZwRjjpUrDB4wR0JFYaTuoyoBOfzqQXbMrK4G49MCnY5ZQsbMhxHjcR6cVjSJI8hwxwO5OKcsw24JAx35pk8oVGKAnHfGeaESlYlEKyNuc5I6deKcVjhGXAyKqrcP827B44wKdBIgDmUFg3Ycc/jRYpMY19uY+WpzjjIqMX5TIIYsfQCnrCjEKTgehIoeBOCpBx0oubxktmJHqD5yqEkeoFP+3yup559MDNVmQLyOWJpGQbstjI6EGqRba6FxEZ2yxxnnk9arrcqJGCn5h1GBTlJwHYkEdD2qo0iLK0hIZj3qmTe+5ZaZpDkuQp7YqG4nKjHJGO9VDOwGeCD0qnJcPOfLXllOenAoREpJEtzcllAQEZPX1qssJDB2GWI70jSIsn7xwTnoKtQDzQCoG09Ce9M53LmFaP7OUbO5s8AilKqCpkz8xxgjvTtvIA9fTpV7S9Pk1K5kADGKBGmcrgYUd+aq6W5k2kylEpgWXY4jlI6kcEHtUBskacXDBM4weASatxwm5mW3YqDIQAzdB9ajkR7eR48hgpKnHQ4oTv1JlZiKAozg8cAe1I7FgwUE+3pS7wpztOO+e1IGZyxAwGFA9tjptJ8OeFr74fXd/d6iI9aKsUDSbdjDou3ODn+tcnZqywAMqg8HgdTSPAHBIUKF/hyeT61JkbFQZBUdaST6kddWK7bVBPPrVaa3imJRwNuM8+tTM6quOCD2qMnI+bj0HrWiJZFHGkAMcA47kUjOF2gDJ7+tNd9mcAlj0xVaaYWsbSsdzY4WnsQ3cwvHUu3RJ4uCWdSTn0NeZmvS/iFous6Vo8E2safLbRXYDQu2CHHBzx7EV5oa7KDTjoefX+ISinU2tTEKKKKACiiigAooooAUUGkooA6/Tp2OlRRljt2gYzTIrkQvtAychRgZ71n6JdDb5DHDE4XPeu48CROdfSKy0k6jfl1MaFdyg56tweKxmtTppy0M6OR4ZQJVKOOeRg4rVtptxwchSO/Wrnjqwvo/Fd6NSlhOoHaZEiACx8cAAcVkxb4+uenXFYtG8XdGxHtK8Dk9c1YWJAAMA+xqhbXXARhk461pwlGwc89KyehtHct2oK4GBzW3p2VYAgHPvWJEpXbyck56Vr27lSuTjFYyOqOxtqSwG0cDsTk1f0eBXlZ3IG3pms+Bgw4JB7jrWtpJIt3LqSue3pUXE3ZDNSuoyHiUjKjrmsOzmIzlySD93d1rT1OAyI7xoc9j61gRq6q2QQe+apaI1oK7NNmjm3FXEbY5Gev8qdFtwSzjI6HPNZkJZSSRkn0FW13gjOMHoOlK538qLt0EeMNEwLDgrU8BeBVMe1iw5BxVKJdrZbv361oK42qNhP+1SuQ9NEPkmiVXMwQs3bAFZVxdQqdrxKR2Ix/hU90odmGwn3zUEUURYmQgKPX1pNoqOmpTkt5JtxhRye2AcVCsEwUhgwZevBFbyXkES7AhB9cDFUJZSzsWHBPpU3FKqzNVgj5YlVAx8x5zUdxKkboElDsRkhSD/I1aaITOVGFyM85wf50qSxRebvtgZCNqtk4Hv1/pVJ3MJO5SilLnJGV+tWnkIh2BQEJycdTVRmZckDI7iomumYc5/ShGbJZ7kowOQBjoTVd7uQgYYqO3OKS5RHcvuwo6Z61LDCkqqW4BPHNNWCwkckrKSJT+f8A9ekSScE73YYPTJq42nADET4fGQM1KukvlTK4Ge5NJpDUrFRXAAJySemDmhBK+SWOB/Dnir0mmiLa6knHJxzxT5BarFuDlWH944FNWQKpczbqaV12nKqeMdqrSKkSqXcHjoKfc3kUTgRZmY9s8A1VKSzSb5l687elUS5vYr3ErzOERTGh6tzSRwy+ZHFa53yHazk4A/GrMahyFYAGpbdQEMbEo4fcrA4x+Ip6mbbe5Y0iz0Ww1K5fVRcahiJTEsZKgSZOVbjmoyriNggABJYL6DPSnx26B3cNuYcnn9TQZMbWbJc9MGmmxppIjDkxFWADgc89a2L3WEudMsLKytRaNbIVmlB5lJ9T6VkyKJgCwwM9vWneXg5U59iaGrhZLoOhheeVUUDceOTTChWQkjocH60wtIshLEh+2DUhYspJOOae4nZjZWARlY5JII9h3FNZweQpAUcDNJIylcZ3EHrnpSSYGFBBBo2IYhYB8jIyOcU1ypHQA5pCM5xwvb3phkBwM8DvTRDZHKqlCQBnFQvcKAPMOD0weP51MGIU/wB085qoyiYl2A9qtIhsPNTbiM5b0zUEenXetXDWGnwPcXJUsUXjAHeq1/N9mOQAGx61vx3N34CvbXV9B1i1vbm9tysirk+WDjIwVGOlaQjd6mUm7aHH+PNY17UNAS21u+aeK1YLHExyUx8vP4DFeZmur8W6x5/mWyssju++Vx/ezkj865WuqC5UcNVpvQbRRRVmQUUUUAFFFFABRRRQBaWzuXjEiW8zIeQyxkg/jiqxr6a+Hn/JIbP/AK95/wCb18yUAPRyjhlJDA5BHau98D+Mr/RBcvpjJHqEq7fOYAkD1GR1rgDT4pGikV1OGByDSauVGVmemWLyTF5bmUzTyEtI7HJY+taIiRkKkD8a5bQ9TS4TKnbIo+Zf6iurtGEy5GMY9c1yzVnqd0GmtCBbV1mwpHl9hU0MxhnZGzgdvSr6oQcZJwfSq19aFrgzxgkEAHbWUldGkdDXtnVwMYJHA9q0IGwyjP41zNq0qbmVmwOvPWte0u1YAP8ALx3OM1ztM6Iu5tMSeAc+nvXWafJHBpuGIBUc5OK5XRYZL28WOBDIVGSFBY/pV3xBcG3RYASC3BB7VNrmjd1Y3bjUIms9qkE/hWIVWQbuvPIqpAoaBckA9QcirCZh5BBz1AOaV7GtNKOoohTnnBqTySwXBJ245pRsmyRkNjmphlYxtGD9KLm6qCLuaPa4BWpoLp7dWQAbTwOtRI3HB/Cmtl2wwA6jOORSuNu+5LKGd88fNzkCopIAq4I+Y+o61LGpXBU7gOnNNlcvnIxxxUNi5rFUxKrgsOnSoWwzED86ne3eRgSSFHqcU0REsVBBwO3WhML3KrRqCcHn6UwgnAPI7dsVZ8jOfmzj8ajeJgVwM7vXtTEkkVHYY2kH2qpMpZdoHGPbitMow4xgDqcdagEQVm6n0qkiWkUUiTYQ4Jz0Aq7YKIWeSZVPGFU+v50NGN4b7uD0xSSxN5yuxIU9s8VW5KSLbSo8oIJjUAZI55/Knecj2N07kuY/uluD/IVTDorhHVgezHuPrU5wsTI0YZGIJJHp70JNA0upny306WzhHyzDgHsKzAHkQGV2JbqDWzLCjD5Yxz2XnAqCWzYcOCn1GKF5kNdikhjJUhAMccevrU0Y8zd8+DngHrUSwlGIVyHB44pykKybx8y9D3P6VQuUeypFIAo3MOrClgwDJ5gDA9PaoUG2UFmBU8nPSpEdjKSqZB5OB/8AWpoWiJlCKzFcA46VIoeF1docNtyAwOCPXrTFVGzh8vjlfepLi4muJEExyyIFXHYCqQr66CSDcGG0Z6ioyhO044xk5pZI5p3htrbm5nkEMYJx8zEAVpeK/DuoeFLu0hum+1xyw+ZI0SkiI5AwfQe/ejQbnFbmSV3LtdidvI9KgEo6MmADjIqyGEmApBU8g1FKDv2/jRYTuRF16k5J7U1iWAIIXHTHU0EKOQoIJx+NV5n8iVTn5T69qaRm2TMWYfOcjocCmscDjn0zUazGVhtB29zSbsMcngdBVIyYty/lw5xyTjAqsZVVTwSMdaJpjI4LElcdM9agmb5HxkAA4qluQ13KYdZLl3fJA4Ga5nxLqcdozRWpxcsBll/hH+NTa5qzWVsBE6GaQn5c5IA7kdvbNcS7M7lmJJPJJ7muqnDqzlr1EvdiNZixJJyT3ptFFbHILikpRSUAFFFFABRRRQAUUUUAej6B8UrnR/CsOiJpkMsccbxiUykH5iTnGP8AarznNJRQAtGaSigCxa3L20yyxHDD9a6K38XtCADZ5+kuP6VytFS4qW5UZuOx3KePtoA/s3OPWf8A+xqQfELjB0sEd/8ASP8A7GuCopezj2L9tPuet+HdSfWLGS9ht/JRJTGYy+7OADnOB61txOjjPRh2rnPhYu7w/cDv9qbGP9xK6u4tBI6gAhmOM45NcVWKTaR6FFuUU2dT4EtZ1L3cbgNyAGAP8xVLxVdm+1YZADxjaccZ/Cui0iJtP0MZGQAT8wrhFl+0ajJI2chj2IrBRsap3ZopeBUCMpyO/H+NTpdswwAcDtVNDk8fnU5w4XcMMOM4NS0jojJ2NO3uIm7kfWriKzDIfhvUf/WrHEMkpwrA+9OFrcx8qM/QVm15mqkjZMbBssQOOKQberP+QrKWWaNcSoSfYVYtZg55Ugf7QNJp9SlLTUvBweFyfSl2llAcEEdeKEXcBtOB16VIFB6npSsK5GVwcLkdxzULoApC5Dnrk1bxjAbOOtMZQ+RnBosNOxTiUZAYjaByc0/ehbGQcdhT5gFiKHqRWckc6bVUAZ6EDt+dUi0k9S06gheOM+tV54SjKygEH1NSF5AFRVy3qRT9jNAoY4OO1NENWKNzFIuGI+U9MGpHtnUqCcqQCOT3q0UI2oSSB69qiGFYp1APHFUiXuN2q2AeOvWnMo2nH4Uu0ld+Dtzjp0pw3ZGOBnnNOzC9yFlGDuIBHIPWo7ieW5UeY6si9AqAZ/IVNKoZSfbHNVlVVjVcEdeTTSsKxWWAnPAyc8mq1xbFjjow6VpLho9yjjoeMZ/SoZQrNjPJOOnSgbRkEsjFcEHHU1ZtHlQNtx8wwM4/SnXEKuGBGG7VXJaJQcZXoPY01YnoOYkORLgAnIZeKPMkiIZCJFPfvSll8vBAI75prYhYFBmM9M9M1SIaFaeXbFcWbBLmGRZEY8kMCCD+ddzfeMYY/CS3wMN/4h1aIWuoQPIR5QAYB1XnGM9B1zmuGnwg3pgMeuOlIFj3K6qBnkmk4J7mcoqT1EssLAqKTlQev1odyzcdvX0okfaBjgDrgVCzAE5x/jVqKQ7paIJGwMLy3fHSoRECrbwSx9e1PyCCffimlioyT19adjN6ldH8lcjlQeRmkBMjF29OMnrVeWXMhU8qTyRTgcAt1A79MU9yJNoUkHljx/drB8QaxHp8JAIMpztXOPz9ql1fU0sbIzOQXzgKp5PNedX95Le3DSzsSxPTsB6Ct6VO+rOatUUVZbkdzM9xO8spy7HJNQ5oNFdVrHC3cWm0UUCCiiigAooooAKKKKAClxSUUAOxxSYpKKAFxRj14pKKAFxS7fwptFADgvPpWxZ+Hrm7VWjntgG7lj/hWMK1NG1FrOYI5Pksefb3FKV7aFw5b2Z6X4I0yfR9LkgnlheRpjIDE2Rgqo7gehrr9ER7nU4gRuVTk96860/xBbwja11FtPq4r0TwB4l0G0WeW/1awjdgAqyTgH+dcc4ybud8akYxsmdl4sultNJAhPzHGBXIRzQXke/7MsMo4JQABvfgDFJ4y8U6LdlEtNXsXQAE7Z1PP51hW2vaVGuP7StBz/z1H+NS6bsXCpFvc6iCOI8AZPrV1IYtoygyK5+28S6KqgNqVlnuTMvP61YHiXQzjOrWI/7br/jWDpy7HYqkLatG/FBCcBCQceuKlCsvQ5Ue9c//AMJXoUXJ1ayxntKGP6GlTxnoG8H+1rQDP96p9nJdBe0iuqPQfDvgm+163N1FdRQQkkKpGTkdfpWZrmlXui3K2up2wTcPklUhgR68d652x+I9lpd8bjTfEFqgIIMbNlTnvjpmpNR+J9tq6ouqa3p8ojJKkYGKpQdrOJl7SXNpJWNhYztULjHHenFCD0PHXmueXxr4ewM6taA+z0o8a6Bz/wATi0OexcVLpO+xsqke6OjKkrgEY7VE0OWBzyOetZI8X6AoJXWNPz6eev8AjTR4v0AjP9saeDn/AJ7r/jR7OXYftI/zI1pBjggEnpVeaeJDh8AgfQ1mXHi3QFwf7YsSPRZgf5Gue1LxLo09xui1W02njl+go9m+xpGrDrI7QlGRHQ4B565JqOcvhQq5JHrWFb+LfD0MYH9qWzPjHL8CnL4w0DndqtqSf9uj2cuxEqsb6M2pW+bC46YJNV92ZMAAgdTWbD4l8PXl5BDLrlnBAzYeZnGVHrS3+ueH9O1GRbLxFp13aAja5lAYjHOQKahK9rESqx7o1QzHKAkKTnB6UvVjyayT4v8ADrD/AJC1qPcOKibxboGMDVrT67xT9nLsNVI2+JGlKNzbGOB2HrSBEkQiQEPnqPSsyPxNoEknOr2e71aQAfmac/iLRI5QE1jT3UD73njr+NHJLsUqkerRpMg27Rn8utRFRuwRj14ql/wkmicf8TaxP1mX/GmN4k0UnP8AathnGP8AXD/Gjkl2D2kO5PJCWlIQbm7Af4VXeMLuBPOeB6VXTxFpEcm9dVst3b98v+NRS+IdIY86nZE5ySJlH9afJLsHtI90SsCrANgg88UFRIFRn2jOevSqcuuaQznOo2hGMD98P8aqtrGlbuNStNvfEwBpqEuxm6ke5euDIqFMcc4yKIpQIsMQBj15qmdd0y43NJqFnHtGFUyjJ/Liq/8Abml7dpvbbHqJB/jVKD7Euce5pbywY4GT021EpckllwATnNZj61py8xX9uRjoZB/jTf7bsGGWvrUexkFUoy7EucbbmszAJliNoPHNQZMj7m4QdBWdcavpzRgC+tuD0EgpG1nTioze2/0EgoUJPoQ5R7lydFxlBgk5z2rM1W9FnbNJMQIwfxPpikfXLBQWN1AQvIAYHP4A1wniHWJNTuickQqcIv8AU+9a06bb1MalZRWjKep30l/cGWQ47ADoBVKlpOtda00PObb1YlFFFAgooooAKKKKACiiigAooooAUUlFFABRRRQAUUUUAFFFFABRRRQAuaM0UUAGSe9JRRQAuaM+9FFABk0lFFAC5oz70UUAGfegknvRRQAZozRRQAZozRRQAZ96M0UUAGT60ZoooAM0ZoooAM0ZoooAM0ZoooAM0ZoooAM0Z96KKADPvRmiigAzRmiigAzRmiigAzSUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy of a polyp demonstrating a reddish lesion with adherent mucous, findings suggestive of cap polyposis. The surrounding mucosa is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16082=[""].join("\n");
var outline_f15_45_16082=null;
var title_f15_45_16083="Jaundice in newborn infants";
var content_f15_45_16083=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Jaundice in newborn infants (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/45/16083/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16083/contributors\" id=\"au7201\">",
"       Ronald J Wong, BA",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16083/contributors\" id=\"au2220\">",
"       Vinod K Bhutani, MD, FAAP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/45/16083/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16083/contributors\" id=\"se4702\">",
"       Steven A Abrams, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/45/16083/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16083/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/45/16083?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      JAUNDICE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Jaundice is a yellow discoloration of the skin",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     whites of the eyes that is often seen in newborn infants. The discoloration is caused by a yellow substance called bilirubin. Infants with high blood levels of bilirubin, called hyperbilirubinemia, develop the yellow color when bilirubin accumulates in the skin.",
"    </p>",
"    <p>",
"     Jaundice is not a disease but is a symptom of an elevated blood bilirubin level. Jaundice is not painful, but serious complications can occur if elevated bilirubin levels are not treated in a timely manner. Jaundice is a marker used to identify those infants who may be at risk for developing severe hyperbilirubinemia. Severe hyperbilirubinemia can be toxic to the nervous system of infants, potentially causing brain damage.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      JAUNDICE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Jaundice initially causes the skin to become yellowed. Later, the whites of the eyes may have a yellowish tinge. These changes may be hard to recognize in children with a dark skin color or if a baby is unable to open eyelids. The color change:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Is noticeable in the face first, may progress down the chest, abdomen, arms, and then finally the legs.",
"      </li>",
"      <li>",
"       Can be checked by pressing one finger on your baby's forehead or nose. If the skin is jaundiced, it will appear yellow when you release pressure from the skin.",
"      </li>",
"      <li>",
"       Can be tracked in some babies by pressing over the bony prominences of the chest, hips, and knees to check if the jaundice is progressing.",
"      </li>",
"      <li>",
"       Should be checked before your baby leaves the hospital. If your baby goes home sooner than 72 hours after birth, you will need to monitor the baby's skin color at home every day. In addition, your infant should see a doctor or nurse within one to three days after going home.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Signs of worsening jaundice",
"     </span>",
"     &nbsp;&mdash;&nbsp;Call your child's healthcare provider if you notice any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       If the yellow coloring is at the knee or lower, or if the yellow color is more intense, lemon yellow to orange yellow",
"      </li>",
"      <li>",
"       If the baby has any difficulty in feeding",
"      </li>",
"      <li>",
"       If it is hard to wake up your infant",
"      </li>",
"      <li>",
"       If your infant is irritable and is difficult to console",
"      </li>",
"      <li>",
"       If your infant arches",
"       <span class=\"nowrap\">",
"        his/her",
"       </span>",
"       neck or body backwards",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      JAUNDICE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Jaundice is caused by the accumulation of bilirubin in the blood. Bilirubin is formed when red blood cells are broken down. Bilirubin (a yellow pigment) is naturally cleared through the liver, and then excreted in stool and urine. Bilirubin levels become elevated when bilirubin is produced faster than it can be eliminated.",
"    </p>",
"    <p>",
"     Jaundice is common in newborns, since two to three times more bilirubin is produced during this period as compared to during adulthood. \"Physiologic jaundice\" or benign jaundice, which affects nearly all newborns, is caused by a mild elevation of bilirubin and is not usually harmful to infants. It develops between 72 and 96 hours after birth, and usually goes away by one to two weeks after birth. In infants who are born at 35 to 37 weeks of gestation and those who are severely jaundiced, the jaundice may require more time to resolve.",
"    </p>",
"    <p>",
"     Newborns with higher levels of bilirubin in the blood have \"severe hyperbilirubinemia\", a more serious condition than physiologic jaundice. Infants may develop severe hyperbilirubinemia within the first 24 hours of life. If this happens, you must consult your doctor urgently.",
"    </p>",
"    <p>",
"     One reason that bilirubin levels are higher in infants is that more red blood cells are broken down (and as a result, more bilirubin is produced). This can be related to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bruising and mild injuries from the birth process",
"      </li>",
"      <li>",
"       If the mother and infant's blood types are incompatible; the mother's immune system may attack the infant's red blood cells",
"      </li>",
"      <li>",
"       Inherited causes of red blood cell breakdown (such as deficiency of an enzyme called glucose-6-phosphate dehydrogenase [G6PD], which may occur more frequently among African-American, Mediterranean, and Asian races).",
"      </li>",
"      <li>",
"       Asian race or ancestry.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Bilirubin is also more slowly eliminated in the newborn compared to adults because a newborn&rsquo;s liver and intestines are not fully mature.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Jaundice is common in infants who are breastfed because of two different reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breastfeeding failure occurs in infants with inadequate intake of breast milk because of difficulty in feeding or if the mother does not have an adequate milk supply. These infants lose a large amount of weight, thereby increasing bilirubin concentration. Increasing the mother's milk supply, frequent feeding, and ensuring good sucking (latch) are the best treatments for inadequate intake jaundice. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"        \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Breast milk jaundice is thought to be due to the infant&rsquo;s immature liver and intestines. It typically begins the first week after birth, peaks within two weeks after birth, and declines over the next few weeks. Breast milk jaundice is not a reason to stop breastfeeding as long as the baby is feeding well, gaining weight, and otherwise thriving. Infants with breast milk jaundice rarely need treatment unless severe hyperbilirubinemia develops. All infants with jaundice should be monitored by a doctor or nurse. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"        \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In either setting, the mother should be encouraged to continue breastfeeding because of the overall benefits of human milk.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      JAUNDICE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Newborn jaundice can be diagnosed by examining the infant and testing blood levels of bilirubin. A blood test involves collecting a small amount (less than one-half teaspoon or 2.5 mL) of blood. Results of blood testing are available in most hospitals within a few hours.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      JAUNDICE COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     In babies whose bilirubin blood levels reach harmful levels, bilirubin may get into the brain and cause reversible damage (called early acute bilirubin encephalopathy) or permanent damage (called kernicterus). Frequent monitoring and early treatment of infants at high risk for jaundice can help to prevent severe hyperbilirubinemia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      JAUNDICE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goal of jaundice treatment is to quickly and safely reduce the level of bilirubin. Infants with mild jaundice may need no treatment. Infants with higher bilirubin levels or hyperbilirubinemia will require treatment, which is described below. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"      \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Jaundice is common in premature infants (those born before 38 weeks of gestation). Premature infants are at greater risk for hyperbilirubinemia because brain toxicity occurs at lower levels of bilirubin than in term infants. As a result, premature infants are treated at lower levels of bilirubin but with the same treatments discussed here.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Encourage feeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Providing adequate breastmilk or formula is an important part of preventing and treating jaundice because it promotes elimination of the yellow pigment in stools and urine. You will know that your child is getting enough milk or formula if",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     has at least six wet diapers per day, the color of the bowel movements changes from dark green to yellow, and",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     seems satisfied after feeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Phototherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Phototherapy (light therapy) is the most common medical treatment for jaundice in newborns. In most cases, phototherapy is the only treatment required. It consists of exposing an infant's skin to a special blue light, which breaks bilirubin down into parts that are easier to eliminate in the stool and urine. Treatment with phototherapy is successful for almost all infants.",
"    </p>",
"    <p>",
"     Phototherapy is usually done in the hospital, but in select cases, it can be done in the home if the baby is healthy and at low risk of complications.",
"    </p>",
"    <p>",
"     Infants undergoing phototherapy should have as much skin exposed to the light as possible. Infants are usually naked (or wearing only a diaper) in an open bassinet or warmer, but wear eye patches to protect the eyes (",
"     <a class=\"graphic graphic_picture graphicRef55964 \" href=\"UTD.htm?2/49/2833\">",
"      picture 1",
"     </a>",
"     ). It is important to ensure that the lamps do not generate excessive heat, which could injure an infant's skin. In some institutions, phototherapy blankets are used (",
"     <a class=\"graphic graphic_picture graphicRef73723 \" href=\"UTD.htm?1/23/1394\">",
"      picture 2",
"     </a>",
"     ). Phototherapy should be continuous, with breaks only for feeding.",
"    </p>",
"    <p>",
"     Exposure to sunlight was previously thought to be helpful but is not currently recommended due to the risk of sunburn. Sunburn does not occur with the lights used in phototherapy when used properly.",
"    </p>",
"    <p>",
"     Phototherapy is stopped when bilirubin levels decline to a safe level. It is not unusual for infants to still appear jaundiced after phototherapy is completed. Bilirubin levels may rebound 18 to 24 hours after stopping phototherapy, although this rarely requires further treatment.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &ndash; Phototherapy is very safe, but it can have temporary side effects, including a skin rash and loose bowel movements. Overheating and dehydration can occur if the infant does not get enough breast milk or formula. Therefore, the infant's skin color, body temperature, and number of wet diapers are closely monitored.",
"      </li>",
"      <li>",
"       Rarely, some infants will develop \"bronze baby\" syndrome, a dark, grayish-brown discoloration of the skin and urine. Bronze baby syndrome is not harmful and gradually resolves without treatment after several weeks.",
"      </li>",
"      <li>",
"       Hydration &ndash; It is important for infants receiving phototherapy to drink adequate fluids (breast milk or a supplement) since bilirubin is excreted in urine and bowel movements. Breast- or bottle-feeding should continue during phototherapy. Use of oral glucose water is not necessary. In some babies with severe dehydration, intravenous fluids may be necessary.",
"      </li>",
"      <li>",
"       Breastfeeding &ndash; Breastfed infants who are not able to consume enough breast milk, whose weight loss is excessive, or who are dehydrated may need extra expressed breast milk or other milk supplements. Mothers who supplement should continue to breastfeed",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       pump to maintain their milk supply.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There is some controversy about the practice of using cow milk or soy formula to exclusively breastfed infants. Parents should discuss these issues with the child's doctor. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Exchange transfusion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exchange transfusion is a procedure that is done urgently to prevent or minimize bilirubin-related brain damage. The transfusion replaces an infant's blood with donated blood in an attempt to quickly lower bilirubin levels. Exchange transfusion may be performed in infants who have not responded to other treatments and who have signs of or are at significant neurologic risk of bilirubin toxicity.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PREVENTION OF SEVERE HYPERBILIRUBINEMIA",
"     </span>",
"    </p>",
"    <p>",
"     Prevention of severe hyperbilirubinemia is important in avoiding serious complications. Infants who are at risk for hyperbilirubinemia need close surveillance and follow-up. The following information applies to infants who are healthy and late preterm or older (greater than or equal to 35 weeks of gestation).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Screen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leading experts recommend that all infants have bilirubin blood testing before going home. This is especially true for infants who are jaundiced before 24 hours of age.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Monitor",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents and healthcare providers should monitor the infant closely if jaundice develops. Hyperbilirubinemia is usually easy to prevent and treat initially, but the complications can be serious and irreversible if treatment is delayed. You should contact your child's healthcare provider immediately if you are concerned about worsening jaundice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Treat promptly",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infants with elevated bilirubin levels should be treated by a qualified doctor or nurse to safely reduce bilirubin levels and prevent the risk of brain damage. Parents and healthcare providers should not delay treatment for any reason.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804622309\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2878064\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/28/21953?source=see_link\">",
"      Patient information: Gilbert&rsquo;s syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/19/34097?source=see_link\">",
"      Patient information: Screening for hearing loss in newborns (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/41/12946?source=see_link\">",
"      Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2878072\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6201?source=see_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.healthychildren.org/English/ages-stages/baby/pages/Jaundice.aspx\">",
"      www.healthychildren.org/English/ages-stages/baby/pages/Jaundice.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Parents of Infants and Children with Kernicterus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.pickonline.org/\">",
"      www.pickonline.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/jaundice/index.html\">",
"      www.cdc.gov/ncbddd/jaundice/index.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Academy of Breastfeeding Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.bfmed.org\">",
"      www.bfmed.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/45/16083/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/45/16083?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16083/abstract/1\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16083/abstract/2\">",
"      Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16083/abstract/3\">",
"      Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the newborn infant &gt; or =35 weeks' gestation: an update with clarifications. Pediatrics 2009; 124:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16083/abstract/4\">",
"      Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004; 114:e130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16083/abstract/5\">",
"      Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med 2008; 358:920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_45_16083=[""].join("\n");
var outline_f15_45_16083=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           JAUNDICE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           JAUNDICE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           JAUNDICE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           JAUNDICE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           JAUNDICE COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           JAUNDICE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PREVENTION OF SEVERE HYPERBILIRUBINEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/49/2833\" title=\"picture 1\">",
"           Hospital phototherapy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/23/1394\" title=\"picture 2\">",
"           Blanket phototherapy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16084="Instant glucose and intravenous dextrose: Patient drug information";
var content_f15_45_16084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Instant glucose and intravenous dextrose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/40/13958?source=see_link\">",
"     see \"Instant glucose and intravenous dextrose: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/7/16502?source=see_link\">",
"     see \"Instant glucose and intravenous dextrose: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BD&trade; Glucose [OTC];",
"     </li>",
"     <li>",
"      Dex4&reg; [OTC];",
"     </li>",
"     <li>",
"      Enfamil&reg; Glucose [OTC];",
"     </li>",
"     <li>",
"      GlucoBurst&reg; [OTC];",
"     </li>",
"     <li>",
"      Glutol&trade; [OTC];",
"     </li>",
"     <li>",
"      Glutose 15&trade; [OTC];",
"     </li>",
"     <li>",
"      Glutose 45&trade; [OTC];",
"     </li>",
"     <li>",
"      Insta-Glucose&reg; [OTC];",
"     </li>",
"     <li>",
"      Similac&reg; Glucose [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701927",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextrose, corn or corn products, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give the oral drug to someone who has passed out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood sugar stays low after stopping the drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695331",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure to swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may repeat in 10 minutes if blood sugar is still low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be closely watched by your doctor while getting the shot.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11483 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-124.240.187.80-1825C1B6E2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16084=[""].join("\n");
var outline_f15_45_16084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158911\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012067\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012066\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012071\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012072\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012074\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012069\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012070\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012075\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012076\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/40/13958?source=related_link\">",
"      Instant glucose and intravenous dextrose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/7/16502?source=related_link\">",
"      Instant glucose and intravenous dextrose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16085="Significance of hypomagnesemia in cardiovascular disease";
var content_f15_45_16085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Significance of hypomagnesemia in cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16085/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16085/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16085/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16085/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16085/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16085/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/45/16085/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 1, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild hypomagnesemia is a common electrolyte abnormality, particularly in the elderly who may have increased urinary magnesium losses due to diuretic therapy or interstitial renal disease. Whether this abnormality should be treated or prevented with prophylactic magnesium administration is unclear. The major concern is whether mild magnesium depletion predisposes to cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There are conflicting data as to whether this occurs in otherwise healthy subjects. A report on over 3000 patients from the Framingham Heart Study suggests that how arrhythmia is defined is an important determinant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/3\">",
"     3",
"    </a>",
"    ]. No association with hypomagnesemia was noted for more than 10 ventricular premature complexes (VPCs) per hour or for repetitive VPCs. There was, however, an increased risk of complex or frequent",
"    <span class=\"nowrap\">",
"     (&ge;30/h)",
"    </span>",
"    PVCs with reductions in the plasma magnesium concentration of 0.16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 0.08",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or more. The formulas to convert between these units can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, attempts have been made to identify those patients who might be at risk. The data suggest that this might occur when hypomagnesemia occurs in the setting of an acute ischemic event, congestive heart failure, torsades de pointes, after cardiopulmonary bypass, or in the acutely ill patient in the intensive care unit.",
"   </p>",
"   <p>",
"    The mechanisms underlying the possible association between hypomagnesemia and arrhythmias is at present unknown. Arrhythmias could be due to concurrent hypokalemia, hypomagnesemia itself, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Magnesium regulates several cardiac ion channels, including the calcium channel and outward potassium currents through the delayed rectifier [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/4\">",
"     4",
"    </a>",
"    ]. Lowering the cytosolic magnesium concentration in magnesium depletion will markedly increase these outward currents, shortening the action potential and increasing susceptibility to arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ISCHEMIC HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute myocardial infarction who have mild hypomagnesemia appear to have a two to three-fold increase in the frequency of ventricular arrhythmias in the first 24 hours when compared to those with normal plasma magnesium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Uncontrolled studies suggest that the administration of intravenous magnesium at this time can reduce the frequency of potentially fatal ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relationship has also been found between the plasma magnesium concentration and ventricular arrhythmias occurring in the second or third week after myocardial infarction. In one study, for example, the mean plasma magnesium concentration was 1.83",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.76",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with no abnormal rhythms, 1.68",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in those with multifocal ventricular premature complexes, and 1.55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.65",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in those with unsustained ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/9\">",
"     9",
"    </a>",
"    ]. Thirteen patients with complex arrhythmias and hypomagnesemia received intravenous magnesium over 24 hours; a normal rhythm was restored in ten.",
"   </p>",
"   <p>",
"    A related issue is the possible protective effect of doubling the normal plasma magnesium concentration in patients with suspected acute myocardial infarction. The main rationale behind this regimen is that mild hypermagnesemia protects the myocardium from ischemia-reperfusion injury, at least in part by promoting restoration of high energy phosphates. Some studies have suggested that magnesium may be beneficial if given before reperfusion with thrombolysis or angioplasty. However a randomized clinical trial (MAGIC) specifically designed to test the role of magnesium found no benefit to magnesium infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/10\">",
"     10",
"    </a>",
"    ]. The MAGIC trial is discussed elsewhere.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/469?source=see_link&amp;anchor=H7#H7\">",
"     \"Intravenous magnesium sulfate in acute myocardial infarction\", section on 'MAGIC trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased incidence of hypomagnesemia has been found repeatedly in patients with heart failure and may be due in part to diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/11\">",
"     11",
"    </a>",
"    ]. A role for magnesium depletion in sudden death has been suggested but not proven. In a prospective study involving over 1000 patients with class III or IV heart failure, for example, no correlation was found between hypomagnesemia at the beginning of the study and survival at a median follow-up of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/12\">",
"     12",
"    </a>",
"    ]. However, measurements were not made later in the study and all patients were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, and an angiotensin converting enzyme inhibitor, any or all of which may have altered magnesium balance during the course of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TORSADES DE POINTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia increases the risk of a unique form of polymorphic ventricular tachycardia called torsades de pointes. The risk is particularly increased in patients taking class IA or class III antiarrhythmic drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H14#H14\">",
"     \"Acquired long QT syndrome\", section on 'Hypokalemia, hypomagnesemia, and hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care include a recommendation that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    be added for the management of torsades de pointes, severe hypomagnesemia, or refractory ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Treatment is aimed at accelerating the heart rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shortening the QT interval. Intravenous magnesium is now regarded as the treatment of choice even when hypomagnesemia is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY BYPASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia may both develop during cardiopulmonary bypass and predispose to arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/16\">",
"     16",
"    </a>",
"    ]. The causes of hypomagnesemia in this setting are unclear. Possible contributing factors include hemodilution, increased fractional excretion by the kidney, chelation by free fatty acids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    citrate, and enhanced cellular uptake induced by increasing circulating levels of catecholamines.",
"   </p>",
"   <p>",
"    One prospective study, for example, evaluated 101 patients: 18 percent had hypomagnesemia before induction as compared to 71 percent following cessation of bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/17\">",
"     17",
"    </a>",
"    ]. The hypomagnesemic patients had a significantly higher frequency of atrial dysrhythmias and an increased requirement for prolonged mechanical ventilatory support. A separate study suggested that two grams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    given after surgery reduced the level of ventricular ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were corroborated in a prospective study of 100 patients who were randomized to either placebo or two grams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/22/24933?source=see_link\">",
"     magnesium chloride",
"    </a>",
"    intravenously after the termination of cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/19\">",
"     19",
"    </a>",
"    ]. Normomagnesemic patients had significantly fewer postoperative supraventricular and ventricular dysrhythmias, higher indices of cardiac performance, and a less frequent requirement for prolonged mechanical ventilatory support than patients with low plasma magnesium levels.",
"   </p>",
"   <p>",
"    In a randomized controlled trial of 99 pediatric patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    supplementation during cardiopulmonary bypass reduced the incidence of hypomagnesemia and junctional ectopic tachycardia on admission to the cardiac intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INTENSIVE CARE UNIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia is extremely common in patients in the intensive care unit and is frequently associated with hypokalemia and hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .) In one study, for example, hypomagnesemia present on admission to the intensive care unit was associated with a mortality rate approximately twice that of comparably ill normomagnesemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/23\">",
"     23",
"    </a>",
"    ]. It has not been shown, however, that treatment with magnesium supplementation would improve the outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large prospective epidemiologic studies have examined the relationship between the serum magnesium concentration and the subsequent development of coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Both suggest that a low serum magnesium is a risk factor for coronary disease.",
"   </p>",
"   <p>",
"    One study, for example, examined and followed a cohort of 15,792 subjects aged 45 to 64 years old over a four to seven year period as part of the Atherosclerosis Risk in Communities (ARIC) study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/25\">",
"     25",
"    </a>",
"    ]. The relative risk of CHD across quartiles of serum magnesium in women was 1.0 (in the lowest quartile), 0.92, 0.48 and 0.44. The data in men showed a similar trend but was less striking and did not achieve statistical significance. Both men and women who developed CHD had lower mean baseline serum magnesium concentration than the disease-free controls. How a low serum magnesium might predispose to CHD is not known. However, it may be related to its effects on endothelial function. Support for this comes from one study of 50 patients with coronary heart disease which found that oral magnesium therapy (30",
"    <span class=\"nowrap\">",
"     mmol/day",
"    </span>",
"    for 30 days) improved endothelial function and exercise tolerance compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16085/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3980450\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild hypomagnesemia is a common electrolyte abnormality, particularly in the elderly and among patients with heart failure, due to diuretic therapy. Data suggest that mild magnesium depletion predisposes to cardiac arrhythmias when it occurs in the setting of an acute ischemic event, congestive heart failure, torsades de pointes, after cardiopulmonary bypass, or in the acutely ill patient in the intensive care unit. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute myocardial infarction who have mild hypomagnesemia appear to have increased frequency of ventricular arrhythmias particularly in the first 24 hours. The administration of intravenous magnesium may reduce the frequency of potentially fatal ventricular arrhythmias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute ischemic heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypomagnesemia increases the risk of torsades de pointes, particularly in patients taking class IA or class III antiarrhythmic drugs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Torsades de pointes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypomagnesemia may both develop during cardiopulmonary bypass and predispose to arrhythmias. Possible contributing factors include hemodilution, increased fractional excretion by the kidney, chelation by free fatty acids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      citrate, and enhanced cellular uptake induced by increasing circulating levels of catecholamines. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiopulmonary bypass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low serum magnesium is a risk factor for coronary disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/1\">",
"      Millane TA, Ward DE, Camm AJ. Is hypomagnesemia arrhythmogenic? Clin Cardiol 1992; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/2\">",
"      Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 1992; 85:I70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/3\">",
"      Tsuji H, Venditti FJ Jr, Evans JC, et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994; 74:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/4\">",
"      Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol 1991; 53:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/5\">",
"      Dyckner T. Serum magnesium in acute myocardial infarction. Relation to arrhythmias. Acta Med Scand 1980; 207:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/6\">",
"      Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 1987; 147:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/7\">",
"      Rasmussen HS, Suenson M, McNair P, et al. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study. Clin Cardiol 1987; 10:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/8\">",
"      Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987; 147:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/9\">",
"      Ceremuzy��ski L, Van Hao N. Ventricular arrhythmias late after myocardial infarction are related to hypomagnesemia and magnesium loss: preliminary trial of corrective therapy. Clin Cardiol 1993; 16:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/10\">",
"      Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/11\">",
"      Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/12\">",
"      Eichhorn EJ, Tandon PK, DiBianco R, et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. J Am Coll Cardiol 1993; 21:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/13\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/14\">",
"      Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/15\">",
"      Banai S, Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol 1993; 4:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/16\">",
"      Inoue S, Akazawa S, Nakaigawa Y, et al. Changes in plasma total and ionized magnesium concentrations and factors affecting magnesium concentrations during cardiac surgery. J Anesth 2004; 18:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/17\">",
"      Aglio LS, Stanford GG, Maddi R, et al. Hypomagnesemia is common following cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/18\">",
"      Yurvati AH, Sanders SP, Dullye LJ, et al. Antiarrhythmic response to intravenously administered magnesium after cardiac surgery. South Med J 1992; 85:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/19\">",
"      England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/20\">",
"      Manrique AM, Arroyo M, Lin Y, et al. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. J Thorac Cardiovasc Surg 2010; 139:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/21\">",
"      Chernow B, Bamberger S, Stoiko M, et al. Hypomagnesemia in patients in postoperative intensive care. Chest 1989; 95:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/22\">",
"      Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med 1988; 84:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/23\">",
"      Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 1993; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/24\">",
"      Gartside PS, Glueck CJ. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr 1995; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/25\">",
"      Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16085/abstract/26\">",
"      Shechter M, Sharir M, Labrador MJ, et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102:2353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 846 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16085=[""].join("\n");
var outline_f15_45_16085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3980450\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ISCHEMIC HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TORSADES DE POINTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CARDIOPULMONARY BYPASS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INTENSIVE CARE UNIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3980450\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/469?source=related_link\">",
"      Intravenous magnesium sulfate in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16086="Ethinyl estradiol and norgestimate: Patient drug information";
var content_f15_45_16086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norgestimate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/36/40521?source=see_link\">",
"     see \"Ethinyl estradiol and norgestimate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Estarylla&trade;;",
"     </li>",
"     <li>",
"      MonoNessa&reg;;",
"     </li>",
"     <li>",
"      Ortho Tri-Cyclen&reg;;",
"     </li>",
"     <li>",
"      Ortho Tri-Cyclen&reg; Lo;",
"     </li>",
"     <li>",
"      Ortho-Cyclen&reg;;",
"     </li>",
"     <li>",
"      Previfem&reg;;",
"     </li>",
"     <li>",
"      Sprintec&reg;;",
"     </li>",
"     <li>",
"      Tri-Estarylla&trade;;",
"     </li>",
"     <li>",
"      Tri-Previfem&reg;;",
"     </li>",
"     <li>",
"      Tri-Sprintec&reg;;",
"     </li>",
"     <li>",
"      TriNessa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclen&reg;;",
"     </li>",
"     <li>",
"      Tri-Cyclen&reg; ;",
"     </li>",
"     <li>",
"      Tri-Cyclen&reg; Lo",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, norgestimate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12452 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16086=[""].join("\n");
var outline_f15_45_16086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027200\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027202\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027201\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027206\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027207\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027209\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027204\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027205\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027210\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027211\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/36/40521?source=related_link\">",
"      Ethinyl estradiol and norgestimate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16087="Overview of sex cord-stromal tumors of the ovary";
var content_f15_45_16087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of sex cord-stromal tumors of the ovary",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16087/contributors\">",
"     David M Gershenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16087/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/45/16087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4402092\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian sex cord-stromal neoplasms are a heterogeneous group of benign or malignant neoplasms that develop from the dividing cell population that would normally give rise to cells surrounding the oocytes, including the cells that produce ovarian hormones (the nongerm cell and nonepithelial components of the gonads) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/1\">",
"     1",
"    </a>",
"    ]. Malignant ovarian sex cord-stromal neoplasms are rare, comprising only 1.2 percent of all primary ovarian cancers (malignant neoplasms) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast with epithelial ovarian cancer, most patients with malignant sex cord-stromal neoplasms are diagnosed with early-stage disease; even malignant neoplasms are generally considered to be low-grade [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"     2",
"    </a>",
"    ]. Lymph node metastases are rare from these neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some sex cord-stromal neoplasms produce sex steroid hormones, including estrogen and androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These may result in symptoms of estrogen excess or other effects, and measurement of these and other tumor markers may play a role in diagnosis.",
"   </p>",
"   <p>",
"    General principles of ovarian sex cord-stromal neoplasms are reviewed here. Histologic subtypes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727542\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex-cord stromal ovarian neoplasms are rare. Based upon data from the Surveillance Epidemiology and End Results (SEER) United States national cancer database from 1992 to 1999, the overall incidence of these neoplasms was 0.2 per 100,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate was higher for black women than white women (0.44 versus 0.18 per 100,000). Malignant sex cord stromal neoplasms comprised only 1.2 percent of all cases of ovarian cancer (malignant neoplasms); granulosa cells neoplasms were the most common subtype (1.0 percent of all ovarian cancer cases).",
"   </p>",
"   <p>",
"    The age distribution of sex cord-stromal neoplasms is somewhat younger than for epithelial neoplasms, which are the most common histologic type of ovarian cancer. The average age at diagnosis of sex cord-stromal neoplasms was 50 years (compared with 61 years for epithelial cancer) in the SEER data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"     2",
"    </a>",
"    ]. Among women with sex cord-stromal neoplasms, 12 percent were younger than 30 years and 57 percent were between ages 30 to 59.",
"   </p>",
"   <p>",
"    Malignant sex cord-stromal neoplasms are often diagnosed at an early stage (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). Disease was confined to the ovary in 57 percent women, based upon the SEER data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding risk factors for sex cord-stromal neoplasms. Some data suggest that granulosa cell neoplasms are more likely to occur in women who are non-white, obese, and have a family history of breast or ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk appears to be decreased in women who are current or past smokers or users of oral contraceptive pills, and in those who are parous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22874274\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic mutations affecting the RNase IIIb domain of",
"    <em>",
"     DICER1",
"    </em>",
"    have been found in nonepithelial ovarian cancer, particularly Sertoli-Leydig cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, a somatic mutation in",
"    <em>",
"     FOXL2",
"    </em>",
"    , a gene that encodes a transcription factor, may be associated with granulosa cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sex cord-stromal neoplasms have no known association with the BRCA germline mutations or a genetic predisposition to breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4401832\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529744\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian sex cord-stromal neoplasms arise from the dividing cells that would typically give rise to specialized gonadal stroma surrounding the oocytes, including granulosa cells, theca cells, Sertoli cells, Leydig cells, and fibroblasts. (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ). By comparison, epithelial ovarian carcinoma derives from the dividing cell population that gives rise to M&uuml;llerian epithelium, ovarian surface epithelium, or fallopian tube epithelium.",
"   </p>",
"   <p>",
"    Morphologically, sex cord-stromal neoplasms display at least some areas with unequivocal gonadal stromal differentiation, such as granulosa, theca, Sertoli, or Leydig differentiation. They may display indifferent morphologic features, such as fibroblastic differentiation, and may contain other areas of nonepithelial differentiation (eg, cartilage or skeletal muscle) or areas of epithelial differentiation (&ldquo;heterologous elements&rdquo;). This may happen because the dividing cell population from which these neoplasms arise may still have capacity for various lines of differentiation. Most consist of ovarian cell types, but testicular (Sertoli cell) and mixed ovarian and testicular (gynandroblastoma) cell types can occur.",
"   </p>",
"   <p>",
"    The histology of sex cord-stromal neoplasms subtypes is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529444\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian sex cord-stromal neoplasms are divided into several histologic subtypes, including fibromas, fibro-thecomas, granulosa cell neoplasms, Sertoli, or Sertoli-Leydig cell neoplasms, and gynandroblastoma. The World Health Organization classification of ovarian sex cord-stromal and other ovarian neoplasms is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77703 \" href=\"UTD.htm?1/41/1693\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728063\">",
"    <span class=\"h2\">",
"     Patterns of spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex cord-stromal neoplasms are often diagnosed at an early stage, as noted above. Surveillance Epidemiology and End Results (SEER) United States national cancer database data reported the following distribution of stage at diagnosis: confined to the ovary (57 percent); spread to surrounding or organs or tissues or local lymph nodes (15 percent); and distant metastases (22 percent). The pattern of spread and likelihood of distant metastases varies greatly by histologic subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ovarian sex cord-stromal neoplasms may spread by local or regional extension, but nodal metastases are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As an example, in a retrospective series of 87 patients with mostly granulosa cell or Sertoli-Leydig cell neoplasms, there were no patients with positive lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/5\">",
"     5",
"    </a>",
"    ]. Among women with stage III and IV, regional spread was abdominal (eg, diaphragm and omentum).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727597\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4401840\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with sex cord-stromal neoplasms generally present in the same manner as women with epithelial ovarian neoplasms (eg, abdominal or pelvic symptoms, finding of adnexal mass on examination or imaging). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H27#H27\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, sex cord-stromal neoplasms that secrete estrogens or androgens result in endocrine-dependent clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 3",
"    </a>",
"    ). The diagnosis should therefore be suspected in patients who present with signs of estrogen excess (eg, precocious puberty in a child, abnormal uterine bleeding, endometrial hyperplasia or carcinoma) or androgen excess (virilization), especially if an adnexal mass is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727614\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a suspected ovarian sex cord-stromal tumor should have a complete pelvic examination to evaluate for an adnexal mass, and if present, to determine size and mobility. In addition, a general physical examination should be performed to evaluate for findings that suggest advanced or metastatic disease (eg, ascites). The physical examination of women with suspected ovarian cancer is discussed in detail separately. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727701\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some sex cord-stromal neoplasms secrete proteins (eg, inhibin, estrogen, androgens), which can serve as diagnostic markers (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 3",
"    </a>",
"    ). In patients with symptoms of hormonal abnormalities (eg, estrogen or androgen excess), appropriate hormonal testing should be performed. Use of individual tumor markers is discussed separately for each type of sex-cord stromal tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727742\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a suspected sex cord-stromal tumor should undergo pelvic imaging. Transvaginal pelvic ultrasound is typically the study of choice for initial evaluation. The presence and characteristics of an adnexal mass can be described. In addition, women with a suspected sex cord-stromal tumor should have evaluation of the endometrium to exclude endometrial thickening as a result of estrogen excess.",
"   </p>",
"   <p>",
"    Ultrasound is typically sufficient for the evaluation of adnexal masses, but magnetic resonance imaging (MRI) may be used if further characterization of an adnexal mass is needed. In addition, computed tomography, MRI, or positron emission tomography may be used for preoperative detection of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530204\">",
"    <span class=\"h2\">",
"     Endometrial sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen excess may result from estrogen-secreting ovarian sex cord-stromal neoplasms. Endometrial neoplasia should be diagnosed preoperatively, if possible, to allow appropriate surgical planning. For women with a suspected sex cord-stromal neoplasm, endometrial sampling should be performed to evaluate premenopausal women with irregular or heavy uterine bleeding, postmenopausal women with an adnexal mass and a thickened (&gt;4 to 5 mm) endometrial stripe, and in the occasional patient who has a preoperative diagnosis of ovarian granulosa cell neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link&amp;anchor=H13#H13\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727968\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ovarian sex cord-stromal neoplasms is a histologic diagnosis made based upon evaluation of the involved ovary. While the diagnosis may be suspected preoperatively based on the presence of an adnexal mass combined with signs of estrogen or androgen excess or elevated levels of serum tumor markers, the specific tumor type and classification into benign or malignant can be confirmed only with histologic evaluation of the ovary.",
"   </p>",
"   <p>",
"    When an ovarian malignancy is suspected, the entire ovary must be removed. Biopsy of the ovary or cystectomy results potential in spread of neoplastic cells and upstaging that impacts prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H25#H25\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Spillage of malignant cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic diagnosis is typically made postoperatively upon final pathologic evaluation. Since these are rare neoplasms, many expert gynecologic pathologists will not provide a definite diagnosis based upon intraoperative frozen section examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529921\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727859\">",
"    <span class=\"h2\">",
"     Staging and surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant ovarian sex cord-stromal neoplasms are surgically staged. Assessment of stage is the most important factor in determining prognosis and to guide postoperative treatment recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529949\">",
"    <span class=\"h3\">",
"     Preoperative preparation and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative counseling and informed consent should include the possibility of benign, malignant, or indeterminate intraoperative findings. Patients should be counseled about issues of fertility preservation. This discussion should be documented in the medical record.",
"   </p>",
"   <p>",
"    Preoperative evaluation is generally the same as for other suspected ovarian cancers, with the addition of endometrial sampling in some women. (See",
"    <a class=\"local\" href=\"#H530204\">",
"     'Endometrial sampling'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H13733533#H13733533\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529930\">",
"    <span class=\"h3\">",
"     Staging system and procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system for ovarian sex cord-stromal cancer is the same as that used for other primary ovarian cancers (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). In brief, stage I disease is confined to the ovaries; stage II includes extension into other pelvic tissues; stage III refers to disease that has spread beyond the pelvis or to retroperitoneal lymph nodes but remains in the abdomen; and stage IV refers to the presence of distant metastasis or involvement of liver parenchyma.",
"   </p>",
"   <p>",
"    Complete surgical staging includes a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 4",
"    </a>",
"    ). One notable difference between sex cord-stromal versus other ovarian neoplasms is that lymph node metastases are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H728063\">",
"     'Patterns of spread'",
"    </a>",
"    above). Pelvic and paraaortic lymphadenectomy may result in lymphedema that impacts postoperative quality of life. Thus, for most women with malignant sex cord-stromal neoplasms, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    performing pelvic and paraaortic lymphadenectomy. Nodes should be palpated, however, and lymphadenectomy is required for women with palpable nodal enlargement. Pelvic and paraaortic lymphadenectomy should also be performed in women in whom there is a suspicion of a different histologic type of ovarian malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"     \"Cellulitis following pelvic lymph node dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the definitive diagnosis is often not made pre- or intraoperatively, the surgeon will need to make a decision about which surgical option to employ based on imperfect histologic information. As noted above, since these are rare neoplasms, even expert gynecologic pathologists will not provide a definite diagnosis based upon intraoperative frozen section examination. Epithelial neoplasms (particularly endometrioid carcinoma) can mimic sex-cord stromal neoplasms and if diagnosis is uncertain this should be communicated.",
"   </p>",
"   <p>",
"    Intraoperative decisions regarding TAH-BSO versus conservative surgery are made based upon the patient's preferences and the operative findings. For example, for a young patient desirous of fertility preservation with a unilateral ovarian mass, conservative surgery is appropriate if the intraoperative frozen section is indeterminate. On the other hand, for a 60 year-old woman, a TAH-BSO may be preferred by the patient even if the mass is unilateral and benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529995\">",
"    <span class=\"h3\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who wish to preserve fertility should be counseled about the possibility of intraoperative findings of metastatic disease, issues regarding incomplete staging, and the potential need for further surgery.",
"   </p>",
"   <p>",
"    Recommendations for conservative surgery (ie, retaining the ipsilateral ovary or the uterus if they contain no disease) vary by tumor histology and childbearing plans, and are addressed separately for each type of sex cord-stromal tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728071\">",
"    <span class=\"h2\">",
"     Adjuvant treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to adjuvant therapy varies by histologic subtype of ovarian sex cord-stromal tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4401872\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no high quality evidence to support one posttreatment surveillance strategy over another for ovarian sex cord-stromal neoplasms. The Society of Gynecologic Oncologists (SGO) and the National Comprehensive Cancer Network (NCCN) have published guidelines for posttreatment surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16087/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of symptoms and physical examination &ndash; for the first two years, every two to four months; then every six months thereafter.",
"     </li>",
"     <li>",
"      Serum tumor markers examination &ndash; for the first two years, every two to four months; then every six months thereafter.",
"     </li>",
"     <li>",
"      Routine use of imaging studies is not recommended.",
"     </li>",
"     <li>",
"      If a recurrence is suspected, patients should be evaluated with serum tumor markers and computed tomography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727664\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis varies by histologic subtype of ovarian sex cord-stromal tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727648\">",
"    <span class=\"h1\">",
"     HORMONE THERAPY FOLLOWING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some ovarian sex cord-stromal neoplasms produce estrogens and androgens. In general, it does not appear that postmenopausal hormone therapy increases the risk of recurrence in women with ovarian cancer. Women considering this therapy for the management of postmenopausal symptoms or effects should be counseled about all risks and benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H37#H37\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Other postoperative issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099467#H6099467\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Postmenopausal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=see_link\">",
"       \"Patient information: Sertoli-Leydig cell tumor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4402156\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian sex cord-stromal neoplasms arise from the dividing cells that would give rise to specialized gonadal stroma surrounding the oocytes, including granulosa cells, theca cells, Sertoli cells, Leydig cells, and fibroblasts (",
"      <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"       figure 1",
"      </a>",
"      ). The World Health Organization classification of ovarian sex cord-stromal and other ovarian neoplasms is shown in the table (",
"      <a class=\"graphic graphic_table graphicRef77703 \" href=\"UTD.htm?1/41/1693\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4401832\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some sex cord-stromal neoplasms produce sex steroid hormones, including estrogen and androgens. These may result in symptoms of estrogen excess or virilization. Measurement of these and other tumor markers (eg, inhibin) may play a role in diagnosis. (See",
"      <a class=\"local\" href=\"#H727701\">",
"       'Tumor markers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H530204\">",
"       'Endometrial sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with malignant sex cord-stromal neoplasms are diagnosed with early-stage disease. Lymph node metastases are rare. (See",
"      <a class=\"local\" href=\"#H728063\">",
"       'Patterns of spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ovarian sex cord-stromal tumors is a histologic diagnosis made based upon evaluation of the involved ovary. For women with a suspected ovarian malignancy, we recommend oophorectomy rather than ovarian cystectomy or biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H529930\">",
"       'Staging system and procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staging of malignant sex cord-stromal neoplasms is generally the same as for other primary ovarian cancers (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      ). For most women with malignant sex cord-stromal neoplasms, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing pelvic and paraaortic lymphadenectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Lymphadenectomy is required for women with palpable enlargement of these nodes and may be performed in women in whom there is a suspicion of diagnosis of another histologic type of ovarian malignancy. (See",
"      <a class=\"local\" href=\"#H727968\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H529930\">",
"       'Staging system and procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservation of a contralateral ovary or the uterus if they have no evidence of disease is possible in some women who wish to preserve fertility, but the feasibility varies by tumor histology. (See",
"      <a class=\"local\" href=\"#H727859\">",
"       'Staging and surgical treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"       \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"       \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"       \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/1\">",
"      Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/2\">",
"      Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/3\">",
"      Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/4\">",
"      Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol 2006; 103:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/5\">",
"      Thrall MM, Paley P, Pizer E, et al. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol 2011; 122:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/6\">",
"      Varras M, Vasilakaki T, Skafida E, Akrivis C. Clinical, ultrasonographic, computed tomography and histopathological manifestations of ovarian steroid cell tumour, not otherwise specified: our experience of a rare case with female virilisation and review of the literature. Gynecol Endocrinol 2011; 27:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/7\">",
"      Busquets M, Gonzalez-Bosquet E, Muchart J, et al. Granulosa cell tumor and endometrial cancer: a case report and review of the literature. Eur J Gynaecol Oncol 2010; 31:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/8\">",
"      Boyce EA, Costaggini I, Vitonis A, et al. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol 2009; 115:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/9\">",
"      Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012; 366:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/10\">",
"      Shah SP, K&ouml;bel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360:2719.",
"     </a>",
"    </li>",
"    <li>",
"     Scully R, Sobin L. Histologic typing of ovarian tumors, World Health Organization (Ed), Springer-Verlag, Berlin Heidelberg 1999. Vol 9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/12\">",
"      Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer 2003; 97:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/13\">",
"      Outwater EK, Wagner BJ, Mannion C, et al. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics 1998; 18:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/14\">",
"      Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 1997; 79:1951.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16087/abstract/16\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16833 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16087=[""].join("\n");
var outline_f15_45_16087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4402156\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4402092\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727542\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22874274\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4401832\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H529744\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H529444\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H728063\">",
"      Patterns of spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727597\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4401840\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H727614\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H727701\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H727742\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530204\">",
"      Endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727968\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H529921\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H727859\">",
"      Staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H529949\">",
"      - Preoperative preparation and evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H529930\">",
"      - Staging system and procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H529995\">",
"      - Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H728071\">",
"      Adjuvant treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4401872\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727664\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727648\">",
"      HORMONE THERAPY FOLLOWING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4402156\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16833|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1693\" title=\"table 2\">",
"      Sex cord stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 3\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 4\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=related_link\">",
"      Cellulitis following pelvic lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/61/28626?source=related_link\">",
"      Patient information: Sertoli-Leydig cell tumor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16088="Epidemiology and pathogenesis of West Nile virus infection";
var content_f15_45_16088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of West Nile virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Lyle R Petersen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16088/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/45/16088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;West Nile (WN) virus, a member of the Japanese encephalitis virus antigenic complex, was first isolated in a blood sample in a patient from the West Nile province of Uganda in 1937 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/1\">",
"     1",
"    </a>",
"    ]. This RNA virus was initially considered of minor public health importance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/2\">",
"     2",
"    </a>",
"    ]. It emerged from obscurity in 1999 when the first incursion of the virus into North America caused 62 cases of encephalitis and seven deaths in New York [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/3\">",
"     3",
"    </a>",
"    ]. Since that time, the virus has dramatically spread, and WN virus activity has now been detected in all 48 continental states, the District of Columbia, and Puerto Rico [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/4\">",
"     4",
"    </a>",
"    ]. WN virus causes both sporadic infection and outbreaks that may be associated with severe neurologic disease.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of West Nile virus will be addressed here. The clinical manifestations, diagnosis and treatment of infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=see_link\">",
"     \"Clinical manifestations and diagnosis of West Nile virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33958?source=see_link\">",
"     \"Treatment and prevention of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;West Nile (WN) virus is one of the most widely distributed of all arboviruses with an extensive distribution in the Old World, throughout Africa, the Middle East, parts of Europe and the former Soviet Union, South Asia, and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/2\">",
"     2",
"    </a>",
"    ]. The virus had not been detected in the Americas before the 1999 New York City outbreak. It is unknown how WN virus got to the United States. However, the circulating strain is nearly genetically identical to a virus identified in Israel, suggesting importation from the Middle East [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. WN virus is now considered endemic in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patterns of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the first discovery of WN virus, infrequent human outbreaks were mostly reported in groups of soldiers, children, and healthy adults in Israel and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. These outbreaks were associated with only minor illness in the majority of patients; some case fatalities were associated with increasing age. In one of the largest outbreaks reported, thousands of self-limited and relatively mild clinical cases, consisting of fever, rash, and polyarthralgias occurred in South Africa, resulting in an epidemic attack rate of 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, since the mid-1990s, outbreaks of WN virus infection associated with severe neurologic disease have occurred in Algeria (1994, 1997), Tunisia (1997), Romania (1996), Russia (1999), Israel (2000), the United States (1999, 2002-2007), Sudan (2002), and Canada (2002, 2003, 2007) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. In each of these outbreaks, mortality among patients with meningitis and encephalitis was approximately 10 percent and occurred more often in elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence in the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2000, the ArboNET national surveillance system has tracked West Nile virus in the United States. West Nile fever cases are considerably underreported since most infected persons are asymptomatic, others do not seek medical care for mild symptoms, and routine diagnostic testing for uncomplicated West Nile fever cases is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the most accurate trend data derive from monitoring cases of invasive neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/4\">",
"     4",
"    </a>",
"    ]. Only 19 human cases of WN neuroinvasive disease were reported in the United States in 2000 and 64 in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/18\">",
"     18",
"    </a>",
"    ]. However, in 2002, a multistate outbreak throughout the Midwest involved 2946 neuroinvasive disease cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/13\">",
"     13",
"    </a>",
"    ]. At the peak of the outbreak in 2003, WN virus was reported in all but three states in the continental United States, with a total of 2866 with neuroinvasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/19\">",
"     19",
"    </a>",
"    ]. From 1999 to 2008, a total of 28,961 confirmed and probable cases of WN virus disease, including 11,822 (41 percent) of neuroinvasive disease cases, were reported to the CDC from 47 states and the District of Columbia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, serologic surveys and extrapolations from blood donor screening data indicate that neuroinvasive disease following infection is infrequent, with estimates ranging from 1 in 140 to 1 in 256 infections resulting in meningitis or encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/14,21-24\">",
"     14,21-24",
"    </a>",
"    ]. By extrapolation, the nearly 12,000 cases of invasive neurologic disease reported in the United States through 2008 would imply that from 1.6 to 3.1 million persons have been infected. Serological surveys indicate that even in areas experiencing outbreaks, less than 10 percent of the population is infected with WN virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/14,21,25\">",
"     14,21,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human illness peaks in late summer or early fall [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/23\">",
"     23",
"    </a>",
"    ]. Sporadic cases occur throughout the year in southern states. The seasonal variation is due to the fact that mosquitoes emerge in the spring in temperate climates, which begins viral amplification in the bird-mosquito-bird cycle. Viral amplification peaks in early fall; the risk of infection then decreases in humans when female mosquitoes begin diapause and infrequently bite.",
"   </p>",
"   <p>",
"    Updated weekly reports are available at (",
"    <a class=\"external\" href=\"file://cdc.gov/ncidod/dvbid/westnile/surv&amp;control.htm\">",
"     file://cdc.gov/ncidod/dvbid/westnile/surv&amp;control.htm",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H13#H13\">",
"     \"Laboratory testing of donated blood\", section on 'West Nile virus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence in Canada",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and ecology of WN virus in Canada reflects that of the northern United States. The first human cases were reported in 2002, with 414 reported illnesses and deaths reported from Quebec and Ontario. In 2003, 1481 cases were reported, of whom 217 had neuroinvasive disease and 10 died. In 2004 to 2006, fewer than 50 cases of neuroinvasive disease were reported each year, only to be followed by a large outbreak in Alberta, Saskatchewan, and Manitoba in 2007 with 2338 cases reported, including 130 cases with neuroinvasive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence in Latin America and the Caribbean",
"    </span>",
"    &nbsp;&mdash;&nbsp;WN virus was first detected south of the United States border in 2001, when a resident of the Cayman Islands developed WNV encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/18\">",
"     18",
"    </a>",
"    ]. Subsequently, serologic studies in birds and horses suggested that WN virus has circulated in Argentina (2006), Colombia (2004) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/26\">",
"     26",
"    </a>",
"    ], Cuba (2004) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/27\">",
"     27",
"    </a>",
"    ], Dominican Republic (2002), El Salvador (2005) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/28\">",
"     28",
"    </a>",
"    ], Guadeloupe (2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/29\">",
"     29",
"    </a>",
"    ], Guatemala (2003), Haiti (2004), Jamaica (2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/30\">",
"     30",
"    </a>",
"    ], Mexico (2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/31\">",
"     31",
"    </a>",
"    ], Puerto Rico (2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/32\">",
"     32",
"    </a>",
"    ], and Venezuela (2004).",
"   </p>",
"   <p>",
"    However, viral isolations have been infrequent and documented avian, equine, and human morbidity are scant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Documented human infections have been limited to a few patients in the Cayman Islands, Cuba [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/27\">",
"     27",
"    </a>",
"    ], Haiti [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/35\">",
"     35",
"    </a>",
"    ], and northern Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for the discrepancy between the serologic evidence indicating widespread WN virus circulation in the Caribbean, Central and South America, and Mexico and the lack of substantial avian, equine, or human morbidity remain a mystery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all human infections of WN virus are due to mosquito bites. Birds are the primary amplifying hosts, and the virus is maintained in a bird-mosquito-bird cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Humans, horses, and many other vertebrates serve as incidental hosts and are not felt to be important for transmission since viremia is both short-lived and low-grade [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Birds as amplifying hosts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mosquitoes that transmit WN virus are usually of the Culex species, which vary by geographic area. The major mosquito vectors in Africa and the Middle East are Cx. univittatus and Cx. pipiens molestus, and in Asia, Cx. tritaeniorhynchus. WN virus has been recovered from ticks in Russia, but it is not clear what role they play in maintaining or disseminating the virus.",
"   </p>",
"   <p>",
"    Surveillance has identified 64 mosquito species infected with the WN virus in North America. However, WN and the St. Louis encephalitis viruses appear to share the same maintenance vectors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38023?source=see_link\">",
"     \"St. Louis encephalitis\"",
"    </a>",
"    .) Cx. pipiens pipiens (northern house mosquito) is an important maintenance vector in the northern United States and Canada, while Cx. pipiens quinquefasciatus (southern house mosquito) is important in the southern United States, and Cx. tarsalis is important in the western United States and Canada, respectively. The relative proportion of human infections caused by each mosquito species is difficult to discern, but likely varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Birds as amplifying hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wild birds develop prolonged high levels of viremia and serve as amplifying hosts but generally remain asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Nevertheless, dead bird surveillance has noted more than 320 species of native and captive birds in the United States. Significant avian mortality has only been noted in Israel, the United States, and Canada, in which similar strains of the virus have circulated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. High mortality has been noted among American crows and other North American corvids (ravens, jays, and other crows) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/45\">",
"     45",
"    </a>",
"    ]. A single nucleotide change in the NS3 gene appears responsible for the increased mortality in American crows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crows are amplifying hosts and also herald disease activity in humans. As West Nile virus spread across the United States, a higher incidence of West Nile infection was noted in residents of high crow-mortality areas relative to those outside of these areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/47\">",
"     47",
"    </a>",
"    ] and clusters of dead crows predicted an increased risk for one to two weeks prior to appearance of human cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/48\">",
"     48",
"    </a>",
"    ]. However, decreasing susceptible bird populations and waning interest in avian mortality surveillance have decreased the value of dead crow sightings as an indicator of virus activity in recent years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other routes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission has also been described via transfused blood, red blood cells, platelets, and fresh frozen plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/49\">",
"     49",
"    </a>",
"    ]. However, universal screening of the US and Canadian blood supplies has nearly eliminated the risk of transfusion-transmitted WNV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .) Nevertheless, a small residual risk remains from donations with low viremia not detected by nucleic acid detection tests (NAT) tested in the minipool format used by blood centers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/51\">",
"     51",
"    </a>",
"    ]. Transmission has also been documented by transplanted organs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], transplacental transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/54\">",
"     54",
"    </a>",
"    ], occupational transmission via percutaneous exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/55\">",
"     55",
"    </a>",
"    ], conjunctival exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/56\">",
"     56",
"    </a>",
"    ], and in a dialysis center by unidentified means [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/57\">",
"     57",
"    </a>",
"    ]. Transmission via breast milk is also likely [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2002, transmission via donated organs was first documented when four recipients of organs from a common donor developed WN virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/52\">",
"     52",
"    </a>",
"    ]. Serum from the day of organ harvest was positive for WN virus by NAT and culture. A second transmission occurred in 2005 in which three of four organ recipients developed WN virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/56\">",
"     56",
"    </a>",
"    ]. Serum from the day of organ harvesting was positive for WN virus-specific IgG and IgM antibodies, but was negative for WN virus RNA, suggesting that transmission can occur from virus sequestered in organs in the absence of detectable viremia in serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of severe infection with West Nile (WN) virus is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dissemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;During feeding, the mosquito injects virus-laden saliva into the host. Initial WN virus replication is thought to occur in skin Langerhans dendritic cells. These cells migrate to regional lymph nodes, where virus replication produces a viremia that seeds various organs and tissues, such as liver and kidney. In animal models, the primary viremia is cleared in approximately one week, at which time virus levels in the central nervous system infection increase and neurological symptoms become clinically manifest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/59\">",
"     59",
"    </a>",
"    ]. The mechanisms by which WN virus enters the CNS are not precisely known, but likely include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematogenous spread",
"     </li>",
"     <li>",
"      Infection or passive transport through endothelium or choroid plexus epithelial cells",
"     </li>",
"     <li>",
"      Transport by infected immune cells that traffic to the CNS",
"     </li>",
"     <li>",
"      Direct axonal retrograde transport from infected peripheral neurons",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Humoral and cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other flaviviruses, humoral immunity is critical for protection from WN virus. Mice genetically deficient in B cells had increased WN viral loads in the CNS, and the infection was lethal at lower doses of virus than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/62\">",
"     62",
"    </a>",
"    ]. The presence of neutralizing antibody correlates with protection from flaviviruses and passive transfer of IgG antibody can protect against WN challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/63\">",
"     63",
"    </a>",
"    ]. T cell responses are also critical for protection from WN virus, as demonstrated in animal models and extreme susceptibility to infection in persons with certain immunocompromising conditions. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Host susceptibility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Role of interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons likely play a critical role in control of initial WN virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/64\">",
"     64",
"    </a>",
"    ]. Mice lacking type 1 interferon (IFN-alpha and IFN-beta) receptor had uncontrolled viral replication, rapid dissemination to the CNS, and enhanced lethality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/65\">",
"     65",
"    </a>",
"    ]. Mice deficient in type 2 interferon (IFN-gamma) also showed greater viral burden, early CNS entry, and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/60,66\">",
"     60,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of toll-like receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toll-like receptors help cells to recognize and respond to infections by RNA viruses. Mice deficient in toll-like receptor 3 have decreased viral RNA production and inflammation in the CNS with subsequent decreased neuronal injury compared to mice with wild-type receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other mechanisms are also important in modulating early WN viremia. Complement is required for protection from lethal infection in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/60\">",
"     60",
"    </a>",
"    ] and an immunomodulatory function has been demonstrated for WN virus nonstructural protein (NS)-1, which binds and recruits the complement regulatory protein factor H [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/68\">",
"     68",
"    </a>",
"    ]. This may lower the ability of the immune system to target WN virus by decreasing complement-mediated recognition of infected cells. Macrophage depletion led to higher levels of viremia and accelerated development of encephalitis and death compared to control mice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 23 patients who died from WN encephalomyelitis, glial nodules with variable loss of neurons and perivascular cuffing by mononuclear cells was observed in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/70\">",
"     70",
"    </a>",
"    ]. Mononuclear infiltration and loss of neurons were most prominent in the gray matter of the medulla, pons, and midbrain. Inflammation of the spinal cord was universally present, particularly in the anterior horns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HOST SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of West Nile (WN) virus encephalitis in 11 solid organ transplant recipients, the clinical presentation and laboratory findings were similar to those in immunocompetent patients, but the degree of neurologic damage was at the severe end of the spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/71\">",
"     71",
"    </a>",
"    ]. Other reports, based upon a small number of cases and extrapolation to a larger population, suggest that neuroinvasive disease is approximately 40 times more likely to develop in transplant recipients than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports suggest that certain cancers, particularly hematological malignancies, increase the risk of severe disease after infection. A case-control study showed that cancer and chemotherapy increased at least sixfold the risk of developing neuroinvasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/74\">",
"     74",
"    </a>",
"    ]. Eleven percent of patients inoculated with WN virus as a cancer treatment in the 1950s developed encephalitis, particularly among patients with hematological malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Host genetic factors, such as CCR5 deficiency, may increase the risk of severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/77\">",
"     77",
"    </a>",
"    ], but do not appear to be a risk factor for acquisition of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16088/abstract/78\">",
"     78",
"    </a>",
"    ]. Advanced age is the most important risk factor for severe neurological disease, although the mechanism for increased susceptibility is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=see_link\">",
"       \"Patient information: West Nile virus infection (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      West Nile (WN) virus is one of the most widely distributed of all arboviruses with an extensive distribution in the Old World, throughout Africa, the Middle East, parts of Europe and the former Soviet Union, South Asia, and Australia. The virus had not been detected in North America before the 1999 New York City outbreak. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wild birds develop high levels of viremia and serve as amplifying hosts but generally remain asymptomatic.",
"     </li>",
"     <li>",
"      Nearly all human infections of WN virus are due to mosquito bites; mosquitoes that transmit WN virus are usually of the Culex species, which vary by geographic area.",
"     </li>",
"     <li>",
"      Other less common routes include transfused blood and transplanted organs.",
"     </li>",
"     <li>",
"      The risk of neuroinvasive disease is increased in the setting of increased age and immunosuppression. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis and treatment of WN virus is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=see_link\">",
"     \"Clinical manifestations and diagnosis of West Nile virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33958?source=see_link\">",
"     \"Treatment and prevention of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/1\">",
"      Smithburn K, Hughes T, Burke A, et al. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med 1940; 20:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/2\">",
"      Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 2007; 45:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/3\">",
"      Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/4\">",
"      Petersen LR, Hayes EB. West Nile virus in the Americas. Med Clin North Am 2008; 92:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/5\">",
"      Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/6\">",
"      Giladi M, Metzkor-Cotter E, Martin DA, et al. West Nile encephalitis in Israel, 1999: the New York connection. Emerg Infect Dis 2001; 7:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/7\">",
"      Brown CM, DeMaria A Jr. The resurgence of West Nile virus. Ann Intern Med 2012; 157:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/8\">",
"      Petersen LR, Roehrig JT. West Nile virus: a reemerging global pathogen. Emerg Infect Dis 2001; 7:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/9\">",
"      Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis 2004; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/10\">",
"      Murgue B, Murri S, Triki H, et al. West Nile in the Mediterranean basin: 1950-2000. Ann N Y Acad Sci 2001; 951:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/11\">",
"      Jupp PG. The ecology of West Nile virus in South Africa and the occurrence of outbreaks in humans. Ann N Y Acad Sci 2001; 951:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/12\">",
"      McIntosh BM, Jupp PG, Dos Santos I, et al. Epidemics of West Nile and Sindbis viruses in South Africa with Culex (Culex) univittatus Theobold as vector. S Afr J Sci 1970; 72:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/13\">",
"      O'Leary DR, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/14\">",
"      Tsai TF, Popovici F, Cernescu C, et al. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998; 352:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/15\">",
"      Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/16\">",
"      Platonov AE, Shipulin GA, Shipulina OY, et al. Outbreak of West Nile virus infection, Volgograd Region, Russia, 1999. Emerg Infect Dis 2001; 7:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/17\">",
"      Drebot MA, Lindsay R, Barker IK, et al. West Nile virus surveillance and diagnostics: A Canadian perspective. Can J Infect Dis 2003; 14:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). West Nile Virus activity--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). West Nile virus activity--United States, November 20-25, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/20\">",
"      Lindsey NP, Staples JE, Lehman JA, et al. Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/21\">",
"      Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Serosurveys for West Nile virus infection--New York and Connecticut counties, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/23\">",
"      Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/24\">",
"      Busch MP, Wright DJ, Custer B, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/25\">",
"      Schellenberg TL, Anderson ME, Drebot MA, et al. Seroprevalence of West Nile virus in Saskatchewan's Five Hills Health Region, 2003. Can J Public Health 2006; 97:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/26\">",
"      Mattar S, Edwards E, Laguado J, et al. West Nile virus antibodies in Colombian horses. Emerg Infect Dis 2005; 11:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/27\">",
"      Pupo M, Guzm&aacute;n MG, Fern&aacute;ndez R, et al. West Nile Virus infection in humans and horses, Cuba. Emerg Infect Dis 2006; 12:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/28\">",
"      Cruz L, Cardenas VM, Abarca M, et al. Short report: serological evidence of West Nile virus activity in El Salvador. Am J Trop Med Hyg 2005; 72:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/29\">",
"      Quirin R, Salas M, Zientara S, et al. West Nile virus, Guadeloupe. Emerg Infect Dis 2004; 10:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/30\">",
"      Dupuis AP 2nd, Marra PP, Kramer LD. Serologic evidence of West Nile virus transmission, Jamaica, West Indies. Emerg Infect Dis 2003; 9:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/31\">",
"      Blitvich BJ, Fernandez-Salas I, Contreras-Cordero JF, et al. Serologic evidence of West Nile virus infection in horses, Coahuila State, Mexico. Emerg Infect Dis 2003; 9:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/32\">",
"      Dupuis AP 2nd, Marra PP, Reitsma R, et al. Serologic evidence for West Nile virus transmission in Puerto Rico and Cuba. Am J Trop Med Hyg 2005; 73:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/33\">",
"      Morales MA, Barrandeguy M, Fabbri C, et al. West Nile virus isolation from equines in Argentina, 2006. Emerg Infect Dis 2006; 12:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/34\">",
"      Estrada-Franco JG, Navarro-Lopez R, Beasley DW, et al. West Nile virus in Mexico: evidence of widespread circulation since July 2002. Emerg Infect Dis 2003; 9:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/35\">",
"      Beatty ME, Hunsperger E, Long E, et al. Mosquitoborne infections after Hurricane Jeanne, Haiti, 2004. Emerg Infect Dis 2007; 13:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/36\">",
"      Elizondo-Quiroga D, Davis CT, Fernandez-Salas I, et al. West Nile Virus isolation in human and mosquitoes, Mexico. Emerg Infect Dis 2005; 11:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/37\">",
"      Hub&aacute;lek Z, Halouzka J. West Nile fever--a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999; 5:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/38\">",
"      Kilpatrick AM, Daszak P, Jones MJ, et al. Host heterogeneity dominates West Nile virus transmission. Proc Biol Sci 2006; 273:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/39\">",
"      Bunning ML, Bowen RA, Cropp CB, et al. Experimental infection of horses with West Nile virus. Emerg Infect Dis 2002; 8:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/40\">",
"      Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005; 353:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/41\">",
"      Turell MJ, Sardelis MR, Dohm DJ, O'Guinn ML. Potential North American vectors of West Nile virus. Ann N Y Acad Sci 2001; 951:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/42\">",
"      Komar N, Langevin S, Hinten S, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis 2003; 9:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/43\">",
"      Komar O, Robbins MB, Klenk K, et al. West Nile virus transmission in resident birds, Dominican Republic. Emerg Infect Dis 2003; 9:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/44\">",
"      Swayne DE, Beck JR, Smith CS, et al. Fatal encephalitis and myocarditis in young domestic geese (Anser anser domesticus) caused by West Nile virus. Emerg Infect Dis 2001; 7:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/45\">",
"      LaDeau SL, Kilpatrick AM, Marra PP. West Nile virus emergence and large-scale declines of North American bird populations. Nature 2007; 447:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/46\">",
"      Brault AC, Huang CY, Langevin SA, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet 2007; 39:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/47\">",
"      Watson JT, Jones RC, Gibbs K, Paul W. Dead crow reports and location of human West Nile virus cases, Chicago, 2002. Emerg Infect Dis 2004; 10:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/48\">",
"      Johnson GD, Eidson M, Schmit K, et al. Geographic prediction of human onset of West Nile virus using dead crow clusters: an evaluation of year 2002 data in New York State. Am J Epidemiol 2006; 163:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/49\">",
"      Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/50\">",
"      Petersen LR, Epstein JS. Problem solved? West Nile virus and transfusion safety. N Engl J Med 2005; 353:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). West Nile virus transmission through blood transfusion--South Dakota, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/52\">",
"      Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). West Nile virus infections in organ transplant recipients--New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Intrauterine West Nile virus infection--New York, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory-acquired West Nile virus infections--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/56\">",
"      Fonseca K, Prince GD, Bratvold J, et al. West Nile virus infection and conjunctival exposure. Emerg Infect Dis 2005; 11:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/57\">",
"      Centers for Disease Control and Prevention (CDC). Possible dialysis-related west nile virus transmission--Georgia, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/58\">",
"      Centers for Disease Control and Prevention (CDC). Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/59\">",
"      Gea-Banacloche J, Johnson RT, Bagic A, et al. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004; 140:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/60\">",
"      Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 2006; 80:9349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/61\">",
"      Samuel MA, Wang H, Siddharthan V, et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 2007; 104:17140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/62\">",
"      Diamond MS, Shrestha B, Marri A, et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/63\">",
"      Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003; 188:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/64\">",
"      Tobler LH, Cameron MJ, Lanteri MC, et al. Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis 2008; 198:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/65\">",
"      Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005; 79:13350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/66\">",
"      Shrestha B, Wang T, Samuel MA, et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 2006; 80:5338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/67\">",
"      Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/68\">",
"      Chung KM, Liszewski MK, Nybakken G, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 2006; 103:19111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/69\">",
"      Ben-Nathan D, Huitinga I, Lustig S, et al. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol 1996; 141:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/70\">",
"      Guarner J, Shieh WJ, Hunter S, et al. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol 2004; 35:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/71\">",
"      Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol 2004; 61:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/72\">",
"      Kumar D, Drebot MA, Wong SJ, et al. A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant 2004; 4:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/73\">",
"      Kumar D, Prasad GV, Zaltzman J, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004; 77:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/74\">",
"      Patnaik JL, Harmon H, Vogt RL. Follow-up of 2003 human West Nile virus infections, Denver, Colorado. Emerg Infect Dis 2006; 12:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/75\">",
"      SOUTHAM CM, MOORE AE. West Nile, Ilheus, and Bunyamwera virus infections in man. Am J Trop Med Hyg 1951; 31:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/76\">",
"      SOUTHAM CM, MOORE AE. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 1954; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/77\">",
"      Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16088/abstract/78\">",
"      Lim JK, McDermott DH, Lisco A, et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 2010; 201:178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1304 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16088=[""].join("\n");
var outline_f15_45_16088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patterns of illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence in Canada",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence in Latin America and the Caribbean",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Birds as amplifying hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other routes of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dissemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Humoral and cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Role of interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of toll-like receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HOST SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=related_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=related_link\">",
"      Patient information: West Nile virus infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38023?source=related_link\">",
"      St. Louis encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33958?source=related_link\">",
"      Treatment and prevention of West Nile virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16089="Microsporidiosis";
var content_f15_45_16089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microsporidiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16089/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/45/16089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsporidia are intracellular spore-forming organisms that are ubiquitous in the environment and can infect a wide range of vertebrate and invertebrate hosts, including insects, birds, fish, and mammals. The clinical manifestations of microsporidiosis are diverse and include intestinal, pulmonary, ocular, muscular, and renal disease. Microsporidiosis has been identified in immunosuppressed hosts (eg, transplant and HIV-infected patients), travelers, children, and the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 150 genera and more than 1300 species of microsporidia have been described, which are classified based on spore size, arrangement of the nucleus, mode of replication within the host cell and rRNA analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/2\">",
"     2",
"    </a>",
"    ]. Microsporidia are considered protozoa, although comparative molecular phylogenetic studies support a relationship between the microsporidia and fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/1\">",
"     1",
"    </a>",
"    ]. Fourteen different species have been reported to infect humans, many of which were discovered as opportunistic infections in association with the AIDS epidemic (",
"    <a class=\"graphic graphic_table graphicRef70473 \" href=\"UTD.htm?34/47/35580\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The spores vary in size; those that infect humans are typically oval and 1 to 2 microns in diameter (",
"    <a class=\"graphic graphic_figure graphicRef78496 \" href=\"UTD.htm?24/8/24706\">",
"     figure 1",
"    </a>",
"    ). The spores are highly resistant to degradation and can survive in the environment for up to four months. Their structure is distinguished by the presence of a polar filament, which facilitates injection of the spore contents into the host cell.",
"   </p>",
"   <p>",
"    The most common species causing infection in humans is Enterocytozoon bieneusi, followed by the Encephalitozoon species, particularly Encephalitozoon intestinalis. E. bieneusi consists of multiple genotypes; 26 different genotypes have been found in humans only,",
"    <sup>",
"    </sup>",
"    and 8 genotypes reported in both humans",
"    <sup>",
"    </sup>",
"    and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/3\">",
"     3",
"    </a>",
"    ]. Among E. intestinalis isolates there have been no molecular differences observed among those originating from infected humans and infected animals, which may imply there is no transmission barrier between different",
"    <sup>",
"    </sup>",
"    host species. Other Encephalitozoon species causing human infection are E. cuniculi and E. hellem. Antigenic diversity has also been demonstrated among these isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    E. bieneusi and Encephalitozoon species usually infect the gastrointestinal and biliary tracts, although there have been a few case reports of isolation of E. bieneusi from the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/7\">",
"     7",
"    </a>",
"    ]. Enterocytozoon infections normally cause localized infection; in contrast, Encephalitozoon species have the ability to disseminate widely via macrophages, thus causing systemic infection involving the intestinal and hepatobiliary tracts, respiratory tract, sinuses, kidney, eye, and brain.",
"   </p>",
"   <p>",
"    Several other species are capable of causing disseminated disease, including Trachipleistophora species (T. hominis and T. anthropopthera), Pleistophora species (P. ronneafiei and others), and Anncaliia species, also known as Brachiola species (A. vesicularum and A. algerae) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/8\">",
"     8",
"    </a>",
"    ]. Nosema spp and Vittaforma cornea most commonly cause ocular infections. Myositis associated with Pleistophora spp, Trachipleistophora spp, and Anncaliia algerae has been described in individual reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/2,9-12\">",
"     2,9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of microsporidiosis is poorly understood. The minimal number of microsporidia required to cause human disease is unknown, and no toxins have been described. It is possible that a \"carrier state\" exists and that reactivation occurs with immunosuppression, although this has not been definitively documented [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intestinal disease is characterized by distortion of the villus architecture, particularly within the small intestine, without a significant inflammatory response. Progressive morphological and functional abnormalities of the small intestine appear to occur as the number of organisms increases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Infection may interfere with intestinal absorption and secretion. In one study of 21 patients with chronic diarrhea or wasting secondary to microsporidiosis, evidence of crypt hyperplasia and a decrease in villous absorptive surface area was demonstrated on jejunal biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some microsporidia species are associated with disseminated infection, which occur via spread by migrating macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/18\">",
"     18",
"    </a>",
"    ]. Antibodies to microsporidia are detectable in some patients, although their clinical significance is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsporidia spores typically enter the host via ingestion or inhalation. Once within the intestinal or respiratory tract, the spores are propelled into the host cell by their polar filament, enabling the infective sporoplasm (nucleus) to be injected from the spore into the host cell. Once within the host epithelial cell, proliferation occurs via merogony (binary fission) or schizogony (multiple fission) to form multinucleate plasmodial forms. This is followed by a period of maturation via a process known as sporogony, which involves thickening and development of the spore membranes, further divisions, and finally formation of new mature spores. These spores ultimately burst out of the infected cell, and the released spores can infect nearby host cells or pass out into the environment. Thus, the spores can complete their life cycle within a single host (",
"    <a class=\"graphic graphic_figure graphicRef78098 \" href=\"UTD.htm?14/59/15287\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsporidia exist worldwide, although an accurate assessment of their prevalence in the general population has not been established. In one European study of 576 immunocompetent adults, a seroprevalence of 5 to 8 percent was observed; the prevalence of diarrhea was not reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/19\">",
"     19",
"    </a>",
"    ]. In one review, the prevalence of microsporidiosis ranged from 1 to 42 percent in HIV positive individuals and from 0 to 24 percent in HIV negative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most symptomatic infections in humans occur among patients with HIV infection who are significantly immunocompromised (CD4 &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL).",
"    </span>",
"    The prevalence of infection rises with increased levels of immunosuppression, ranging from 7 to 50 percent in reports of symptomatic patients with diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/2,21-29\">",
"     2,21-29",
"    </a>",
"    ]. In a study of 2652 HIV-infected patients with diarrhea in Peru, 3 percent were diagnosed with microsporidiosis; risk factors included contact with duck or chicken droppings and poor sanitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HIV infection may also be asymptomatic. In one study of 106 patients with HIV infection, 15 percent of patients had evidence of microsporidia on small bowel biopsy, regardless of intestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/31\">",
"     31",
"    </a>",
"    ]. However, much lower colonization rates have been observed in other reports of HIV patients without diarrhea (approximately 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/21,32\">",
"     21,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microsporidia infections have also been described in HIV-negative patients who are otherwise immunocompromised, such as organ transplant recipients and bone marrow graft recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. Among renal transplant recipients, it is a relatively late-occurring opportunistic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/39\">",
"     39",
"    </a>",
"    ]. Elderly individuals may also be at risk for microsporidiosis; in one report of 47 elderly patients with diarrhea, intestinal microsporidiosis due to E. bieneusi was identified in 17 percent of cases by polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection can also occur in immunocompetent hosts, largely in the form of diarrheal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. E. intestinalis has been found in stool samples of travelers with chronic diarrhea, but a pathogenic role has not been definitively demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unknown whether microsporidia infection routinely persists in a latent state or if reactivation occurs during conditions of immune compromise. It is also unknown if persistently infected individuals can transmit infection to others at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of microsporidiosis is not fully understood. Foodborne, waterborne, person-to-person, animal-to-person, vector-borne, and airborne transmission may all be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/13,14,20,45-48\">",
"     13,14,20,45-48",
"    </a>",
"    ]. Microsporidia spores have been detected in urine, feces, and respiratory secretions.",
"   </p>",
"   <p>",
"    Many animals shed E. bieneusi oocysts; it is uncertain whether household pets represent a source of human infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/49\">",
"     49",
"    </a>",
"    ]. E. intestinalis has been identified in humans and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of microsporidiosis vary depending upon the infecting species and the host immune status. Both asymptomatic and symptomatic infections have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunocompetent patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsporidia can cause asymptomatic infection, a self-limited diarrheal illness or, less commonly, chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Clinical manifestations include watery, nonbloody diarrhea, nausea, diffuse abdominal pain, and fever. Diarrhea tends to be self-limited in immunocompetent patients. The correlation between detection of microsporidia in stool and gastrointestinal symptoms may be transient; microsporidia infection may cause clinical symptoms during the early stages of infection that resolve even though evidence of microsporidia may persist on diagnostic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to diarrhea, other manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular infections with superficial punctate keratitis and stromal keratitis",
"      <sup>",
"      </sup>",
"      associated with eye pain have been reported in immunocompetent patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Risk factors include contact lens use, eye surgery, use of topical corticosteroids, and exposure to soil, mud, dirty water, or thermal springs [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/58\">",
"       58",
"      </a>",
"      ]. Associated organisms include Microsporidium africanus, Microsporidium ceylonensis, N. ocularum, N. corneum (now V. cornea), and A. algerae [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/59-61\">",
"       59-61",
"      </a>",
"      ]. Outcomes have included enucleation, corneal transplant, and keratoplasty (with variable success).",
"     </li>",
"     <li>",
"      Cerebral infections due to E. cuniculi have been reportedly rarely in immunocompetent individuals. Manifestations include seizures, headache, and vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. One case of pacemaker endocarditis due to E. cuniculi has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myositis associated with Pleistophora spp and Brachiola algerae (recently reclassified as Anncaliia algerae) has been described in individual reports [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/2,9-11\">",
"       2,9-11",
"      </a>",
"      ]. Symptoms include fever, myalgia, weakness, and muscle tenderness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of microsporidiosis has declined dramatically with the widespread use of antiretroviral therapy. Most microsporidial infections occur in the setting of severe immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/65\">",
"     65",
"    </a>",
"    ]. In one retrospective study of 42 patients with microsporidia identified on modified trichrome blue stain, the median CD4 cell count was 20",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    E. bieneusi or E. intestinalis are most commonly associated with diarrhea, which is typically nonbloody, watery, may be continuous or intermittent, and can be associated with crampy abdominal pain. Patients may also have weight loss, wasting, nausea and vomiting, and malabsorption; fever is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other disorders associated with the individual microsporidia species have been described in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      E. bieneusi or E. intestinalis infection can lead to biliary tract involvement, causing cholangitis or acalculous cholecystitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/2,68\">",
"       2,68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"       \"AIDS cholangiopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      E. bieneusi has been identified in nasal and bronchial secretions, although its clinical significance is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/7,66,69-71\">",
"       7,66,69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      E. intestinalis disseminates widely and has been implicated in sinus, respiratory, liver, and renal disease. The renal disease is often asymptomatic, although impaired renal function has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Encephalitozoon hellem, Encephalitozoon cuniculi, and Trachipleistophora species usually cause disseminated infection, including bronchiolitis, pneumonitis, sinusitis, nephritis, cystitis, prostatitis, hepatitis, peritonitis, chronic keratoconjunctivitis, encephalitis, and nodular cutaneous lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/15,72,73\">",
"       15,72,73",
"      </a>",
"      ]. Some patients are asymptomatic. Intestinal infection with E. cuniculi is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trachipleistophora hominis, a newly described species, and Pleistophora spp have been associated with myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/9,12,75\">",
"       9,12,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vittaforma corneae has been isolated from urine and sinonasal aspirate in a patient with AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Encephalitozoon cuniculi has been reported to cause central nervous system infection in one AIDS patient with multifocal hypodense lesions on brain imaging; the diagnosis was established with the detection of microsporidial spores in cerebrospinal fluid, sputum, stool, and urine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. Trachipleistophora species have also been associated with encephalitis and death [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective review of 73 HIV-infected patients with microsporidiosis describing the natural history of infection, 55 percent of patients had persistent diarrhea after six months and 51 percent had weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/79\">",
"     79",
"    </a>",
"    ]. Symptomatic disease was associated with a high RNA viral load and absence of protease inhibitors from the antiretroviral regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of microsporidiosis consists of microscopic detection of the spores in stool, body fluids, or tissue specimens. Endoscopic biopsy is not more sensitive than stool examination because infection can be patchy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/66,80\">",
"     66,80",
"    </a>",
"    ]. The spores are typically oval and 1 to 2 mcm in diameter.",
"   </p>",
"   <p>",
"    The laboratory should be alerted to the potential diagnosis, and specific stains for microsporidia should be requested since routine examination for ova and parasites does not usually detect microsporidia spores. Fecal leukocytes and blood are usually absent since microsporidia infection is not associated with a significant inflammation. When present, these findings should raise suspicion for coinfection with another organism.",
"   </p>",
"   <p>",
"    Light microscopy with a modified trichrome stain is often used for microscopy. This technique stains microsporidia spores pink against a blue-green background; it can be used on stool, urine, mucus, or tissue specimens (",
"    <a class=\"graphic graphic_figure graphicRef78496 \" href=\"UTD.htm?24/8/24706\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Other techniques include serologic assays (which detect IgM and IgG anti-microsporidial antibodies), tissue culture, and indirect immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/83-91\">",
"     83-91",
"    </a>",
"    ]. Fluorescent techniques including Uvitex 2B (Ciba Geigy), Calcofluor White M2R (Sigma), the FungiFluor Kit (Polysciences) and Fungiqual A are also available and have similar sensitivity and specificity to the modified trichrome stain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/80,92,93\">",
"     80,92,93",
"    </a>",
"    ]. These stains have a number of advantages compared to other methods because they can be performed rapidly, are equally effective on unfixed or formalin-fixed specimens, and can detect spores in stool, intestinal fluid, biopsy imprints, and paraffin biopsy sections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. However, species identification is not possible.",
"   </p>",
"   <p>",
"    Transmission electron microscopy (TEM) is also used for microscopic detection of microsporidia, and traditionally has been the primary method for species identification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/77\">",
"     77",
"    </a>",
"    ]. Alternatively, classification can be based on molecular sequencing. Polymerase chain reaction (PCR) assays for the simultaneous detection and species identification of microsporidial infections have been developed, although in general are performed only in specialized laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/46,94-100\">",
"     46,94-100",
"    </a>",
"    ]. Indirect immunofluorescence using monoclonal antibodies to Encephalitozoon spp and to E. bieneusi are becoming increasingly available and are simplifying detection of microsporidia in clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of any of the above techniques depends in part upon the site and intensity of infection. However, the following test characteristics were observed in one study comparing the different methods to electron microscopy as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/90\">",
"     90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modified trichrome stain &mdash; sensitivity and specificity of 100 and 83 percent, respectively.",
"     </li>",
"     <li>",
"      Calcoflour White stain &mdash; sensitivity and specificity of 100 and 77 percent, respectively.",
"     </li>",
"     <li>",
"      Indirect immunofluorescent stain &mdash; sensitivity and specificity of 83 and 96 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20620119\">",
"    <span class=\"h2\">",
"     Gastrointestinal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is effective against most microsporidia species, particularly Encephalitozoon infections, but has minimal efficacy against E. bieneusi (",
"    <a class=\"graphic graphic_table graphicRef54051 \" href=\"UTD.htm?38/35/39485\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/104-107\">",
"     104-107",
"    </a>",
"    ]. The duration of therapy depends on the host immune status and whether the infection is localized or disseminated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/108\">",
"     108",
"    </a>",
"    ]. In immunocompromised patients with disseminated infection, the usual treatment is two to four weeks of albendazole (400 mg orally twice daily).",
"   </p>",
"   <p>",
"    Immunocompetent hosts can receive shorter courses of therapy and may even resolve their symptoms with no therapy at all. In a randomized trial including immunocompetent 200 children in Costa Rica hospitalized with subacute diarrhea due to microsporidiosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    twice daily for seven days) was more effective than placebo in improving the clinical manifestations and decreasing the duration of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    does not reliably cure E. bieneusi infections, many other agents have been tried including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , sparfloxacin, quinacrine, sulfa drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    , furazolidone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    . None of these agents has consistently or effectively eradicated the infection; further study is needed.",
"   </p>",
"   <p>",
"    Along with specific therapy for microsporidiosis, treatment of immune suppression is critically important in patients with HIV infection, since restoration of immunity has been associated with clinical and microbiological cure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. Clearance of microsporidial infections has even been reported with antiretroviral therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Dietary supplementation is also helpful, particularly in patients who have had weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For treatment of E. bieneusi infection, systemic fumagillin (60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally in three divided doses for 14 days) has been tried with some success [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. In one small dose-response study of fumagillin in HIV-infected patients with E. bieneusi infection, the highest dose of 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with clearance of the organism in 72 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/117\">",
"     117",
"    </a>",
"    ]. The majority of patients in the lower dose groups had transient clearance from stools but all relapsed within one year. Fumagillin may also be active in other immunosuppressed hosts. A randomized, double-blind study in 12 patients (10 with HIV and 2 post-transplantation) documented clearance of the organism in all patients who received fumagillin and in none of patients receiving placebo; the six placebo recipients subsequently cleared the organism with open-label fumagillin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/118\">",
"     118",
"    </a>",
"    ]. In a report of 10 cases of E. bieneusi in renal transplant patients who were treated with fumagillin, all patients responded well clinically and all cleared the microsporidial spores from their stools [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fumagillin can cause dose related bone marrow toxicity. In addition, abdominal pain, diarrhea, vomiting, and hyperlipasemia have been noted with the use of fumagillin. These adverse effects have limited the clinical use of the drug, and it is not available for systemic use in the United States. A less toxic analogue of fumagillin is under evaluation, as are combination therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/112,119-121\">",
"     112,119-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other agents being studied in vivo against microsporidia include polyamines and fluoroquinolones, but clinical data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/122\">",
"     122",
"    </a>",
"    ]. Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    (1 g twice daily) for 60 days may also be effective for the treatment of E. bieneusi infections in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20620126\">",
"    <span class=\"h2\">",
"     Ocular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular infections due to microsporidia should be treated with topical Fumidil B (fumagillin bicyclohexylammonium) in saline (to achieve a concentration of 70",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of fumagillin) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/124\">",
"     124",
"    </a>",
"    ]. In HIV infected patients, lesions due to E. hellem may respond to this regimen, although lesions due to V. corneae generally respond poorly to topical therapy and keratoplasty may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. The concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is often warranted, particularly in patients with ocular infections who have evidence of systemic involvement. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (1 percent) has been reported to be effective for treatment of microsporidial keratitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/127\">",
"     127",
"    </a>",
"    ], and success has also been reported with topical fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/128\">",
"     128",
"    </a>",
"    ]; further trials are needed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    has also been used in the treatment of ocular microsporidiosis (especially superficial keratoconjunctivitis) due to Encephalitozoon spp; experience with this agent is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/108\">",
"     108",
"    </a>",
"    ]. In cases not responsive to medical therapy, keratoplasty and debulking by corneal scraping has been tried [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16089/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885865781\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to management in pregnancy is uncertain;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is pregnancy category C and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    is category B. Minimizing immunosuppression is an important component of management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific measures important in preventing infection are not known since the sources of infection are not fully understood. Attention to personal hygiene is probably the most important factor. Boiled",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bottled water may also be helpful for immunosuppressed patients, but the relative importance of tap water as a source of infection is still unknown. No vaccine is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10139391\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microsporidia are intracellular spore-forming organisms that are ubiquitous in the environment and can infect a wide range of vertebrate and invertebrate hosts. Fourteen different species have been reported in humans, many of which were discovered as opportunistic infections in association with the AIDS epidemic (",
"      <a class=\"graphic graphic_table graphicRef70473 \" href=\"UTD.htm?34/47/35580\">",
"       table 1",
"      </a>",
"      ). The most common species causing infection in humans is Enterocytozoon bieneusi, followed by the Encephalitozoon species, particularly Encephalitozoon intestinalis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of microsporidiosis is not fully understood. Microsporidia spores typically enter the host via ingestion or inhalation. Most symptomatic infections in humans occur among patients with HIV infection who are significantly immunocompromised (CD4 &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      or other immunocompromised individuals (such as organ transplant recipients). Microsporidiosis can also occur in immunocompetent individuals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations include watery, nonbloody diarrhea, nausea, diffuse abdominal pain, and fever. Among immunocompetent and immunosuppressed individuals, other manifestations include ocular infection, cerebral infection, and myositis. In addition, a variety of other manifestations can occur in the setting of HIV infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of microsporidiosis consists of microscopic detection of the spores in stool, body fluids, or tissue specimens. Light microscopy with a modified trichrome stain demonstrates pink microsporidia spores against a blue-green background (",
"      <a class=\"graphic graphic_figure graphicRef78496 \" href=\"UTD.htm?24/8/24706\">",
"       figure 1",
"      </a>",
"      ). The laboratory should be alerted to the potential diagnosis, and specific stains for microsporidia should be requested since routine examination for ova and parasites does not usually detect microsporidia spores. Other assays have also been described. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg orally twice daily for two to four weeks) for treatment of intestinal microsporidiosis due to E. intestinalis, and for treatment of disseminated microsporidiosis (",
"      <a class=\"graphic graphic_table graphicRef54051 \" href=\"UTD.htm?38/35/39485\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The optimal approach for treatment of intestinal infection due to E. bieneusi or for treatment of ocular infection is uncertain; fumagillin may be effective though further study is needed. Reversal of immune suppression whenever possible is also important. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/1\">",
"      Didier ES, Weiss LM. Microsporidiosis: current status. Curr Opin Infect Dis 2006; 19:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/2\">",
"      Weber R, Bryan RT, Schwartz DA, Owen RL. Human microsporidial infections. Clin Microbiol Rev 1994; 7:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/3\">",
"      Sant&iacute;n M, Fayer R. Enterocytozoon bieneusi genotype nomenclature based on the internal transcribed spacer sequence: a consensus. J Eukaryot Microbiol 2009; 56:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/4\">",
"      Mo L, Drancourt M. Antigenic diversity of Encephalitozoon hellem demonstrated by subspecies-specific monoclonal antibodies. J Eukaryot Microbiol 2002; 49:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/5\">",
"      Xiao L, Li L, Visvesvara GS, et al. Genotyping Encephalitozoon cuniculi by multilocus analyses of genes with repetitive sequences. J Clin Microbiol 2001; 39:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/6\">",
"      Xiao L, Li L, Moura H, et al. Genotyping Encephalitozoon hellem isolates by analysis of the polar tube protein gene. J Clin Microbiol 2001; 39:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/7\">",
"      Botterel F, Minozzi C, Vittecoq D, Bour&eacute;e P. Pulmonary localization of Enterocytozoon bieneusi in an AIDS patient: case report and review. J Clin Microbiol 2002; 40:4800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/8\">",
"      Walker M, Kublin JG, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin Infect Dis 2006; 42:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/9\">",
"      Chupp GL, Alroy J, Adelman LS, et al. Myositis due to Pleistophora (Microsporidia) in a patient with AIDS. Clin Infect Dis 1993; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/10\">",
"      Coyle CM, Weiss LM, Rhodes LV 3rd, et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004; 351:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/11\">",
"      Cali A, Takvorian PM. Ultrastructure and development of Pleistophora ronneafiei n. sp., a microsporidium (Protista) in the skeletal muscle of an immune-compromised individual. J Eukaryot Microbiol 2003; 50:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/12\">",
"      Curry A, Beeching NJ, Gilbert JD, et al. Trachipleistophora hominis infection in the myocardium and skeletal muscle of a patient with AIDS. J Infect 2005; 51:e139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/13\">",
"      Bryan RT. Microsporidiosis as an AIDS-related opportunistic infection. Clin Infect Dis 1995; 21 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/14\">",
"      Didier ES. Microsporidiosis. Clin Infect Dis 1998; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/15\">",
"      Kotler DP, Orenstein JM. Clinical syndromes associated with microsporidiosis. Adv Parasitol 1998; 40:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/16\">",
"      Orenstein JM, Chiang J, Steinberg W, et al. Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patients: a report of 20 cases. Hum Pathol 1990; 21:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/17\">",
"      Batman PA, Kotler DP, Kapembwa MS, et al. HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa. AIDS 2007; 21:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/18\">",
"      Orenstein JM, Gaetz HP, Yachnis AT, et al. Disseminated microsporidiosis in AIDS: are any organs spared? AIDS 1997; 11:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/19\">",
"      van Gool T, Vetter JC, Weinmayr B, et al. High seroprevalence of Encephalitozoon species in immunocompetent subjects. J Infect Dis 1997; 175:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/20\">",
"      Anane S, Attouchi H. Microsporidiosis: epidemiology, clinical data and therapy. Gastroenterol Clin Biol 2010; 34:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/21\">",
"      Kotler DP, Orenstein JM. Prevalence of intestinal microsporidiosis in HIV-infected individuals referred for gastroenterological evaluation. Am J Gastroenterol 1994; 89:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/22\">",
"      Eeftinck Schattenkerk JK, van Gool T, van Ketel RJ, et al. Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet 1991; 337:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/23\">",
"      Kotler DP, Francisco A, Clayton F, et al. Small intestinal injury and parasitic diseases in AIDS. Ann Intern Med 1990; 113:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/24\">",
"      Conteas CN, Berlin OG, Lariviere MJ, et al. Examination of the prevalence and seasonal variation of intestinal microsporidiosis in the stools of persons with chronic diarrhea and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 58:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/25\">",
"      Framm SR, Soave R. Agents of diarrhea. Med Clin North Am 1997; 81:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/26\">",
"      Wuhib T, Silva TM, Newman RD, et al. Cryptosporidial and microsporidial infections in human immunodeficiency virus-infected patients in northeastern Brazil. J Infect Dis 1994; 170:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/27\">",
"      Drobniewski F, Kelly P, Carew A, et al. Human microsporidiosis in African AIDS patients with chronic diarrhea. J Infect Dis 1995; 171:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/28\">",
"      van Gool T, Luderhoff E, Nathoo KJ, et al. High prevalence of Enterocytozoon bieneusi infections among HIV-positive individuals with persistent diarrhoea in Harare, Zimbabwe. Trans R Soc Trop Med Hyg 1995; 89:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/29\">",
"      Sobottka I, Schwartz DA, Schottelius J, et al. Prevalence and clinical significance of intestinal microsporidiosis in human immunodeficiency virus-infected patients with and without diarrhea in Germany: a prospective coprodiagnostic study. Clin Infect Dis 1998; 26:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/30\">",
"      Bern C, Kawai V, Vargas D, et al. The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru. J Infect Dis 2005; 191:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/31\">",
"      Rabeneck L, Gyorkey F, Genta RM, et al. The role of Microsporidia in the pathogenesis of HIV-related chronic diarrhea. Ann Intern Med 1993; 119:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/32\">",
"      Coyle CM, Wittner M, Kotler DP, et al. Prevalence of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon (Septata) intestinalis among patients with AIDS-related diarrhea: determination by polymerase chain reaction to the microsporidian small-subunit rRNA gene. Clin Infect Dis 1996; 23:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/33\">",
"      Weber R, Bryan RT. Microsporidial infections in immunodeficient and immunocompetent patients. Clin Infect Dis 1994; 19:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/34\">",
"      Sax PE, Rich JD, Pieciak WS, Trnka YM. Intestinal microsporidiosis occurring in a liver transplant recipient. Transplantation 1995; 60:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/35\">",
"      Gumbo T, Hobbs RE, Carlyn C, et al. Microsporidia infection in transplant patients. Transplantation 1999; 67:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/36\">",
"      Rabodonirina M, Bertocchi M, Desportes-Livage I, et al. Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart-lung transplant recipient who was seronegative for human immunodeficiency virus. Clin Infect Dis 1996; 23:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/37\">",
"      Metge S, Van Nhieu JT, Dahmane D, et al. A case of Enterocytozoon bieneusi infection in an HIV-negative renal transplant recipient. Eur J Clin Microbiol Infect Dis 2000; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/38\">",
"      Lanternier F, Boutboul D, Menotti J, et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/39\">",
"      Champion L, Durrbach A, Lang P, et al. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. Am J Transplant 2010; 10:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/40\">",
"      Lores B, L&oacute;pez-Miragaya I, Arias C, et al. Intestinal microsporidiosis due to Enterocytozoon bieneusi in elderly human immunodeficiency virus--negative patients from Vigo, Spain. Clin Infect Dis 2002; 34:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/41\">",
"      Fournier S, Liguory O, Garrait V, et al. Microsporidiosis due to Enterocytozoon bieneusi infection as a possible cause of traveller's diarrhea. Eur J Clin Microbiol Infect Dis 1998; 17:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/42\">",
"      Bryan RT, Weber R, Schwartz DA. Microsporidiosis in patients who are not infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/43\">",
"      L&oacute;pez-V&eacute;lez R, Turrientes MC, Garr&oacute;n C, et al. Microsporidiosis in travelers with diarrhea from the tropics. J Travel Med 1999; 6:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/44\">",
"      Raynaud L, Delbac F, Broussolle V, et al. Identification of Encephalitozoon intestinalis in travelers with chronic diarrhea by specific PCR amplification. J Clin Microbiol 1998; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/45\">",
"      Decraene V, Lebbad M, Botero-Kleiven S, et al. First reported foodborne outbreak associated with microsporidia, Sweden, October 2009. Epidemiol Infect 2012; 140:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/46\">",
"      Didier ES, Stovall ME, Green LC, et al. Epidemiology of microsporidiosis: sources and modes of transmission. Vet Parasitol 2004; 126:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/47\">",
"      Cotte L, Rabodonirina M, Chapuis F, et al. Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection. J Infect Dis 1999; 180:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/48\">",
"      Slodkowicz-Kowalska A, Graczyk TK, Tamang L, et al. Microsporidian species known to infect humans are present in aquatic birds: implications for transmission via water? Appl Environ Microbiol 2006; 72:4540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/49\">",
"      Hutin YJ, Sombardier MN, Liguory O, et al. Risk factors for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study. J Infect Dis 1998; 178:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/50\">",
"      Bornay-Llinares FJ, da Silva AJ, Moura H, et al. Immunologic, microscopic, and molecular evidence of Encephalitozoon intestinalis (Septata intestinalis) infection in mammals other than humans. J Infect Dis 1998; 178:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/51\">",
"      Cegielski JP, Ortega YR, McKee S, et al. Cryptosporidium, enterocytozoon, and cyclospora infections in pediatric and adult patients with diarrhea in Tanzania. Clin Infect Dis 1999; 28:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/52\">",
"      Sandfort J, Hannemann A, Gelderblom H, et al. Enterocytozoon bieneusi infection in an immunocompetent patient who had acute diarrhea and who was not infected with the human immunodeficiency virus. Clin Infect Dis 1994; 19:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/53\">",
"      Wanke CA, DeGirolami P, Federman M. Enterocytozoon bieneusi infection and diarrheal disease in patients who were not infected with human immunodeficiency virus: case report and review. Clin Infect Dis 1996; 23:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/54\">",
"      Gainzarain JC, Canut A, Lozano M, et al. Detection of Enterocytozoon bieneusi in two human immunodeficiency virus-negative patients with chronic diarrhea by polymerase chain reaction in duodenal biopsy specimens and review. Clin Infect Dis 1998; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/55\">",
"      Wichro E, Hoelzl D, Krause R, et al. Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients. Am J Trop Med Hyg 2005; 73:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/56\">",
"      Lewis NL, Francis IC, Hawkins GS, Coroneo MT. Bilateral microsporidial keratoconjunctivitis in an immunocompetent non-contact lens wearer. Cornea 2003; 22:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/57\">",
"      Chan CM, Theng JT, Li L, Tan DT. Microsporidial keratoconjunctivitis in healthy individuals: a case series. Ophthalmology 2003; 110:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/58\">",
"      Fan NW, Wu CC, Chen TL, et al. Microsporidial keratitis in patients with hot springs exposure. J Clin Microbiol 2012; 50:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/59\">",
"      Visvesvara GS, Belloso M, Moura H, et al. Isolation of Nosema algerae from the cornea of an immunocompetent patient. J Eukaryot Microbiol 1999; 46:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/60\">",
"      Ashton N, Wirasinha PA. Encephalitozoonosis (nosematosis) of the cornea. Br J Ophthalmol 1973; 57:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/61\">",
"      Cali A, Meisler DM, Lowder CY, et al. Corneal microsporidioses: characterization and identification. J Protozool 1991; 38:215S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/62\">",
"      Bergquist NR, Stintzing G, Smedman L, et al. Diagnosis of encephalitozoonosis in man by serological tests. Br Med J (Clin Res Ed) 1984; 288:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/63\">",
"      MATSUBAYASHI H, KOIKE T, MIKATA I, et al. A case of Encephalitozoon-like body infection in man. AMA Arch Pathol 1959; 67:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/64\">",
"      Filho MM, Ribeiro HB, Paula LJ, et al. Images in cardiovascular medicine. Endocarditis secondary to microsporidia: giant vegetation in a pacemaker user. Circulation 2009; 119:e386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/65\">",
"      Dore GJ, Marriott DJ, Hing MC, et al. Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Clin Infect Dis 1995; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/66\">",
"      Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/67\">",
"      American Gastroenterological Association medical position statement: guidelines for the management of malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroenterology 1996; 111:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/68\">",
"      Pol S, Romana CA, Richard S, et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993; 328:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/69\">",
"      Weber R, Kuster H, Keller R, et al. Pulmonary and intestinal microsporidiosis in a patient with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1992; 146:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/70\">",
"      del Aguila C, Lopez-Velez R, Fenoy S, et al. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J Clin Microbiol 1997; 35:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/71\">",
"      Georges E, Rabaud C, Amiel C, et al. Enterocytozoon bieneusi multiorgan microsporidiosis in a HIV-infected patient. J Infect 1998; 36:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/72\">",
"      Schwartz DA, Visvesvara GS, Leitch GJ, et al. Pathology of symptomatic microsporidial (Encephalitozoon hellem) bronchiolitis in the acquired immunodeficiency syndrome: a new respiratory pathogen diagnosed from lung biopsy, bronchoalveolar lavage, sputum, and tissue culture. Hum Pathol 1993; 24:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/73\">",
"      Scaglia M, Gatti S, Sacchi L, et al. Asymptomatic respiratory tract microsporidiosis due to Encephalitozoon hellem in three patients with AIDS. Clin Infect Dis 1998; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/74\">",
"      Franzen C, Schwartz DA, Visvesvara GS, et al. Immunologically confirmed disseminated, asymptomatic Encephalitozoon cuniculi infection of the gastrointestinal tract in a patient with AIDS. Clin Infect Dis 1995; 21:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/75\">",
"      Hollister WS, Canning EU, Weidner E, et al. Development and ultrastructure of Trachipleistophora hominis n.g., n.sp. after in vitro isolation from an AIDS patient and inoculation into athymic mice. Parasitology 1996; 112 ( Pt 1):143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/76\">",
"      Deplazes P, Mathis A, van Saanen M, et al. Dual microsporidial infection due to Vittaforma corneae and Encephalitozoon hellem in a patient with AIDS. Clin Infect Dis 1998; 27:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/77\">",
"      Walker M, Kublin JG, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin Infect Dis 2006; 42:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/78\">",
"      Weber R, Deplazes P, Flepp M, et al. Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection. N Engl J Med 1997; 336:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/79\">",
"      Dascomb K, Clark R, Aberg J, et al. Natural history of intestinal microsporidiosis among patients infected with human immunodeficiency virus. J Clin Microbiol 1999; 37:3421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/80\">",
"      DeGirolami PC, Ezratty CR, Desai G, et al. Diagnosis of intestinal microsporidiosis by examination of stool and duodenal aspirate with Weber's modified trichrome and Uvitex 2B strains. J Clin Microbiol 1995; 33:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/81\">",
"      Ryan NJ, Sutherland G, Coughlan K, et al. A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens. J Clin Microbiol 1993; 31:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/82\">",
"      Matos O, Lobo ML, Gon&ccedil;alves L, Antunes F. Diagnostic use of 3 techniques for identification of microsporidian spores among AIDS patients in Portugal. Scand J Infect Dis 2002; 34:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/83\">",
"      Conteas CN, Sowerby T, Berlin GW, et al. Fluorescence techniques for diagnosing intestinal microsporidiosis in stool, enteric fluid, and biopsy specimens from acquired immunodeficiency syndrome patients with chronic diarrhea. Arch Pathol Lab Med 1996; 120:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/84\">",
"      Fedorko DP, Hijazi YM. Application of molecular techniques to the diagnosis of microsporidial infection. Emerg Infect Dis 1996; 2:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/85\">",
"      van Gool T, Snijders F, Reiss P, et al. Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol 1993; 46:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/86\">",
"      Weiss LM, Vossbrinck CR. Microsporidiosis: molecular and diagnostic aspects. Adv Parasitol 1998; 40:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/87\">",
"      M&uuml;ller A, Stellermann K, Hartmann P, et al. A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens. Clin Diagn Lab Immunol 1999; 6:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/88\">",
"      Liguory O, David F, Sarfati C, et al. Diagnosis of infections caused by Enterocytozoon bieneusi and Encephalitozoon intestinalis using polymerase chain reaction in stool specimens. AIDS 1997; 11:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/89\">",
"      Franzen C, M&uuml;ller A. Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia. Clin Microbiol Rev 1999; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/90\">",
"      Didier ES, Orenstein JM, Aldras A, et al. Comparison of three staining methods for detecting microsporidia in fluids. J Clin Microbiol 1995; 33:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/91\">",
"      Accoceberry I, Thellier M, Desportes-Livage I, et al. Production of monoclonal antibodies directed against the microsporidium Enterocytozoon bieneusi. J Clin Microbiol 1999; 37:4107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/92\">",
"      Weber R, Bryan RT, Owen RL, et al. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. The Enteric Opportunistic Infections Working Group. N Engl J Med 1992; 326:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/93\">",
"      Ignatius R, Henschel S, Liesenfeld O, et al. Comparative evaluation of modified trichrome and Uvitex 2B stains for detection of low numbers of microsporidial spores in stool specimens. J Clin Microbiol 1997; 35:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/94\">",
"      Conners MS, Gibler TS, Van Gelder RN. Diagnosis of microsporidia keratitis by polymerase chain reaction. Arch Ophthalmol 2004; 122:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/95\">",
"      Fedorko DP, Nelson NA, Didier ES, et al. Speciation of human microsporidia by polymerase chain reaction single-strand conformation polymorphism. Am J Trop Med Hyg 2001; 65:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/96\">",
"      Hester JD, Varma M, Bobst AM, et al. Species-specific detection of three human-pathogenic microsporidial species from the genus Encephalitozoon via fluorogenic 5' nuclease PCR assays. Mol Cell Probes 2002; 16:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/97\">",
"      Menotti J, Cassinat B, Porcher R, et al. Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis. J Infect Dis 2003; 187:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/98\">",
"      Subrungruang I, Mungthin M, Chavalitshewinkoon-Petmitr P, et al. Evaluation of DNA extraction and PCR methods for detection of Enterocytozoon bienuesi in stool specimens. J Clin Microbiol 2004; 42:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/99\">",
"      Wolk DM, Schneider SK, Wengenack NL, et al. Real-time PCR method for detection of Encephalitozoon intestinalis from stool specimens. J Clin Microbiol 2002; 40:3922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/100\">",
"      Polley SD, Boadi S, Watson J, et al. Detection and species identification of microsporidial infections using SYBR Green real-time PCR. J Med Microbiol 2011; 60:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/101\">",
"      Mo L, Drancourt M. Monoclonal antibodies for specific detection of Encephalitozoon cuniculi. Clin Diagn Lab Immunol 2004; 11:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/102\">",
"      Sheoran AS, Feng X, Singh I, et al. Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin Diagn Lab Immunol 2005; 12:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/103\">",
"      Al-Mekhlafi MA, Fatmah MS, Anisah N, et al. Species identification of intestinal microsporidia using immunofluorescence antibody assays. Southeast Asian J Trop Med Public Health 2011; 42:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/104\">",
"      Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/105\">",
"      Dionisio D, Manneschi LI, Di Lollo S, et al. Persistent damage to Enterocytozoon bieneusi, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients. J Clin Pathol 1998; 51:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/106\">",
"      Maggi P, Larocca AM, Quarto M, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000; 19:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/107\">",
"      Gross U. Treatment of microsporidiosis including albendazole. Parasitol Res 2003; 90 Supp 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/108\">",
"      Costa SF, Weiss LM. Drug treatment of microsporidiosis. Drug Resist Updat 2000; 3:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/109\">",
"      Tremoulet AH, Avila-Aguero ML, Par&iacute;s MM, et al. Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children. Pediatr Infect Dis J 2004; 23:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/110\">",
"      Goguel J, Katlama C, Sarfati C, et al. Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy. AIDS 1997; 11:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/111\">",
"      Carr A, Marriott D, Field A, et al. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/112\">",
"      Conteas CN, Berlin OG, Ash LR, Pruthi JS. Therapy for human gastrointestinal microsporidiosis. Am J Trop Med Hyg 2000; 63:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/113\">",
"      Conteas CN, Berlin OG, Speck CE, et al. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998; 58:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/114\">",
"      Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/115\">",
"      Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/116\">",
"      Molina JM, Goguel J, Sarfati C, et al. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. The French Microsporidiosis Study Group. AIDS 1997; 11:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/117\">",
"      Molina JM, Goguel J, Sarfati C, et al. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA. AIDS 2000; 14:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/118\">",
"      Molina JM, Tourneur M, Sarfati C, et al. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002; 346:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/119\">",
"      Didier ES. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob Agents Chemother 1997; 41:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/120\">",
"      Didier ES, Maddry JA, Kwong CD, et al. Screening of compounds for antimicrosporidial activity in vitro. Folia Parasitol (Praha) 1998; 45:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/121\">",
"      Coyle C, Kent M, Tanowitz HB, et al. TNP-470 is an effective antimicrosporidial agent. J Infect Dis 1998; 177:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/122\">",
"      Didier ES, Maddry JA, Brindley PJ, et al. Therapeutic strategies for human microsporidia infections. Expert Rev Anti Infect Ther 2005; 3:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/123\">",
"      Bicart-S&eacute;e A, Massip P, Linas MD, Datry A. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob Agents Chemother 2000; 44:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/124\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/125\">",
"      Davis RM, Font RL, Keisler MS, Shadduck JA. Corneal microsporidiosis. A case report including ultrastructural observations. Ophthalmology 1990; 97:953.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, 2nd Ed, The Medical Letter, Inc, New Rochelle, NY 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/127\">",
"      Khandelwal SS, Woodward MA, Hall T, et al. Treatment of microsporidia keratitis with topical voriconazole monotherapy. Arch Ophthalmol 2011; 129:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16089/abstract/128\">",
"      Loh RS, Chan CM, Ti SE, et al. Emerging prevalence of microsporidial keratitis in Singapore: epidemiology, clinical features, and management. Ophthalmology 2009; 116:2348.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss L, Schwartz D. Microsporidiosis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd, Guerrant R, Walker D, Weller P.  (Eds), Elsevier, 2011. p.714.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5731 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16089=[""].join("\n");
var outline_f15_45_16089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10139391\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20620119\">",
"      Gastrointestinal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20620126\">",
"      Ocular infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885865781\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10139391\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5731|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/8/24706\" title=\"figure 1\">",
"      Microsporidiosis spores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/59/15287\" title=\"figure 2\">",
"      Microsporidia life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5731|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/47/35580\" title=\"table 1\">",
"      Diseases hosts Microsporidia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/35/39485\" title=\"table 2\">",
"      Treatment of microsporidiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16090="ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use";
var content_f15_45_16090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/45/16090/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/45/16090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have shown that angiotensin converting enzyme (ACE) inhibitor therapy leads to symptomatic improvement, reduced hospitalization and enhanced survival in patients with heart failure (HF) and systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Therefore, ACE inhibitors are an important component of standard HF therapy in patients with current or prior symptoms of HF and depressed left ventricular (LV) systolic function.",
"   </p>",
"   <p>",
"    The clinical data supporting the use of ACE inhibitors in patients with HF will be reviewed here. The mechanisms of action of these agents in HF, their role in patients with diastolic dysfunction, their use in patients with asymptomatic systolic dysfunction, and the efficacy of angiotensin II receptor blockers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the treatment of heart failure (HF) due to systolic dysfunction is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFIT OF ACE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors are recommended to treat HF due to systolic dysfunction because multiple, large, prospective, randomized trials have consistently demonstrated a significant reduction in mortality&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/1-5\">",
"     1-5",
"    </a>",
"    ] as well as alleviation of symptoms and improvement in clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The benefit of ACE inhibitors has been demonstrated in all severities of symptomatic HF and in patients with asymptomatic left ventricular (LV) dysfunction; a benefit has also been demonstrated after myocardial infarction (MI).",
"   </p>",
"   <p>",
"    A meta-analysis evaluated five trials (three starting during the first one to three weeks post-MI) involving 12,763 patients with left ventricular ejection fraction (LVEF) &le;35 percent or &lt;40 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical heart failure. ACE inhibition had the following benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower total mortality (23 versus 27 percent for placebo, odds ratio 0.80, 95% CI 0.74-0.87) (",
"      <a class=\"graphic graphic_figure graphicRef80210 \" href=\"UTD.htm?28/57/29597\">",
"       figure 1",
"      </a>",
"      ). Most of the mortality benefit was due to fewer deaths from progressive HF. This benefit of treatment was apparent soon after the start of treatment and continued to increase after more than four years.",
"     </li>",
"     <li>",
"      A lower rate of readmission for HF (14 versus 19 percent, odds ratio 0.67, 95% CI 0.61-0.74).",
"     </li>",
"     <li>",
"      A lower incidence of MI (9 versus 11 percent, odds ratio 0.79, 95% CI 0.70-0.89), but no difference in stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, there was a significant reduction in death, MI, and hospital admission for HF (odds ratio 0.72, 95% CI 67 to 78 percent). This translates into seven patients with at least one event prevented for every 100 patients treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Severity of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitor trials were conducted in patients with a range of severity of HF symptoms using the New York Heart Association (NYHA) classification (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ). ACE inhibitors were compared to placebo and, in one trial, to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CONSENSUS study group evaluated 253 patients with advanced NYHA III or IV HF who were being treated with diuretics, digitalis, and vasodilating agents, primarily nitrates&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/1\">",
"       1",
"      </a>",
"      ]. The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      significantly reduced the six-month mortality by 40 percent when compared to placebo (26 versus 44 percent) and the 12-month mortality by 31 percent (36 versus 52 percent) (",
"      <a class=\"graphic graphic_figure graphicRef62325 \" href=\"UTD.htm?22/61/23517\">",
"       figure 2",
"      </a>",
"      ). This benefit was sustained for at least four years, and the risk reduction averaged over the 10-year duration of the trial was 30 percent (",
"      <a class=\"graphic graphic_figure graphicRef66501 \" href=\"UTD.htm?24/7/24701\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition to the mortality benefit, enalapril was associated with significant reductions in NYHA class and in the requirement for other HF therapies.",
"     </li>",
"     <li>",
"      The SOLVD treatment trial evaluated 2569 patients with symptomatic NYHA class II to III HF with LVEF &le;35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/2\">",
"       2",
"      </a>",
"      ]. When compared to placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      resulted in a significant reduction in all-cause mortality (35 versus 40 percent, risk reduction 16 percent, 95% confidence interval [CI] 5 to 26 percent) (",
"      <a class=\"graphic graphic_figure graphicRef70015 \" href=\"UTD.htm?10/28/10701\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      A subsequent analysis, called XSOLVD, followed the patients in the SOLVD treatment trial up to a median of 12 years; the outcome was determined in virtually all of the original participants [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/12\">",
"       12",
"      </a>",
"      ]. The reduction in all-cause mortality in the enalapril group narrowed over time and was no longer significant at 12 years, at which time 80 percent of patients in both groups had died (hazard ratio 0.93, 95% CI 0.85-1.01). Overall, enalapril significantly increased median life expectancy by 8.6 months.",
"     </li>",
"     <li>",
"      The efficacy of ACE inhibitors compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      in patients with NYHA class II and III HF was evaluated in the V-HeFT II trial of 806 men [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/3\">",
"       3",
"      </a>",
"      ]. After two years, the mortality rate was significantly lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      (18 versus 25 percent with",
"      <span class=\"nowrap\">",
"       isosorbide/hydralazine)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"       figure 5",
"      </a>",
"      ). Subgroup analyses revealed a survival benefit from enalapril versus hydralazine plus isosorbide dinitrate in white patients but not black patients, although the interaction between race and treatment was not statistically significant (P=0.09) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Influence of race'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     After MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors improve the outcome in patients with asymptomatic LV dysfunction or overt HF occurring after an acute MI. Evidence confirming these benefits and recommendations for use are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Use in elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the major randomized trials included many elderly patients. It is possible, however, that some elderly patients with comorbidities would have been excluded from these trials. Despite this concern, community-based observational studies support a benefit from ACE inhibitors in elderly patients with HF that is similar in magnitude to that seen in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Long-term benefit is seen even in those who have a perceived contraindication to ACE inhibitors (systolic pressure &le;90 mmHg, serum creatinine &ge;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221",
"    <span class=\"nowrap\">",
"     micromol/L],",
"    </span>",
"    serum potassium &ge;5.5",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    and severe aortic stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Although lower doses are associated with improved outcomes, the benefit is greater if the dose is titrated up to that used in the clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/14,19\">",
"     14,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Effect of dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Influence of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors should be used in women as well as men with systolic HF, although the available data are not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/20\">",
"     20",
"    </a>",
"    ], as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of ACE inhibitor trials suggested that the benefit from these drugs might not apply to women [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/21\">",
"       21",
"      </a>",
"      ]. A total of 3492 men and 1079 women from three trials were included. The relative mortality risk with ACE inhibitor therapy was significantly reduced in men at 0.80 (95% CI 0.68-0.93) but showed only a trend toward significance in women at 0.90 (95% CI 0.78-1.05). However, the difference in effect between men and women did not reach statistical significance (P=0.07).",
"     </li>",
"     <li>",
"      An observational study of 27,837 patients with a discharge diagnosis of heart failure suggested that ACE inhibitors improve survival in women and men although the estimated effect was larger in men (adjusted hazard ratio [95% confidence interval]: women 0.80 (0.76-0.85); men 0.71 (0.67-0.75)) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Influence of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether blacks have a lesser response to ACE inhibition than whites. Given the available evidence, ACE inhibitor therapy recommendations are the same for blacks as for whites [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9,20\">",
"     9,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A post-hoc analysis of data from the V-HeFT trials and a matched cohort study of the SOLVD trials suggested that there may be differences between blacks and whites in their responses to ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ]. Two major findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both studies, black and white patients randomly assigned to placebo had similar rates of hospitalization for heart failure and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/13,24\">",
"       13,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the SOLVD matched cohort study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      compared to placebo was associated with a 44 percent reduction in hospitalization in whites; in contrast there was no significant reduction among blacks (",
"      <a class=\"graphic graphic_figure graphicRef71327 \" href=\"UTD.htm?27/17/27934\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lack of response in blacks has some biologic plausibility since similar findings have been noted in patients with hypertension. Blacks respond less well to ACE inhibitors than to most other antihypertensive drugs (",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"UTD.htm?37/22/38253\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/25\">",
"     25",
"    </a>",
"    ]. In the matched cohort study from SOLVD, there were significant reductions in systolic and diastolic pressure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    in whites",
"    <span class=\"nowrap\">",
"     (5/3.6)",
"    </span>",
"    but not blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/24\">",
"     24",
"    </a>",
"    ]. It is not known if higher doses of an ACE inhibitor might be more effective, although such a relationship has been noted in hypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/26\">",
"     26",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, other observations suggest that ACE inhibitors have similar effects in blacks and whites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of mortality data from the SOLVD trials found no significant difference in the relative risk reduction for blacks as compared to whites (RR for blacks 0.89, 95% CI 0.74-1.06; RR for whites 0.89, 95% CI 0.82-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/21\">",
"       21",
"      </a>",
"      ]. The risk reduction was significant in whites but not blacks, an observation that is likely to be explained by the smaller number of blacks in the trials (800 versus 5718).",
"     </li>",
"     <li>",
"      In an analysis limited to the SOLVD prevention trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      was largely as effective in blacks as whites in preventing progression from asymptomatic LV dysfunction to symptomatic HF [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/27\">",
"       27",
"      </a>",
"      ]. As in the matched-cohort study, a significant reduction in first hospitalization for HF was seen only in whites (relative risk 0.64 versus 0.85 in blacks). However, this endpoint was much less frequent than progression to symptomatic HF and it is therefore uncertain if the difference in response was real. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"       \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is the relative effect of another type of vasodilating therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , on survival in blacks and whites. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23942?source=see_link\">",
"     \"Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Influence of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above meta-analysis of ACE inhibitor trials found that the beneficial effect of ACE inhibitors in HF was the same for patients with and without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link\">",
"     \"Heart failure in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Effect of dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that the benefit of ACE inhibitors is greater with higher doses. Support for the use of high doses comes from the observation that, in patients on chronic ACE inhibitor therapy, gradual reactivation of vascular tissue formation of angiotensin II occurs over time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This is seen in those with progressive heart failure as well as those who are clinically stable. Conversion can be suppressed by increasing the dose of the ACE inhibitor.",
"   </p>",
"   <p>",
"    However, it is uncertain if high doses are more effective than standard doses, both of which may be associated with similar plasma angiotensin II and aldosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/30\">",
"     30",
"    </a>",
"    ]. One analysis evaluated 16,539 patients with a first HF hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/31\">",
"     31",
"    </a>",
"    ]. During one year of follow-up, 4186 (25 percent) died. Compared to patients on a low-dose ACE inhibitor, those on a high dose had a significant reduction in mortality (hazard ratio 0.76).",
"   </p>",
"   <p>",
"    Three controlled trials have addressed the issue of optimal dosing (low compared to standard or high doses) and clinical outcome, with conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 1532 patients with HF to three different doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      (2.5, 5, and 10 mg twice per day) for six months; the incidence of the primary endpoint of death, HF related hospitalization, or worsening of HF was similar in the three groups (12, 13, and 15 percent, respectively) (",
"      <a class=\"graphic graphic_figure graphicRef76818 \" href=\"UTD.htm?13/28/13774\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar lack of dose-dependence was noted in a second study of 248 patients that compared standard doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to high doses of up to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (mean dose achieved 42",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ATLAS trial randomly assigned 3164 patients to either low- (2.5 to 5 mg) or high-dose (32.5 to 35 mg)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      . Compared to the low-dose regimens, high-dose lisinopril reduced mortality by an insignificant 8 percent, although it significantly lowered the combined endpoint of mortality and hospitalization for any cause by 12 percent and hospitalizations for HF by 24 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/19\">",
"       19",
"      </a>",
"      ]. These benefits of high-dose lisinopril were also seen in high-risk patients, including those with diabetes, hypotension, hyponatremia, renal dysfunction, and elderly patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Use with other HF drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to ACE inhibitors, several other drugs, including beta blockers, angiotensin II receptor blockers (ARBs), and aldosterone antagonists have been shown to improve survival in patients with systolic HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .) Most patients in the major trials evaluating beta blockers were also treated with an ACE inhibitor (as well as diuretics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    as necessary). These studies showed that combination therapy with an ACE inhibitor and beta blocker was more effective than an ACE inhibitor or beta blocker alone in both symptomatic HF and asymptomatic LV dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef70054 \" href=\"UTD.htm?28/9/28829\">",
"     figure 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56213 \" href=\"UTD.htm?25/49/26398\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been recommended that therapy with an ACE inhibitor should be instituted before beta blockade is implemented. However, a small study using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    suggested that initiation of the beta blocker before the ACE inhibitor results in higher tolerated doses of beta blocker and better improvements in NYHA class and left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/36\">",
"     36",
"    </a>",
"    ]. We do not recommend a change in practice based upon this report due to the small number of patients and lack of long-term outcome data.",
"   </p>",
"   <p>",
"    ACE gene polymorphisms may affect the response to combination therapy. The DD genotype of the ACE gene has been associated with increases in ACE activity and mortality and a reduction in transplant-free survival in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/37\">",
"     37",
"    </a>",
"    ]. This difference may be abolished with beta blocker therapy as transplant-free survival is equivalent in patients with the DD, ID, and II genotypes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link&amp;anchor=H4#H4\">",
"     \"Actions of angiotensin II on the heart\", section on 'ACE gene polymorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also is an additive survival benefit with ACE inhibitors and aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) in appropriately monitored patients with systolic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. A potential concern is that ACE inhibitors and aldosterone antagonists both tend to raise the plasma potassium concentration with risk of potentially life-threatening hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of an ACE inhibitor and an angiotensin II receptor blocker (ARB) has been evaluated in several studies. The role of combined therapy with an ACE inhibitor and an ARB is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link&amp;anchor=H11#H11\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\", section on 'In addition to ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Use with aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors reduce kinin degradation. Increased kinin levels may contribute to the observed benefit seen with these drugs, an effect that may be mediated by enhanced release of vasodilator prostaglandins.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , which is commonly given to patients with HF due to coronary heart disease, is a prostaglandin synthesis inhibitor and therefore might interfere with the efficacy of ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for such an interaction comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      attenuates the beneficial effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      on systemic vascular resistance and cardiac output in patients with severe HF [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/42\">",
"       42",
"      </a>",
"      ]. These vascular effects are not seen with enalapril plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      , a potent antiplatelet agent that does not interact with kinin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/43\">",
"       43",
"      </a>",
"      ], or with the angiotensin II receptor blocker",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      , which also does not affect kinin metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      may also offset some of the survival benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. The SOLVD trial reviewed data on 6797 patients, 46 percent of whom were taking aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/46\">",
"       46",
"      </a>",
"      ]. In the entire population (ie, enalapril and placebo groups), the use of aspirin significantly reduced all-cause mortality (hazard ratio 0.82, 95% CI 0.73-0.92) due to reductions in sudden death (not preceded by worsening of HF) and fatal MI. Among the patients receiving enalapril, there was no beneficial effect of aspirin on survival, nor was there a beneficial effect of enalapril on survival among patients receiving aspirin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, no negative interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and ACE inhibitor therapy was noted in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     Bezafibrate",
"    </a>",
"    Infarction Prevention study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/48\">",
"     48",
"    </a>",
"    ]. Subset analysis of 464 patients in this trial who were taking an ACE inhibitor for HF found that the mortality at five years was significantly lower among those taking aspirin (24 versus 34 percent for no aspirin); this difference persisted after adjustment for confounders (relative risk 0.7, 95% CI 0.49-0.99).",
"   </p>",
"   <p>",
"    Systematic reviews and a large observational series have also not demonstrated a significant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on the efficacy of ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/10,35,49\">",
"     10,35,49",
"    </a>",
"    ]. In the meta-analysis of five trials (three post-MI and including SOLVD) involving 12,763 patients with HF or LV dysfunction described above, aspirin did not significantly affect the benefits of ACE inhibitors on mortality or the composite endpoint of death, heart failure, or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may attenuate some of the acute hemodynamic effects of ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/42\">",
"     42",
"    </a>",
"    ], most of the evidence does not support an inhibitory effect of aspirin on the long-term outcome benefits of ACE inhibitors in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients with known coronary artery disease, ASA should still be used. However, there is no evidence for using aspirin in patients with HF without coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative is the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . However, since available data does not suggest that important outcomes are worse with aspirin, we do not recommend this approach because of much higher cost [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9,41\">",
"     9,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     After revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prognosis of patients with coronary artery disease and reduced LV function is improved with revascularization, their outcome is still worse than those who have normal LV function. Since ACE inhibitors improve the outcome of patients with asymptomatic LV dysfunction, they may be of benefit after revascularization (",
"    <a class=\"graphic graphic_figure graphicRef53107 \" href=\"UTD.htm?12/45/13021\">",
"     figure 11",
"    </a>",
"    ). The data supporting this association are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H33#H33\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Use in patients with reduced GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduced glomerular filtration rate (GFR) is associated with a worse prognosis in patients with HF, at least in part because it reflects decreased renal perfusion due to more severe cardiac disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44456?source=see_link&amp;anchor=H28486377#H28486377\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\", section on 'Reduced GFR and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not known if reduced renal function reduces the beneficial effects of angiotensin converting enzyme inhibitors and other therapies for HF such as beta blockers. Evidence for therapeutic benefit from blockade of the renin-angiotensin-aldosterone system in chronic HF patients with kidney impairment is lacking, particularly since patients with a serum creatinine &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    have generally been excluded from therapeutic trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In a prospective cohort of 6427 ambulatory patients with ischemic HF who were treated with ACE inhibitors, a significant mortality benefit was seen in patients with a creatinine clearance (CrCl) &gt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    but not in patients with a CrCl &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/50\">",
"     50",
"    </a>",
"    ]. However, this observation does not prove lack of efficacy in patients with a reduced GFR, and a trial of ACE inhibitors is warranted in such patients with careful initial monitoring of the serum creatinine and potassium.",
"   </p>",
"   <p>",
"    A separate issue is a decline in GFR after the initiation of ACE inhibitor therapy. (See",
"    <a class=\"local\" href=\"#H6654443\">",
"     'Effect on GFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the proven benefit of ACE inhibitors for reducing mortality in HF due to systolic dysfunction, many patients are not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/15,16,51-55\">",
"     15,16,51-55",
"    </a>",
"    ], and treated patients often receive a less than recommended dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This was illustrated by a study of a national sample of Medicare patients who had survived hospitalization for heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/16\">",
"     16",
"    </a>",
"    ]. Study patients had documented LVEF &lt;40 percent and no documented contraindication to ACE inhibitors. ACE inhibitors were prescribed to 68 percent of this cohort; 76 percent received either an ACE inhibitor or an ARB. Patient, physician, and hospital factors were generally weak predictors of prescription except for serum creatinine, which was inversely associated with prescription rate. In addition to underutilization, patients receiving ACE inhibitors are often treated with doses that are less than currently recommended (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Clinical use'",
"    </a>",
"    below). In one series of 314 patients with HF who were readmitted to the hospital for HF over a three-year period, only 22 percent of those treated with an ACE inhibitor were receiving the recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (&ge;20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    while the dose was &le;5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/56\">",
"     56",
"    </a>",
"    ]. Renal impairment may be the most important factor responsible for the use of lower than recommended doses, especially in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of ACE inhibitors in patients with asymptomatic LV dysfunction was demonstrated in the SOLVD prevention and SAVE trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The SOLVD prevention trial, for example, included 4228 patients with asymptomatic LV dysfunction with an LV ejection fraction (LVEF) &lt;35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/4\">",
"     4",
"    </a>",
"    ]. The combined incidence of symptomatic HF or cardiovascular death was reduced 29 percent (95% CI 21-36) by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (30 versus 39 percent for placebo) at a mean follow-up of just over three years (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 12",
"    </a>",
"    ). In the XSOLVD extension of the SOLVD prevention trial, there were significant reductions in all-cause mortality (51 versus 56 percent for placebo) and cardiovascular mortality (37 versus 42 percent for placebo) at 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from a post hoc analysis of the HOPE trial suggest that ACE inhibitor therapy may reduce the risk of developing HF in high-risk patients without LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/57\">",
"     57",
"    </a>",
"    ]. Two prospectively defined endpoints (HF death and HF hospitalization) were combined with two post hoc endpoints (HF leading to open label ACE inhibitor use or development of signs and symptoms of HF).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     Ramipril",
"    </a>",
"    significantly reduced the event rate compared with placebo (9.0 versus 11.5 percent, RR 0.77). However, it is not clear whether this benefit was a specific effect of ACE inhibition or a consequence of blood pressure reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H7#H7\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Trials demonstrating benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prevention of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors and angiotensin II receptor blockers (ARBs) may prevent the development of new or recurrent AF in a variety of clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such a benefit may occur in patients with left ventricular dysfunction. In an analysis from the TRACE trial of patients with left ventricular dysfunction and sinus rhythm after an acute myocardial infarction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    significantly reduced the incidence of subsequent AF (2.8 versus 5.3 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/58\">",
"     58",
"    </a>",
"    ]. In an analysis of data from SOLVD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    significantly reduced the incidence of subsequent AF among patients with chronic left ventricular dysfunction (5.4 versus 24 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use in diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors have not been as widely used in HF due solely to diastolic dysfunction. There have been concerns that peripheral vasodilatation might lead to hypotension, since diastolic filling is impaired and cardiac output possibly reduced. However, some studies have shown that ACE inhibitors may be beneficial in such patients, especially those with hypertensive heart disease or concomitant systolic dysfunction. This subject is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with symptomatic or asymptomatic LV dysfunction (LVEF &le;40 percent), regardless of etiology, should be started on an ACE inhibitor, unless there is a contraindication. This approach was given a strong recommendation by major society guidelines including the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines with 2009 update (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67792 \" href=\"UTD.htm?40/15/41212\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9\">",
"     9",
"    </a>",
"    ], the 2010 Heart Failure Society of America guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/20\">",
"     20",
"    </a>",
"    ] and by the 2008 European Society of Cardiology task force [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17497310\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that the beneficial effect of ACE inhibitor therapy is a class effect, although the best evidence supporting specific target doses is available for agents shown to be effective in clinical trials. As discussed above, evidence for a survival benefit from ACE inhibitor therapy in patients with HF without recent MI is based largely on trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    . Additional support for long-term ACE inhibitor therapy in patients with HF comes from trials in patients with recent MI and either left ventricular systolic dysfunction or HF; long-term trials used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    . or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/10\">",
"     10",
"    </a>",
"    ] and the largest shorter term trials used captopril or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dose titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACE inhibitor is usually initiated prior to beta blocker therapy, with titration to a moderate dose. The beta blocker is then titrated to the maximum dose, following by uptitration of the ACE inhibitor to the maximum recommended and tolerated dose. This approach is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Order of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beginning ACE inhibitor therapy with low doses (eg, 2.5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    twice daily, 6.25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    three times daily, or 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    daily) will reduce the likelihood of complications such as hypotension and azotemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In the screening phase of the SOLVD trial, for example, a test dose of 2.5 mg of enalapril twice daily produced symptomatic hypotension in 2.2 percent of almost 7500 patients with NYHA class III or IV HF; cessation of therapy for hypotension was required in only 0.5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If initial therapy is tolerated, the dose is then gradually increased to a maintenance dose of 10 mg twice daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , 50 mg three times daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or up to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    unless side effects occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/1-3,5,9\">",
"     1-3,5,9",
"    </a>",
"    ]. These relatively",
"    <strong>",
"     high doses",
"    </strong>",
"    reflect those used in the successful trials described above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is uncertainty if these doses are more beneficial than lower doses, maximum-dose therapy, if tolerated, is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9,63\">",
"     9,63",
"    </a>",
"    ]. If the target doses cannot be administered or are poorly tolerated, lower doses should be used with the expectation that there are likely to be only small differences in efficacy between low and high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Effect of dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12462791\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation and continuation of ACE inhibitor therapy during hospitalization for acute decompensated heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6192728\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of ACE inhibitors include hypotension, reduction in GFR (discussed below), hyperkalemia, cough, and angioedema. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H2#H2\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28350354\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring for potential side effects should include routine laboratory assessment of serum electrolytes and renal function prior to and following initiation and uptitration of an ACE inhibitor. The risk of hyperkalemia is further increased if an aldosterone antagonist is administered concomitantly. On the other hand, concomitant potassium wasting diuretic therapy can cause hypokalemia. One suggestion is to check serum electrolytes and renal function at one week and at one month following increases in ACE inhibitor dose and then periodically (eg, every three to six months), depending on patient's stability and baseline renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6654443\">",
"    <span class=\"h2\">",
"     Effect on GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitor therapy has a variable effect on the glomerular filtration rate (GFR) in patients with HF, as usually estimated from the serum creatinine concentration. Increases in serum creatinine and blood urea nitrogen (BUN) are often observed after initiation of an ACE inhibitor, particularly in patients treated with concurrent diuretic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bilateral renal artery stenosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\", section on 'Medical therapy'",
"    </a>",
"    ). The major mechanism is a preferential reduction in resistance at the efferent glomerular arteriole, which will lower the intraglomerular pressure that is the primary driving force to glomerular filtration. However, some patients have no change in serum creatinine, and in different studies, 10 to 25 percent have a reduction in serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal effects of ACE inhibitors in heart failure\", section on 'Effect on glomerular filtration rate'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As an example, the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    on renal function was evaluated in an analysis from the CONSENSUS trial of 123 patients with severe HF (New York Heart Association class IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/64\">",
"     64",
"    </a>",
"    ]. The mean baseline serum creatinine concentration was 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The serum creatinine increased by an average of 10 to 15 percent within the first three weeks. There was substantial variability in the renal response: the serum creatinine fell (ie, GFR improved) in 24 percent of patients, increased by less than 30 percent in 41 percent, by 30 to 100 percent in 24 percent, and by more than 100 percent in 11 percent, most often due to concurrent disease.",
"   </p>",
"   <p>",
"    Not surprisingly, risk factors for a rise in serum creatinine in CONSENSUS and other studies included signs of volume depletion (lower central venous and left ventricular filling pressures) as well as signs of more severe HF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. These included lower arterial pressures, higher doses of loop diuretics, and hyponatremia, the severity of which varies directly with the severity of the HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to appreciate that short-term worsening of renal function in response to an ACE inhibitor does not necessarily indicate long-term intolerance to angiotensin inhibition. In the CONSENSUS trial, the rise in serum creatinine following initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    therapy occurred within the first three weeks and then remained stable to the end of follow-up at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/64\">",
"     64",
"    </a>",
"    ]. In another report in which 34 of 104 HF patients developed a decline in GFR, the serum creatinine returned to pretreatment values with a reduction in diuretic dose and liberalization of salt intake [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of data on 6337 subjects enrolled in the SOLVD trial showed that early worsening renal function (decrease in estimated GFR &ge;20 percent at 14 days) was not associated with increased mortality in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    group but was associated with increased mortality in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/45/16090/abstract/67\">",
"     67",
"    </a>",
"    ]. A significant survival benefit from enalapril therapy was observed in patients who continued enalapril despite early worsening renal function.",
"   </p>",
"   <p>",
"    In the infrequent patient with progressive worsening of renal function, it may be necessary to reduce the ACE inhibitor dose or discontinue therapy. If cessation of angiotensin inhibition is required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus a nitrate is a suggested alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H27821874#H27821874\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Hydralazine plus nitrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16908293\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple, large, prospective, randomized trials have consistently demonstrated that ACE inhibitor therapy in patients with HF due to systolic dysfunction results in a significant reduction in mortality as well as alleviation of symptoms and improvement in clinical status. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of ACE inhibitors has been demonstrated in all severities of symptomatic HF and in patients with asymptomatic left ventricular (LV) dysfunction; a benefit has also been demonstrated after myocardial infarction (MI). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HF with left ventricular systolic dysfunction (LVEF &le;40 percent), we recommend ACE inhibitor therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitor therapy is generally started at low doses (eg, 5 to 10 mg daily of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      ) to reduce the likelihood of complications such as hypotension and azotemia. If initial therapy is tolerated, the dose is then gradually increased to a maintenance dose of up to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of lisinopril or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/29/24024?source=see_link\">",
"       quinapril",
"      </a>",
"      unless side effects occur. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dose titration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitor therapy has a variable effect on the glomerular filtration rate (GFR) in patients with HF, as usually estimated from the serum creatinine concentration. (See",
"      <a class=\"local\" href=\"#H6654443\">",
"       'Effect on GFR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increases in serum creatinine and BUN are often observed after initiation of an ACE inhibitor, particularly in patients treated with concurrent diuretic therapy. However, some patients have no change in serum creatinine, and a minority of patients has a reduction in serum creatinine.",
"     </li>",
"     <li>",
"      Short-term worsening of renal function in response to an ACE inhibitor does not necessarily indicate long-term intolerance to angiotensin inhibition, but should prompt evaluation of the diuretic regimen and other possible causes of worsening renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are conflicting data as to whether blacks have a lesser response to ACE inhibition than whites. Given the available evidence, recommendations for ACE inhibitor therapy for HF are the same for blacks as for whites.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/1\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/2\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/3\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/4\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/5\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/6\">",
"      Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984; 70:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/7\">",
"      Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/8\">",
"      Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J 1995; 16:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/9\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/10\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/11\">",
"      Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/12\">",
"      Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/13\">",
"      Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/14\">",
"      Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/15\">",
"      Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/16\">",
"      Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/17\">",
"      Ahmed A, Kiefe CI, Allman RM, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/18\">",
"      Ahmed A, Centor RM, Weaver MT, Perry GJ. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005; 149:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/19\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/20\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/21\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/22\">",
"      Keyhan G, Chen SF, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail 2007; 9:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/23\">",
"      Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/24\">",
"      Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/25\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/26\">",
"      Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/27\">",
"      Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/28\">",
"      Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/29\">",
"      Lapointe N, Rouleau JL. Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors. J Am Coll Cardiol 2002; 39:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/30\">",
"      Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/31\">",
"      Rochon PA, Sykora K, Bronskill SE, et al. Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community. J Gen Intern Med 2004; 19:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/32\">",
"      Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J 1998; 19:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/33\">",
"      Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000; 36:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/34\">",
"      Ryd&eacute;n L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/35\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/36\">",
"      Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004; 44:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/37\">",
"      McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/38\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/39\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/40\">",
"      Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/41\">",
"      Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000; 160:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/42\">",
"      Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/43\">",
"      Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation 1998; 98:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/44\">",
"      Guazzi M, Melzi G, Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/45\">",
"      Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/46\">",
"      Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/47\">",
"      Guazzi M, Brambilla R, Reina G, et al. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003; 163:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/48\">",
"      Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/49\">",
"      McAlister FA, Ghali WA, Gong Y, et al. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 2006; 113:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/50\">",
"      Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/51\">",
"      Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/52\">",
"      McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997; 134:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/53\">",
"      Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/54\">",
"      Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/55\">",
"      Echemann M, Zannad F, Brian&ccedil;on S, et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 2000; 139:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/56\">",
"      Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/57\">",
"      Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/58\">",
"      Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/59\">",
"      Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/60\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/61\">",
"      Kostis JB, Shelton BJ, Yusuf S, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994; 128:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/62\">",
"      Lang RM, DiBianco R, Broderick GT, et al. First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators. Am Heart J 1994; 128:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/63\">",
"      Delahaye F, de Gevigney G. Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established? J Am Coll Cardiol 2000; 36:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/64\">",
"      Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/65\">",
"      Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/66\">",
"      Packer M, Lee WH, Kessler PD, et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987; 10:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/45/16090/abstract/67\">",
"      Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4:685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3452 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16090=[""].join("\n");
var outline_f15_45_16090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16908293\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFIT OF ACE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Severity of HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - After MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Use in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Influence of gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Influence of race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Influence of diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Effect of dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Use with other HF drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Use with aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - After revascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Use in patients with reduced GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention of HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prevention of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use in diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17497310\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dose titration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12462791\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6192728\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28350354\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6654443\">",
"      Effect on GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16908293\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3452|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/57/29597\" title=\"figure 1\">",
"      Meta analysis ACEI in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/61/23517\" title=\"figure 2\">",
"      ACE inhibitor advanced HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/7/24701\" title=\"figure 3\">",
"      Long term outcome enalapril",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10701\" title=\"figure 4\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/46/20205\" title=\"figure 5\">",
"      ACEI vs hydralazine in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27934\" title=\"figure 6\">",
"      ACEIs in HF in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/22/38253\" title=\"figure 7\">",
"      Response to antihypertensives in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/28/13774\" title=\"figure 8\">",
"      Enalapril dose in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/9/28829\" title=\"figure 9\">",
"      Mortality HF ACE beta block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/49/26398\" title=\"figure 10\">",
"      Beta blocker ACEI HF mort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/45/13021\" title=\"figure 11\">",
"      Ramipril post revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 12\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/15/41212\" title=\"table 3\">",
"      ACC AHA Rx asym LV dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23942?source=related_link\">",
"      Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=related_link\">",
"      Renal effects of ACE inhibitors in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_45_16091="Causes elevated IgE";
var content_f15_45_16091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of elevated immunoglobulin E (IgE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic disease (eg, atopic dermatitis/eczema, asthma, allergic rhinitis, food allergy, eosinophilic esophagitis, urticaria, drug allergy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic worm infestation (eg, helminth infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy (eg, IgE myeloma, Hodgkin's lymphoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary and secondary immunodeficiencies (eg, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, Nezelof syndrome, AIDS, GVHD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious diseases (eg, allergic bronchopulmonary aspergillosis, leprosy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory diseases (eg, Churg-Strauss syndrome, Kawasaki disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug effect (eg, aztronam, penicillin G)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Allergic disease is the most common etiology of elevated IgE in industrialized countries, whereas parasitic infection is the most common cause in developing countries.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16091=[""].join("\n");
var outline_f15_45_16091=null;
var title_f15_45_16092="Classification of FMD";
var content_f15_45_16092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of fibromuscular dysplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Angiographic appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Medial dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medial fibroplasia",
"       </td>",
"       <td>",
"        75-80",
"       </td>",
"       <td>",
"        <p>",
"         Alternating areas of thinned media and thickened fibromuscular ridges containing collagen",
"        </p>",
"        <p>",
"         Internal elastic membrane may be lost in some areas",
"        </p>",
"       </td>",
"       <td>",
"        \"String of Beads\" appearance where the diameter of the \"beading\" is larger than the diameter of the artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perimedial fibroplasia",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        Extensive collagen deposition in the outer half of the media",
"       </td>",
"       <td>",
"        \"Beading\" in which the \"beads\" are smaller than the diameter of the artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medial hyperplasia",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        True smooth muscle cell hyperplasia without fibrosis",
"       </td>",
"       <td>",
"        Concentric smooth stenosis (similar to intimal disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Intimal fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        <p>",
"         Circumferential or eccentric deposition of collagen in the intima",
"        </p>",
"        <p>",
"         No lipid or inflammatory component",
"        </p>",
"        <p>",
"         Internal elastic lamina fragmented or duplicated",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Concentric focal band",
"        </p>",
"        <p>",
"         Long smooth narrowing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Adventitial (periarterial) fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        Dense collagen replacesthe fibrous tissue of theadventia and may extendinto surrounding tissue",
"       </td>",
"       <td>",
"        Sharply localized, tubularareas of stenosis (based onlimited angiographic data)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol 2000; 12:41. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16092=[""].join("\n");
var outline_f15_45_16092=null;
var title_f15_45_16093="General ways to save your energy PI";
var content_f15_45_16093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General ways to save your energy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Planning and organizing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Switch between tasks that take a lot of energy and those that take less energy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to plan ahead so that you aren't doing too many things that take a lot of energy every day or week.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have others help you as much as possible. It helps you get tasks done, and it makes those who want to help feel useful.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combine chores or errands to lower the number of tasks you need to do.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrange your household so that most activities can be done on 1 floor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organize ahead of time so that you don't have to rush.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pacing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be sure to get enough rest. Try to rest in between activities. You can also stop to rest before you get tired, even if it means stopping in the middle of a task.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to avoid bursts of activity, because they can drain your energy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow a routine and pace your activities on good days as well as bad days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sit to do things when possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use assistive devices, which are devices that can help you do things without bending, reaching, or using too much energy. Assistive devices include walkers, scooters, canes, handrails, crutches, and grab bars.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid heavy lifting (such as children, pots and pans, and laundry).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use carts or wagons to move things from room to room and place to place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wear a fanny pack, carpenter's belt, jacket, or sweater with pockets to carry things.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prioritizing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focus on things you enjoy doing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be realistic with yourself.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        When you're too tired to eat or shop for groceries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Let others help prepare or bring food. Family or friends usually like to help!",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shop at less busy times.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Meal preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have all your ingredients on hand before you prepare a meal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use mixes or pre-packaged foods.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use cookware that you can serve from.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use small, lightweight appliances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buy utensils that fit comfortably in your hand.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store items that you use a lot at chest level so that you don't have to bend and reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Line ovens and drip pans with foil for easier cleanup.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Let dishes air dry or use a dishwasher.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childcare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan activities or outings at places where you can sit or lie down.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use daycare programs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have your children help with household chores by making a game out of the chores.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan work around your best times of the day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organize work areas so that your equipment is within easy reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take rest breaks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work part time, if possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Leisure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan activities that allow you to sit or lie down.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan social events for times of the day when you have the most energy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16093=[""].join("\n");
var outline_f15_45_16093=null;
var title_f15_45_16094="RR of HF lisin vs chlor ALLHAT";
var content_f15_45_16094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart failure with lisinopril versus chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of heart failure with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of heart failure in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of heart failure in total and in all specific subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16094=[""].join("\n");
var outline_f15_45_16094=null;
var title_f15_45_16095="Hysteroscopic view3";
var content_f15_45_16095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic view of complex atypical hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hysteroscopic view of complex atypical hyperplasia along the right lateral wall of the uterus while the left side is without significant tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_45_16095=[""].join("\n");
var outline_f15_45_16095=null;
      